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1

I. INTRODUCTION

A. Statement of the Problem

Ibuprofen is a prototypical nonsteroidal anti-inflammatory (NSAI) agent, used for
the treatment of rheumatoid arthritis, post-operative pains, pains associated with common
colds, etc. (1). The drug has also been shown to attenuate the effects of modulators of
inflammation which are implicated in the pathogenesis of Alzheimer’ s disease (2,3).
Ibuprofen is a poorly water-soluble drug with poor flow and compressibility
properties (4,5). Poor compressibility and flowability have continued to present
considerable challenges in pharmaceutical unit processes such as tableting and filling of
hard gelatin capsules. Flowability problems also result in poor content uniformity. Coprocessing of ibuprofen with an excipient into ready-to-use microparticulates (spheroids)
could potentially be useful to improve flowability, friability, compressibility and content
uniformity of the drug (6,7). Moreover, co-processing with less number of excipients
would reduce the problem of bulkiness usually associated with the multicomponent
commercial formulations. In addition, spheroids have been shown to possess lower level
of gastric irritation and fewer dose-dumping accidents (8).
In the development of spherical microparticulates or spheroids, extrusion
spheronization has been the method of choice. However, it involves four major steps,
and the process is difficult to optimize, reproduce and scale-up (9,10). In contrast, rotordisk fluid-bed technology is a one-step closed process that utilizes a rotor, which can also
be used for spheronization, drying, drug layering and coating. Moreover, the rotor-disk
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fluid-bed can be automated, which enhances scalability, batch-to-batch reproducibility
and reduction of process time and cost (6,11,12). The fluidization of the particles can
also lead to cost-effective product with desirable content uniformity.
The fluid-bed operation is a multivariable process and optimization and scale-up
of the process are difficult to accomplish (13,14). This is due to interplay of the variables
and their influence on obtaining products with desirable qualities. Moreover, achieving
desirable batch size, drug loading and the use of different particle sizes of the same drug
to obtain good spheroid qualities were reported as major draw backs of the rotor-disk
spheronization process, thus limiting the utility of the technology (15,16). Reports on this
are limited especially on the optimization and scale-up of rotor-disk fluid-bed technology.
This is possibly due to the fact that many companies could have proprietary information
that are inaccessible to the general public. Therefore, optimization of the process through
statistically designed experiments would lead to understanding of interplay or interaction
of variables and their effects on formulation and subsequent scale-up.
In addition, ibuprofen, being a rapidly absorbed drug with high bioavailability
(>80%) and short biologic half-life (1.5 - 2 hrs; 17), there is high probability for lack of
patient compliance. Therefore, a sustained release formulation will alleviate this problem
through reduction in dosing.
Ibuprofen is a potent non-specific cycloxygenase and prostaglandin inhibitor
which makes it amenable to significant adverse effects, including gastrointestinal tract
irritation, following the large conventional oral delivery (18). The adverse
gastrointestinal side effects of ibuprofen could occur both by local or systemic drug
contact (19,20). This effect might be eliminated by coating for sustained release delivery
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as well as encapsulation of the coated and uncoated microparticulates, which will ensure
that less drug is in contact with the gastric mucosa per unit time (20,21), and also yield
effective, safe and stable delivery systems for use in humans.
Several studies have shown the efficacy of sustained release ibuprofen tablets over
conventional dosage forms (22-25). Brufen Retard, a sustained release ibuprofen that is
marketed in Europe has also been shown to be effective as anti-inflammatory and
analgesic agents at the recommended dose (26). However, no sustained release ibuprofen
formulation has been found to exist in the market in the United States.
Therefore, the specific aims of this research are as follows:
1) Development of spheroids using the one pot rotor-disk fluid-bed technology,
ibuprofen as the model drug, Avicel as the major excipient and spheronization enhancer,
sodium lauryl sulfate as lubricant and water as binder.
2) Optimization of the formulation and process variables using statistically designed
factorial experiment.
3) Evaluation of the effects of drug particle size, different drug loads and scale-up up to
intermediate production batch size on the the developed and optimized ibuprofen
spheroids using the rotor-disk fluid-bed technology.
4) Polymer coating and encapsulation of coated and uncoated microparticulates using
hard gelatin capsules for comparative evaluation of controlled and immediate release
delivery systems.

4

B. Literature Review

1. Ibuprofen

a. Therapeutic uses and side effects
Ibuprofen (Figure 1) is an acidic drug with a pKa of 4.8 and a molecular weight of
206. It is a potent cycloxygenase and prostaglandin inhibitor, an NSAI agent having antiinflammatory, antipyretic and analgesic activity in both animals and humans. It is
developed in 1960s and has been used for the treatment of rheumatoid arthritis,
osteoarthritis, post-operative pains, pains associated with common colds, etc. (1). It has
recently been implicated in Alzheimer’ s disease (2,3).

Figure 1: Structure of ibuprofen (27).
*: Chiral center constituting the R and S isomers of ibuprofen

As an antinflammatory agent, ibuprofen inhibits cycloxygenase (COX) enzymes,
thereby inhibiting prostaglandin production (18,19). Two COX enzymes are known to be
involved in prostaglandin synthesis, COX-1 and COX-2. COX-1 generates prostaglandins
that maintain normal function in several organ systems, and are involved in the protection
of gastrointestinal mucosa. COX-2 generates prostaglandins that mediate inflammatory

5

stimulus, and thereby cause inflammation and pain. The adverse gastrointestinal side
effects of NSAIDs like ibuprofen are therefore related to COX-1 inhibition. Although the
therapeutic efficacy of ibuprofen outweighs the severity of its side-effects (28), studies
have shown an increased tendency of NSAIDs toward gastric irritation at higher doses
(29). This effect could be regulated by coating and encapsulation of the drug, which will
minimize the amount of drug that would be in contact with the gastric mucosa per unit
time (20,21).
Ibuprofen has been implicated in the antiinflammatory modulation of Alzheimer’ s
disease (2,3). Alzheimer’ s lesion is characterized by the development of -amyloid
protein deposits and neurofibrillary tangles. The protein deposits stimulate inflammation
in the brain, which activates the immune cells and consequently elicit harmful substances.
These include inflammatory cytokins, proteases and complement proteins that destroy
nerve cells. Ibuprofen has been shown to interrupt this sequence, and thereby lessen the
abnormal accumulation of -amyloid (2,3,30).
Ibuprofen is also used in the prevention of patent ductus arteriosus (PDA; 31).
The ductus arteriosus is a connection between the aorta and the pulmonary artery. It is
part of the fetal pathway that helps to distribute oxygen from the mother to the baby'
s
organs. Thus it facilitates blood flow and by-passes the lungs, which do not require high
blood flow at this time of the fetal development. At birth, the lungs expand, the baby'
s
blood vessels relax to accept more flow, and the ductus arteriosus usually closes on its
own within the first 15 hours of life. However, sometimes the ductus arteriosus does not
close on its own; a condition referred to as a patent (open) ductus arteriosus. This
condition is prevalent in premature babies and can also occur in full term infants.
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For newborns, NSAID such as indomethacin drug is normally administered which
helps to constrict the muscle in the wall of the PDA in order to close it. Because of the
potential side effects of indomethacin that includes a decline in cerebral blood flow and
cerebral oxygen delivery, surgery is sometimes preferred to tie off the open duct. Some
physicians also prefer to use ibuprofen instead of indomethacin, as the former has been
shown to constrict the duct and also reduce the incidence of PDA in preterm infants,
without the complications of indomethacin (32,33).

b. Dosage Forms/Dosing
Ibuprofen is a high dose drug with a short biologic half-life (1.5 - 2 hrs) and is
therefore administered several times a day orally (34). For the immediate release
products, the usual prescribed adult dose is 400 - 800 mg three or four times daily, with
the maximum daily dose not exceeding 3.2 g. For the sustained release formulation,
Brufen Retard, the recommended once or twice daily dosage (1600 mg) has been shown
to provide effective control of arthritic symptoms for different patient groups compared to
baseline, with significant overall improvements in pain and stiffness (34). Ibuprofen
pediatric dosage form exist as tablets and suspensions, which range between 5 and 50
mg/kg daily with the maximum daily dose not exceeding 2.4 g (34).
For adults, ibuprofen is available (tablets and caplets) as oral immediate release
solid dosage form. The most commercially available dosage form is the regular tablets
(e. g. Motrin®, Advil®), although chewable tablets, liquigel, oral drops and oral
suspensions exist (35). Commercially available ibuprofen consist of not less than twelve
excipients, which often lead to increased bulkiness of the oral dosage form, reduced
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amount of the active and therefore increased frequency of intake. These factors could
consequently reduce patient compliance. Intravenous ibuprofen injection also exists but
as orphan drug (Children’s Motrin®) for the treatment or prevention of patent ductus
arteriosus (PDA; 31).

b. Solubility and flowability
Ibuprofen powder has a slight characteristic odor and is practically insoluble in
water. It also shows poor dissolution and tableting behavior due to its hydrophobic
structure (5). It is also very cohesive and exhibits poor flow characteristics (36). The
physicochemical properties of ibuprofen have been improved by changes in its
crystallinity and in surface properties (37). Also drug dissolution has been improved by
various complexation techniques e.g. with cyclodextrines (38), and by the use of various
excipients (22), including spray-drying of the drug particles with microcrystalline
cellulose (MCC; 39). In the latter study, x-ray diffraction indicated that ibuprofen exists
as very fine crystals on cellulose particles, which is facilitated by the rapid evaporation of
the solvent during spray drying. This restricted crystal growth led to improved
dissolution (39).
In a previous study (40), the incorporation of sodium carboxylmethyl cellulose
(NaCMC) to piroxicam- Avicel® PH-101 formulation (formulation A), or as a coprocessed blend with MCC (Avicel® CL-611; formulation B) enhanced the release of
piroxicam at 45 min from 30% (formulation A) to 95% (formulation B). The use of
Avicel® RC-581 in a spheronization process has been shown to add plasticity to powder
blend, thereby facilitating the formation of spherical pellets, and improving the
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flowability of the formulation (41,42). Therefore, excipients such as MCC or MCC coprocessed with polymers such as NaCMC, have shown good promise in granulation
processes and could be useful in improving ibuprofen flowability, as well as in the
development of ibuprofen microparticulates.

2. Excipients

a. Microcrystalline cellulose/Sodium carboxymethyl cellulose (Avicel®)
Microcrystalline cellulose/Sodium carboxymethyl cellulose (Avicel®) products are
colloidal co-processed mixtures of microcrystalline cellulose (MCC) and sodium
carboxymethyl cellulose (NaCMC). They are dispersible in water, and produce
thixotropic gels at concentrations of >1.2% solids (43,44). They are also insoluble in
organic solvents and dilute acids, and partially soluble in both dilute alkali and water.
They consist of the RC and CL types in which the amount of carboxymethyl cellulose
present can vary between 8.3 - 18.8% w/w. The RC-581 grade has lower concentration of
NaCMC than the CL-611 grade. Both polymers are mostly used in solid dosage forms as
diluents, lubricants, spheronization enhancers and/or binders (45,46).
Several studies (including our previous report in which RC-581 and CL-611 were
co-processed with ibuprofen; 47) have shown that when used in solid dosage forms, there
are no significant differences in granule quality obtained from both grades (44). Major
differences have nevertheless been observed when used in suspensions due to their end
product viscosity/gel strength and methods of dispersion required for complete activation,
and where they exhibit a high degree of thixotropy (43,44). Additionally, differences
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have been observed when compared with other Avicel® types (grades that do not contain
NaCMC), even in solid dosage forms (48). Garcia, et al. showed that in the formulation
of glipizide microparticulate spheres and tablet dosage forms, the former, containing
Avicel® PH-101 gave higher drug release than spheres of the same composition but
prepared with Avicel® RC-581 (48). On the contrary, tableted spherical formulations
containing Avicel® RC-581 gave higher release rate constants than the formulations of
the same composition prepared with Avicel® PH-101. These were attributed to
differences in porosity of the formulations. Spheres prepared with Avicel® PH-101 had
more pores than spheres of the same composition prepared with Avicel® RC-581, that
resulted in swelling of RC-581 and slower drug release. It is also possible that milling of
the spheroids required for tableting as well as tablet compression affected the normal
packing of the polymer in the tablets. This will affect the porosity of the formulations and
also play a role in determining their amount of water retention, and might have led to
higher drug release of tablets produced using RC-581.
Microcrystalline cellulose (e.g. RC-581) has been used as a processing aid in
traditional extrusion spheronization. The MCC acts like a molecular sponge, absorbing
considerable amount of water and facilitate binding and lubrication of the moistened
powder mass during extrusion (49-51). It has also been shown that incorporation of
surfactants, for example, sodium lauryl sulfate (SLS), to a spheronization system can
improve particle-particle and particle-liquid interactions, as well as flowability of the
granules produced (52,53). These observations justified the continued use of Avicel® and
SLS in spheronization process.
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b. Sodium Lauryl Sulfate
Sodium lauryl sulfate is an anionic surfactant that has been extensively used to
reduce the surface tension of pharmaceutical systems. It has been utilized as anionic
emulsifier at 0.5 - 2.5%, tablet lubricant and wetting agent at 1 - 2%. It has been used
widely in traditional extrusion-spheronization as a wetting agent (53,54), and to impart
plasticity to extrudates (55). Studies have shown that the presence of a liquid binder in the
formulation is necessary for the formation of pellets by the extrusion/spheronization
technique (51,56). The spreading of the liquid can be influenced by viscosity and surface
tension. The latter affects possible changes in accessibility of the pore structure within the
powder bed. Both viscosity and surface tension can influence the consistency of the wet
powder mass, and thereby affect the ability to produce spherical pellets.
Incorporation of a surfactant to a spheronization system has been shown to reduce
the contact angle between the solid and ligand, which enhances the interaction between
the ligand and powder (56). Also, the addition of surfactants extends the period of
constant water level slightly, as well as eases the spreading of liquid to a greater extent.
Larger pellets with narrow size distribution are produced due to particle-particle
interaction when surfactants are present. The packing of the particles within the pellets is
also influenced by the presence of surfactants, which results from liquid/solid
interactions. Although SLS had such commendable influence on water movement, it was
observed to have less effect on porosity of the granules (56).
The effects of three surfactants, namely, sorbitan monolaurate (SML), sorbitan
monododecanoate (SMD), and sodium lauryl sulfate (SLS) on the physicochemical
properties of sulfadimidine tablets have been studied (57). Tablets were compressed

11

from granules processed by the fluid-bed granulation method. All batches of the
granulations were compressed to the same weight at constant pressure. The granulations
that contained 0.50 SML, 0.20 or 0.50% SMD produced compressed tablets with high
friability, in contrast to the granulations containing SLS. With regard to their efficiency
to improve both tablet disintegration and dissolution, the surfactants were ranked as
follows: SLS > SML > SMD.
In another study using a solution of 0 to 3% polyoxyethylene 20 oleate as a
granulation liquid, mechanically strong, free flowing pellets were produced with a
decrease in the amount of fines (58). There was also an increase in the over-sized pellets.
The shape and the surface characteristics of the pellets were also improved. For instance,
the pellets became rounder up to 1% addition of the surfactant, with negligible
improvement after this concentration. The roughness of the pellet surfaces also decreased
with an increase in the concentration of the nonionic surfactant. The results suggest that
the addition of nonionic surface-active agent improves the wetting and thereby the
rounding of pellets containing MCC and native maize starch as a co-filler.

3. Microparticulate Drug Delivery Systems and Spheronization

a. Microparticulate drug delivery systems
Microparticulates are drug-loaded small polymeric particles (erodible, nonerodible or ion-exchange resins) that could be delivered as solids or suspended in a liquid
carrier medium. They include microspheres, spheroids and/or pellets. Microparticulates
have been employed in different medical and engineering applications (59-64). In the
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field of medicine, this delivery system (especially in radiolabeled form) has been used in
different disorders in form of diagnostic tools for functional imaging of lungs,
reticuloendothelial system, gastrointestinal system, inflammatory lesions and
tumors (59).
Several distinct approaches have been used to formulate drugs as microparticulate
delivery system for oral, intraocular and topical applications. These include erodible
microparticulates, swelling mucoadhesive particulates, pH responsive microparticulates,
nanoparticles/latex systems, ion-exchange resins, etc. (60). In ophthalmology, ocular
delivery of microparticulates has been shown to improve bioavailability at the target site,
and reduce the potential for ocular and systemic side effects (61). In this regard, the
delivery system was used topically as controlled drug delivery in vitreoretinal disorders
(some of the major causes of blindness in the developed world), to reduce frequency of
intravitreous application (via injection) and optimize intraocular drug levels. This
minimizes the risk of complications that can occur from frequent intravitreous injection
(62). Microparticulates are used therapeutically mostly as spheroids for immediate and
sustained release drug delivery (59,63,64).
Spheroids/pellets are spherical microparticulates of varying diameter depending
on the application and the goal of the formulator (7). Pellets can be manufactured in
different ways. These include drug layering (spraying a solution or suspension of a binder
and a drug onto inert core), hot-melt (hardening of the molten droplets), spray congealing,
spray-drying a solution or suspension of the drug with subsequent formation of the pellets
due to the evaporation of the fluid phase, and spraying a binder solution into a whirling
powder using a fluidized bed (65,66). The most popular method of producing pellets is by
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extrusion-spheronization technique. This entails the simultaneous control of several
formulation and process variables.
Spheroids/pellets manufactured in the pharmaceutical industry are sized between
500 and 1500 µm and are commonly filled into hard gelatin capsules (67), but can also be
compressed in to tablets (68,69). As a drug delivery system, the microparticulates offer
not only therapeutic advantages such as less irritation of the gastrointestinal tract, but also
important bulk material processing advantages (8,67,70). They show better flowability,
produce less friable dosage form, exhibit biopharmaceutical reproducibility, a narrow
particle size distribution, low percentage of fines, and are easy to coat and encapsulate
(6,9). They are also suitable for dosing as multiple-unit dosage formulations (contrary to
the single-unit dosage forms) because of their spherical shape, their mechanical properties
and the ability to readily release their active constituents (71) from hard gelatin capsules,
tablets, and sprinkles. Additionally, the chance of incomplete absorption of a dose is less.
For example, if a single-unit tablet fails to disintegrate, the entire dose would be lost,
however, if few units of the pellets fail to release drug at the desired site, the effect would
not be altered significantly.
The roundness of spheronizedpellets should always be highly considered because
irregular shapes tend to indicate a process that is out of control. Spheroids with low
sphericity and agglomerated pellets also have high density and low porosity, which could
result in poor packaging. Confirmation that the pellets are spherical is obtained using
some measures of roundness, the shape factor and aspect ratios (72).
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b. Spheronization process
Granulation is the process in which primary powder particles are made to adhere
together to form larger, multiparticle entities called granules. Granulation methods are
normally divided into two parts: wet granulation methods in which liquid is used in the
process, and dry granulation methods that use no liquid. The method and conditions of
granulation affect the intergranular and intragranular pore structure by changing the
degree of packing within the granules (73).
Wet granulation involves the massing of a mixture of dry primary powder
particles using a granulation fluid, the latter being mostly water for economical and
ecological reasons (73). Wet granulation methods include wet massing and fluidized bed
processes. The latter could involve the rotor-disk module in which microparticulates are
manufactured directly from dry powder by spheronization.

1. Mechanism of pellet formation
Spheronization is a form of granulation process used in pellet formation and thus
shares the basic granulation mechanism. Like all granulation processes, the mechanism of
pellet formation involves nucleation, coalescence, abrasion, transfer, breakage and
layering (74). Several studies have been performed to study the mechanism of pellet
formation using high shear mixers (Gral 10 and Gral 25; 75,76), and agglomeration by
nucleation and coalescence has been found to dominate such systems. Limited
information is available in literature with regard to the mechanism of pellet formation
using the rotor-disk fluid-bed process.

15

Although the granulation process of the rotor-disk fluid-bed is different from that
of the high shear mixer, it has been shown that similar process variables influence the
product formulation and characteristics in both systems (75-78). In fluid-bed granulation,
the moisture content in the bed and the speed of the rotating disk are the key parameters
controlling the pellet qualities, especially the particle size and size distribution (9,44,7982). Similarly, in high shear mixers, the binder concentration and impeller speed are the
most important variables influencing the mean granule size and size distribution (75,76).
It is therefore possible that the same mechanism of growth will be applicable to both
processing systems, as discussed in the subsequent paragraphs.
The nucleation or growth mechanism of spherical pellets/spheroids has been
defined in a high shear equipment using torque measurement (75). Vonk et al. (76), also
studied growth mechanisms during liquid addition stage in high shear mixers (Figure 2).
They reported that spheroid formation starts with the formation of large primary nuclei
that follows particle-particle contact and adhesion due to liquid bridges (nucleation).
This nucleation process was described by the comparison of the theoretical tensile
strength of the nuclei and the dynamic impact pressure from the measuring system. The
primary nucleus is classified as loosed agglomerate with high porosity and low tensile
strength. The nucleation process is followed by the formation of small secondary nuclei
due to break-up of the primary nuclei. The secondary nuclei are the starting materials for
exponential growth, which starts when the solid mass is sufficiently wetted, leading to
their densification. Due to densification, stronger and spherical pellets are formed that
survive many collisions, and growth proceeds exponentially by coalescence. Additionally,
liquid is squeezed to the pellet surface, which contributes to the growth by coalescence,
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Figure 2: The destructive nucleation growth mechanism of high shear pelletisation (76)

as more particles could adhere to the already formed granule. This liquid addition stage is
followed by the kneading stage (76).
During the kneading stage, net growth diminishes because no more liquid is
applied, and a steady state is observed. Consequently, spheroid break-up becomes
considerably important, depending on the final moisture content in the powder bed.
However, at optimal conditions of binder content, the mean pellet size does not change
during the final stage of the kneading phase (i.e., there is practically no break-up), which
results in a well-defined, spherical product, with a reduced porosity compared to the
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primary nuclei (76). It was therefore concluded that deformation and probably
densification, and not fragmentation, is the dominant compression mechanisms of pellet
formulation. The exponential growth and the final pellet size were linearly related to the
specific liquid addition rate and the impeller speed.
Rashid et al. (77), have described the mechanisms of microcrystalline cellulose
core formation and growth in a centrifugal granulating process as being similar to the
spheronizing process of pellets. Different MCC grades were used as starting materials. In
such a system, the wetting phase (nucleation region) was followed by combination of
coalescence between the previously formed nuclei and the layering of the smaller fine
powder over the nuclei. At a later stage, layering and abrasion became the predominant
mechanisms. Majority of the formulations studied produced granules that were relatively
spherical, smooth, free-flowing and had good mechanical strength, with desirable narrow
range of particle size distribution.
In another study, the wetting and growth profiles of the granules were investigated
using a tracer in the binder liquid and the authors reported a linear relation between tracer
mass and granule mass during the agglomeration stage of the process (78). The result
showed insufficient wetting and rewetting of the granules during the early kneading
stages of the process respectively, which resulted in a decline of granule growth rate, and
consequently to granule attrition. These growth mechanisms are applicable to those in
extrusion/spheronization process and spheronization via rotor-disk fluid-bed processing,
which will be discussed further.
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2. Extrusion/spheronization
Extrusion/spheronization invented by Nakahara in 1964 has been described as the
most popular method of producing pellets (6,8,79,80) and the methodology of choice in
the preparation of spherical particles (71). This traditional spheronization method
involves four different steps, namely, granulation (preparation of the wet mass), extrusion
(shaping the mass into cylindrical form), spheronization (breaking up the extrudate and
rounding of the particles into spheres) and drying of the pellets, as will be elaborated
below.
i. Granulation
Different types of granulators are used to perform the mixing of the powder blend
and the granulation liquid in order to produce plastic mass. The most commonly used
granulator is the planetary mixer (81), although the use of high shear mixers has also been
reported (82). An important problem encountered during the granulation process is the
evaporation of the granulating liquid probably due to the large amount of heat introduced
by most of the mixers. The liquid evaporation influences the extrusion behavior of the
wet mass, especially as a homogenous distribution of the liquid phase throughout the
granulated mass is highly demanded. Consequently, it was reported that the binder
(mostly water) would equilibrate throughout the complete mass when the wet mass was
left for 12 hr in a sealed polythene bag before the extrusion step (83). However, this
measure is very time consuming.
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ii. Extrusion
During extrusion, the wet plastic mass is shaped into long rods. This process is
used not only in the pharmaceutical industry but also in the food, ceramic and polymer
industries. Four classes of extruders exist, namely, screw, sieve and basket, roll, and ram
extruders (7). The contour and position of the screens as well as method of feeding the
wet mass to extruder differ in each case. Recent modifications have allowed in-process
control using extrusion forces as these extrusions could be correlated to the final quality
of the pellets (84). The power consumption of the motor driving the extruder can also be
correlated to the pellet qualities (76).

iii. Spheronization
During spheronization, the formed cylinders are collected onto the spinning plate
of the spheronizer, the friction plate, where the extrudate is broken up into smaller
cylinders with a length equal to their diameter (78), and become rounded due to frictional
forces from the plates. Two types of spheronization methods have been identified (7). In
the first method, the process starts from a cylinder with rounded edges, to dumbbells and
elliptical particles and eventually to perfect spheres (Figure 3A; 85). The second method
reported by Baert and Remon (83) suggests that a twisting of the cylinders occurs after
their formation resulting in rounded edges that finally results in the breaking of the
cylinders into two distinct parts (Figure 3B). Both parts have a round and a flat side. Due
to the rotational and the frictional forces involved in the spheronization process, the edges
of the flat side fold together forming a cavity observed in certain pellets. It has been
suggested that the speed in combination with the diameter of the friction plate (not the
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B

Figure 3: Mechanisms of pellet formation in traditional spheronization methods according
to: (A) I. Cylinder, II. Cylinder with rounded edges, III. Dumb-bell, IV. Ellipse,
V. Sphere (85). (B) I. Cylinder, II. Rope, III. Dumb-bell, IV. Sphere with a cavity outside,
V. sphere (83).

absolute speed), should be used to calculate the plate peripheral velocity. These should be
considered in order to obtain highly spherical pellets (86).

iv. Drying
This is the final stage in pellet formation. The pellets can be dried at room
temperature (87,88), or at elevated temperature in an oven (70,89,90) or a fluidized bed
(86). The use of microwave oven drying has also been reported as the final stage in the
production of pellets (90,91).

Several formulation and process variables influence the final quality of the pellets
derived from the spheronization process. These include the moisture content of the
granulated mass, the type of liquid binder, type of extruder, extrusion speed, properties of
the extrusion screen, etc. (92). It has also been shown that the success or failure of each of
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these steps affects greatly the quality of the final pellets or spheres (7). Consequently,
optimization, batch-to-batch reproducibility and especially scaling up to manufacturing
batch size, that are the ultimate goals of industries in the development of any dosage form
could be difficult to achieve with this traditional method (7). On the contrary, it has been
reported that if several variables in a fluid-bed process are fully controlled, good batch-tobatch reproducibility can be obtained (7,93).

3. Fluidized bed processes
The traditional fluid-bed technology, which was developed over the past 30 years
for rapid drying, was described for the first time in the pharmaceutical field by Reynolds
(94) and by Conine and Hedley (68). In the 1990’s, fluidized bed has been extended to
rotary spheronization process as well as other routine use like agglomeration, air
suspension coating, powder and solution layering (95). Nevertheless, the principles of the
fluid-bed have not changed.

i. Traditional fluid-bed technology
A fluidized bed is essentially a bed of solid particles with a stream of air or gas
passing through them via a slit created by a plate (inserted into the vessel) and the vessel
wall. The air-flow is normally strong enough to keep the particles in motion.
The fluid-bed processing equipment generally consists of the air processing unit, the
product container, and the expansion chamber for proper fluidization of the powder bed
(Figure 4; 95,96). It has one or more binary nozzle(s) each comprising of a solution
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Figure 4: Fluid-bed equipment (97).

delivery system and compressed air to atomize the liquid binder, exhaust filter and
blower, product temperature probe, filter housing, etc. The latter encloses cartridge filters
mostly made of polyester or stainless steel materials. These filters retain products in the
system, which are shaken at pre-determined time intervals to release the retained products
into the product vessel for spheronization (98). The conical shape of the expansion
chamber reduces the velocity of the air in the filter compartment, which helps to keep the
smaller or fine particles out of the upper filter region.
The fluid-bed process has been shown to have several advantages over other
granulation technologies, especially in the development of extended release products
(99,100). In one study, three products were compared in the development of metoprolol
tartrate extended-release matrix tablet formulations, namely directly compressible, fluid-
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bed or high-shear granulated products (99). Metropolol tartrate has a tendency to adhere
to the punch surfaces and has poor flow properties, and all three processes were
sufficiently sensitive to manufacturing variables. Despite the various excipients (MCC
with talc or stearic acid) that were added to address the difficult physico-chemical
characteristics of the drug, direct compressible materials exhibited poor flow, picking and
sticking problems during tableting. High-shear granulation resulted in granules with
improved granule flow and tableting characteristics but also formed hard granules that
were difficult to mill. This was attributed to over-massing of the granules by this
granulation process. On the other hand, the fluid-bed granulation made using various
binders appeared to be satisfactory in terms of flow and tableting performance. The fluidbed technology was therefore designated as the process of choice for further evaluation of
critical and non-critical formulation and processing variables.
The fluid-bed processes include the top-spray process, the bottom-spray process
and the tangential-spray process shown in Figure 5 and Table I (96,101). The three fluidbed processes represented offer different advantages and disadvantages. They are
applicable to both granulation and coating processing, however, the performance
requirement of the finished product and suitable batch size of the product must be
considered when selecting them for a particular product.
The top-spray process is usually used with a conventional granulator-coater, the
bottom-spray process with a Wurster air-suspension column and the tangential-spray
technique is used with a rotary fluid-bed granulator (101). The latter was used for this
study, and will be elaborately discussed in subsequent sections.

A

B

C

Figure 5: Fluidized bed processes. A. Top-spray method; B. Bottom-spray method;
C. Tangential-spray method (101).

ii. Rotor-disk fluid-bed
1. Equipment and components of the rotor-disk fluid-bed
As previously discussed, extrusion/spheronization involves a number of
successive steps such as moistening, extrusion, spheronization and drying. Rotor-disk
spheronization, however, reduces the number of processing steps involved in traditional
spheronization method, and thereby reduces the production time and cost, with good
batch-to-batch reproducibility and consequently faster market time (11,12,102).
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Table I: Characteristics of Fluid-bed Granulation and Coating Processes (96,101).

Processing

Advantages

Disadvantages

Applications

Method
Top-spray

Accommodates large

Limited in its

Hotmelt coating and

coating

batch sizes, is simple

applications

aqueous enteric coatings.

(conventional

to set up, and allows

Not recommended for

mode) .

easy access to nozzle.

sustained release products
due to inefficient coating
uniformity.

Bottom-spray

Accommodates

Tedious to set up,

Sustained-release, enteric-

coating

moderate batch sizes,

does not allow

release, and layering

(Wurster)

produces uniform and access to nozzles

Poor for hotmelt coating

reproducible film

during processing,

because difficult to control

characteristics, and

and is the tallest

and maintain required

allows for widest

fluid-bed machine

temperature

application range

for coating fine
particles

Tangential-

Simple to set up,

Puts mechanical

Very good for layering,

spray coating

allows access to the

stress on the

sustained-release, and

(rotary mode)

nozzle during

product

enteric-coated products.

processing, permits

Hotmelt coating possible.

higher spray rates,

Not recommended for

and is the

friable products because

shortest fluid-bed

of potential for strong

machine for coating

mechanical forces during

fine particles

the process.
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Although rotor-disk fluid-bed comprises of set of processes that depend on each other,
once optimized, each contributes to the successful transformation of the starting powder
mixtures into spheroids.
The components of the fluid-bed processing equipment have been discussed
previously (Figure 4). A rotor-disk, which contributes greatly to the spheronization
process, is inserted in the product container of the rotor-disk fluid-bed. Figure 6 shows
the product vessel with the rotor-disk insert and the spray gun facing the direction of the
powder flow.

Figure 6: Rotor-disk fluid-bed product container with rotor-disk insert and spray gun (97).

2. Rotor-disk fluid-bed process

Rotor-disk fluid-bed utilizes the tangential-

spray process. This has been described as a method of choice for producing spheroids
used for immediate release purposes, as well as for producing pellets that could be coated
for controlled release applications (96,103,104). The tangential spray process is preferred
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over the top- or bottom spray methods because spheroids formulated in this equipment
have a surface morphology (less porous and more spherical) that is more suitable for
coating than that of spheroids prepared using the other processes.
As shown in Figure 7, rotor-disk spheronization is centered around the rotor plate
insert where disk rotation adds centrifugal force (Fc) to the material on it. As the powder
is sprayed tangentially, it is wetted and rolls around the product vessel by the centrifugal
force into a vertical moving air stream with vertical force (Fv) caused by a gap between
the vessel wall and the rotor-disk insert. Because there is no force at the center of the
plate, the rolling product falls back toward the center of the disk by gravitational force
(Fg), thereby creating a rope-like motion (95,105). This process has been demonstrated to

Figure 7: Schematic representation of rotor-disk technology using tangential
spray gun (97).
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be reproducible at the development and pilot stages, but is difficult to achieve further
scale-up and optimization steps.

3. Factors affecting the rotor-disk fluid-bed process and product qualities
Several factors affect the characteristics of products produced in the fluid-bed
spheronization process. These are the formulation, process and equipment variables.
Formulation variables would include the amount of binder added, moisture content of the
granulated mass, type of granulation liquid, and physical properties of the starting
material. Process variables include inlet and outlet air temperatures, binder spray rate,
spheronization speed, fluidization air velocity and volume. Equipment variables include
filter shaking, scalability, plate material type and contour, etc. The amount of added
binder and rotational speed have been identified as the most important variables for
producing good quality spheroids (44).

Effect of type and amount of granulation liquid on the spheronization process.
In order to initiate the agglomeration and granule growth processes, an optimum
amount of binder has to be introduced into the granulator (106). The nature of the
powder to be agglomerated will influence the selection of binder to be used for the
granulation process. Although the amount of binder used in the spheronization process
has been mostly determined empirically (106), special instrumentation and procedures
exist for this purpose (107).
In the spheronization process, the granulating liquid exerts a lubricant effect,
which could be affected by the presence of different additives, used in most cases to
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adjust its properties (108). These include surfactants and polymeric compounds, which
have been shown to tailor the binder to exhibit specific behavior, thereby allowing finetuning of some binder properties, namely, surface wetting, viscosity, adsorption, and solid
bridge strength. These directly affect both the spheronization process and the resulting
product.
It has been shown that the presence of different additives could change the ease
and extent with which liquids could be removed (drying) and reabsorbed (wetting) in the
spheronization process (56). This was demonstrated using water, a 25% solution of
glycerol in water, sodium lauryl sulfate below its critical micellar concentration, and
Pluronic PF68 (a nonionic surfactant at 0.01 and 0.0001%), as granulating liquids. Lower
levels of saturation were obtained with the glycerol solution and considerably increased
levels of saturation with the surfactants. It has also been shown in both traditional
extrusion/spheronization and rotor-disk processes, that the solubility of materials used
(both drugs and fillers) plays an important role in the quantity of binder required to form
satisfactory pellets and on the physical characteristics of pellets (109). These studies
emphasize the importance of using minimal number of excipients in dosage formulations,
as was done in the present study. Additionally, the importance of binder selection for
specific products in granulation/spheronization processes is implicated.

Effects of type and amount of granulation liquid on the spheronized products
qualities.

The spheronizer speed, as well as the initial and final liquid

contents (at the end of spheronization process) have been shown to exhibit significant
effects on the qualities of the spheroid (92,110-112). The qualities mostly affected are

30

sphericity, particle size distribution, and friability. These studies established a correlation
between the amount of granulating liquid used in the formulation and the shape of pellets.
For instance, in one of the reports in which traditional spheronization method was used
(56), pellet shape, a very important spheroid characteristic was demonstrated to be highly
influenced by the liquid content of the extrudate during spheronization. In addition, low
levels of liquid were shown to yield elongated, non-spherical pellets while very wet
blends produced larger, agglomerated pellets with a wide particle size range and a higher
porosity. These were attributed to variations in water content and hence consistency.
In another report (113), it was shown that although the mean diameter of the
granules was influenced by moisture contents at the final stage of spheronization,
however, the effect of moisture on the granule diameter is cumulative or based on all the
operational variables in granulation process. These factors were also considered as
important scale-up parameters.

Influence of the spray rate of the granulating liquid on product qualities.
Liquid distribution by the nozzle influences the pellet growth (78). In addition, the
spray rate and the mixing of atomization air and binder in the spray zone determine the
average granule size. There is also a linear relation between the number of droplets that
comprised a granule and the granule size, especially at the early stage of the process
(113). Therefore, there is a requirement for nozzles that produce uniform droplets, which
allow these droplets to be easily controlled in size independent of liquid- and air-flow of
the nozzle. Thus, a nucleation ratio factor has been proposed as a useful parameter to
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describe the binder liquid efficiency (78). This factor depends on the material properties
of binder liquid and powder particles.

Effect of plate rotational speed.

Spheronization speed affects spheroid

qualities in both the traditional and rotary fluid-bed processing (14,114,115). In the
traditional spheronization, extrudate speed influenced the size and sphericity of the
pellets, with the best results obtained at intermediate spheronization velocities (116,117).
In the one-step rotary process, the use of variable speeds of the rotating plate during the
spheronization run has been investigated in order to achieve optimal spheroid yield (118).
The study was performed due to the occurrence of material adhesion and formation of
oversize particles in the product yield that was attributed to the use of a non-optimized
process speed.
It was shown that when the plate speed was increased during liquid addition
(spheronization process), the greater centrifugal forces generated improved liquid
distribution and the mixing of the moist powder mass, resulting in a decrease in the
amount of oversize particles formed (118). A "low-high-low" speed variation during
rotary processing was shown to be necessary to produce spheroids with a narrow size
distribution and with a minimal amount of oversize particles in the total product yield.
Based on the mechanism of pellet formation already discussed, and on our practical
experience, this could be translated as follows:
’Low’ speed at the initial stages of liquid addition when powders are still light in
weight and could be easily blown into the expansion chambers and filters. This will
reduce product losses. As more liquid is added to powder bed, the material gets very wet
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and heavy such that ’High’ speed is needed to improve powder fluidization, and also
facilitate spheronization. Finally, during the drying period as the powder material bed
looses its moisture and becomes lighter, ’Low’ speed is needed to avoid attrition and
losses into the expansion chambers and filter housing.

Effect of plate contour and plate material type
Plate contour. Rotary fluid-bed spheronization process is centered around a
rotor-disk insert. The air supplied via a split between the product vessel wall and the disk,
the disk rotation, and high air pressure of a pneumatic nozzle tangentially mounted on the
chamber of a conventional fluidized bed granulator impart centrifugal (Fc), vertical (Fv)
and the gravitational (Fg) forces on the product (Figure 7; 97,119). These create a
rotating motion that leads to greater densification and spheronization of the granules than
with conventional fluidized bed granulation (119,120).
The influence of disk surface and its speed on the direct pelletization with rotor
technology has been previously studied in a series of experiments (98,121). For each
experimental set, the process variables were kept constant within specified limits, except
for the rotational speed of the disk during agglomeration and spheronization steps. Two
differently textured rotating disks were used, one with smooth and the other with waffle
surface. It was shown that both surface textures and rotational speed of the disk have
influence on shape, surface and size of pellets, with the two textures having opposite
effects on pellet qualities.
In the traditional spheronization process, pellet shape and size have been used to
describe the influence of different plate geometry on pellet qualities (122). Under
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constant spheronization conditions, the extrudates behaved dissimilarly on the two
spheronizer plates used. The spheronizer with the rougher surface was shown to apply
more mechanical energy to the extrudate and wet pellets, which reduced the water content
necessary for the formation of the desired pellet qualities. Therefore, high differences
were observed in the quality of the extrudates produced by the two extruders (122). These
observations could be applicable to using different plate contours in the rotor-disk
spheronization process (47,121).

Plate material type.

Several authors have demonstrated the use of stainless steel

disk material in the fluid-bed spheronization and coating processes (123,124). This plate
varies in diameter and thickness depending on the size of the fluid-bed, and adds to the
forces supplied to the fluidizing powder bed. The use of stainless steel disk in fluid-bed
processes also facilitates product removal and cleanup. The cleanup step is more feasible
with smooth textured plates than with the rough/waffle contour plates. The heat
conduction of the stainless steel material makes it useful for both drying and coating
processes. It has been shown that heat transfer occurs by a combination of conduction,
convection and radiation, and is enhanced by vigorous mixing of the powder bed
(125,126). The rate of heat transfer to the powder beds during spheronization/coating
from the stainless steel plate rotor-disk insert is minimized by the addition of cold liquid
binder or coating solution, which reduces the rate of evaporation of the liquid during
processing at this stage. This efficient heat transfer would be difficult to be generated
with other materials such as teflon, which could also be used as rotor-disk insert (47).
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Using the stainless steel plate, Balakrishnan et al. (123), reported the coating of
ascorbic acid with a 10% poly(vinylpyrrolidone) solution in ethanol by a process in which
a horizontally rotating stainless steel disk was installed in the lower part of a coating
tower. The latter had a circular horizontal cross-section in which hot air was blown in
below the disk and was guided upwardly between the coating tower and the periphery of
the disk. The flow of air above the disk and the centrifugal force of the disk supplied
fluidized bed of the particle, enabling it to be efficiently coated.
A comparative study on the effects of extrusion/spheronization and rotor direct
pelletization on pellet quality using a smooth disk shows similarity in physicotechnological characteristics of the produced pellets (127). However, several phenomena
have been shown to occur successively in the fluid-bed technology and the spheronization
processes. Thus, a lot of process parameters should be controlled simultaneously during
the process (14). It is therefore important to identify and control the involved process
and formulation variables and conditions. This can be achieved through experimentally
designed studies that identify critical and optimum conditions to obtain high quality
products.

4. Optimization of Equipment and Process Variables

a. Factorially designed experiments
The effect of multiple factors such as plate contour, binder and surfactant levels
can be investigated simultaneously using statistical design of experiments (14,128).
Maximum amounts of information are generated with a minimum number of
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experiments, which assists to estimate the main effects of each experimental factor of the
product (129). Although factorial design has been shown to be effective in predicting the
properties of granulations prepared at conditions within the limits imposed by the
equipment or formulation (79), there are limited reported studies on the effects of process
variables on product quality and characteristics (50). Most of these were confined to
studying few characteristics (128). However, none of the studies in both the traditional
and non-traditional methods has statistically studied the effect of batch-to-batch
reproducibility on both process variables and spheroid qualities. Additionally, apart from
very few studies (9,93) most of them used beads on which drugs were layered, thus
providing ready-made spheronized cores that initiated the spheronization
process (129-133).
Considering the complexities of the spheronization processes, most of the
processing and formulation variables, especially some critical aspects of granulating
liquids, scale-up, drug loading, drug particle size, etc. need to be statistically studied and
validated. This could be achieved using different process and product scales and also
different aspects of the powder material qualities (129,134). Optimization studies can be
based on the results of feasibility studies. Production and scaling up of spherical pellets
or microparticulates will then follow (44,135).
The process variables that could affect scale-up will be discussed in this section,
while the product variables will be discussed in a separate section.
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b. Scale-up
The scale-up of a process or batch is studied to establish the operating conditions
applicable to large scale production batches, with the goal of obtaining products of the
same quality based on previously optimized laboratory scale experiments. Scale-up of
processes that involve powder handling is especially difficult because the dynamic
behaviors of powders are not very well understood (136). Moreover, when applied to
granulation, the effects of the operational variables on powder properties and granule
growth are not clearly known. Although scale-up processes of materials in the solid-state
have been based on dimensional analysis, mathematical modeling and computer
simulation, most of the work in this field still depends on trial and error and the principles
of geometric similarity (137,138). The latter describes the interrelationships among
system properties upon scale-up, thus, the ratio of some variables in a small scale
equipment should be equal to that of similar variables in equivalent large scale
equipment (101).
Scale-up of any chemical process is a complex science. The scale-up of fluidized
bed processes is likewise complicated because it involves several scientific techniques
and problems, including those involved in engineering and pharmaceutical fields
(13,139). These include the problems of air-flow changes and rate (gas bypassing) and
poor contact with bed particles, particle flow patterns, dissolution profiles, drug load and
the physical nature of solid particles that includes the drug particle size. Although most of
the work published on rotor-disk spheronization focused on small-scale equipment, fluidbed systems are designed to maintain critical scale-up factors as constant as possible from
one unit to another (13,139). Nevertheless, these studies emphasized that each fluid-bed
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should operate at identical bed depths, air velocities and air changes as to simplify scaleup of products from one unit to the other. Most of these parameters have been recognized
and incorporated in fluid-bed machinery.
Mehta et al. examined the variables that should be optimized in the scale-up of the
fluid-bed coating process (101). These include, spray rate, powder bed moisture content
at the end of the spraying cycle, the atomization air pressure, the inlet air temperature, the
fluidization air volume, the batch size, and the type of equipment. In this study, the
interplay of various processing parameters presented a great challenge in optimizing the
coating process in a fluidized bed process. As such, continuing efforts to investigate and
understand this interplay were reported as extremely important in order to ensure
reproducible performance of the products.
Computerized techniques are becoming popular for the fluid-bed process control
(140). These include fuzzy logic, neural networks, and experimental design models. In
addition, engineering techniques based on particle size population balance modeling are
under development for both fluid-bed and high-shear granulation processes (140).
Recently, mathematical model software which utilizes a combination of classical
equations for transport phenomena in conjunction with effective algorithms and actual
laboratory, pilot plant, and production data, has been introduced to resolve problematic
scale-up issues for the pharmaceutical engineer and formulator (141). Nevertheless, some
authors have maintained that past experience is very much required in handling the
numerous problems encountered during scale-up in drug development (142). Most
process and formulation scale-up processes are however based on the principles of
geometric similarity (138,143,144).
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1. The principles of geometric similarity
Scale-up from laboratory to production batches is always problematic for the
development of pharmaceuticals. Deviations in expected results in scaling-up can often
be evaluated by the principle of similarity. This attempts to represent a physiological or
chemical process by an unspecified relation between several dimensionless groups, one of
which contains the unknown variable (138,140). If the group containing the known
variables are made to have the same value on the small and large scales, then the group
containing the unknown variable will also have the same values. In this form, the
principle of similarity pre-supposes that the systems to be compared are geometrically
similar (136).
Two methods of deriving similarity criteria are available, dimensional analysis
and differential equations, the latter being preferred where applicable. Alternatively,
extrapolation by means of a power law relation permits model and prototype to be
compared under conditions that are not strictly similar (145).
Dimensional analysis is an algebraic treatment of variables affecting a process.
This technique permits the definition of appropriate composite dimensionless numbers
whose numeric values are process-specific (138). Experimental data are hereby fitted to
an empirical process equation that results in scale-up being achieved more readily. This
indicates that in the scaling up process, any model material system whose dimensionless
material function in question is similar to that of the original material system may be
chosen. Block et al. (141), therefore reported that scale-up may be achieved through the
application of the principles of similarity, wherein effective process translation is based
on the use of dimensionless ratios of measurements, forces, or velocities i.e., geometric,
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mechanical, thermal, and/or chemical ratios of scale. Each of these ratios presupposes the
attainment of the other similarities.
According to the theory of similarity, two processes are similar to one another if
they take place in a similar geometrical space, and if all the dimensionless numbers
necessary to describe the process, have the same numerical value (138,146). A complete
similarity requires a geometrical, material and process-related similarities. However,
according to the principles of similarity stipulated by the Center for Drug Evaluation and
Research (CDER) guidelines which state that, “the equipment used to produce test
batch(es) is of the same design and operating principles as those for scale-up batches.
The same standard operating procedures and controls as well as the same formulation and
manufacturing procedures are used on the test batch(es) and on the full-scale production
batch(es)” (147).
The principle of geometric similarity is therefore the driving force when different
sizes of the same processing equipment are employed in the laboratory, pilot plant, and
commercial production facilities. Consequently, this principle was adapted to two
dimensionless numbers of power, namely, Reynold'
s and Froude'
s, employed in the
present studies.

2. Reynold’s and Froude’s numbers
Scale-up in fixed bowl mixer-granulators has been studied by applying the
classical dimensionless numbers of power, Reynolds and Froude, and a scaling factor, to
end-point prediction in a range of geometrically similar machines. When corrections are
made, data from 25-, 100- and 600 L machines all fall on the same curve, allowing
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predictions of optimum granulation end-point conditions to be made for production-scale
equipment from measurements on laboratory-scale equipment and vice-versa (148,149).
Reynolds’ and Froude’s numbers are dimensionless numbers derived directly from Navier
Stoke’s equations. These equations, often used as the starting point for the analysis of
granular systems, mathematically describe the effect of both inertial and viscous forces on
the motion of fluid elements (150). For a rotating system like the rotary fluid-bed,
Reynolds’ number (Re) is defined as shown in Equation 1:
Re =

wri 2 ρ
µ

Eqn.1

where ρ and µ are respectively the density and dynamic viscosity of the granular medium,
w, the angular velocity, and ri the radius to a blade tip. It is generally interpreted as the
ratio of dynamic to viscous forces. The Froude’s number (Fr) is defined as shown in
Equation 2:
Fr =

N 2D
g

Eqn. 2

where N is the number of revolutions per minute, D the diameter or the impeller or the
rotor plate (as is applicable to our study), and g the gravitational constant. This number is
interpreted as the ratio of the centrifugal force generated by the equipment to the
gravitational force, and is used as a criterion for dynamic similarity. The results obtained
from these numbers using the high shear mixer often show that, for geometrically similar
machines, it is possible to calculate the power consumption at a predefined granulation
endpoint, at any given operating condition and at any scale.
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In the present study, these numbers have been used to estimate scale-up effects
and also to determine important scale-up factors for the rotor-disk spheronization process.

3. Scale-up parameters
i. Rate of addition and amount of liquid binder in powder bed
In granulation, an optimal amount of binder solution determined in a laboratory
scale is often different than that in a production scale (111). As already discussed, the
binder solution plays an essential role in the formation of granules with desired physical
properties in the manufacturing process. This binder role is closely associated with the
manufacturing scale. For wet granulation in high-shear mixers for instance, specific
methods based on the liquid saturation and the consistency of the wet mass have been
described (140,148). These two parameters can be used to quantify the characteristics of
the wet granules, and they also relate well with the particle size of the end products. In
practice, the power consumption of the high-shear mixer is used for monitoring of the wet
granulation process. It has also been helpful to use the underlying relationship between
power consumption and saturation level or wet mass consistency for scale-up purposes.
In fluid-bed granulation, the rate of binder addition, the moisture content and the
air volume in the bed are the key parameters to control (140), and can be used as scale-up
variables. The rate of binder addition and the moisture content in the bed can be
monitored in-process through the volume or weight of the binder added per unit time
interval and by near infrared probes respectively. The moisture content can also be
obtained through monitoring the loss on drying or by Karl Fisher titration studies (139).
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The Karl Fisher method determines the total moisture content including the residual
moisture present in the product.
The scale-up ratio (SUR) involving rate of addition and amount of binder is
expressed as shown in Equation 3, which could be applied to several other scale-up
variables. The air volume in the bed has been mostly monitored using air-volume
indicators on the fluid-bed machine, as will be discussed below.

SUR =

Amount of binder in the large equipment
Amount of binder in the small equipment

Eqn. 3

ii. Fluidization air volume
Besides the rate of spraying and the amount of binder in the powder bed, several
other variables are involved in the fluid-bed processes. These must be prioritized during
the development stages to avoid expending excessive amounts of time during the scale-up
phase. The volume of air required to give an adequate fluidization pattern on the specific
machine is critical to obtain good fluidization pattern necessary to get desired product
qualities. It is necessary to identify optimum operating air-flow and aeration rates
accounting for gaseous emissions and bed temperatures (151), as well as for the powder
bed fluidization. Consequently, air-flow parameter has been used as dimensionless factor
in scale-up processes (152). The air-flow rate can be determined in two ways, in relation
to the spray rate of the binder addition:
If both fluid-bed machines, the small scale size (laboratory) from which the
process is being scaled and the pilot or production sizes have air volume indicators, the
spray rate multiplier can be determined as the ratio of the two air volumes that are
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required to give an adequate fluidization pattern in each machine. Alternatively, in cases
where there are no air volume indicators, an approximation of the spray rate multiplier
can be made using the ratio of the cross-sectional areas of the product bowl screens or
plates. The latter method assumes however that achieving similar fluidization patterns in
both pieces of equipment will require the same air velocity through the bowl screen.
Therefore, the former method involving the use of air volume indicators, and which
relates to the principles of geometric similarity, and is shown in Equation 4, will be
applied in our scale-up processes.
A *B
B2 = 2 1
A1

Eqn. 4

Where A1 and B1 are the air volume and binder addition rate respectively of the small
scale while A2 and B2 refer to the same parameters for subsequent scale-up batches.

iii. Rotational speed, centrifugal force and plate radius
The Froude’s number defined in Equation 2 entails both a gravitational force and
diameter variables, with one being inversely related to the other. The centrifugal force
also relates inversely to the diameter of the impeller/plate. In the rotor-disk module,
spheronization is achieved by the powder bed rotation caused by both centrifugal and
gravitational forces during the densification of the powder. It has been reported that for
high shear mixers, this densification could depend on the impeller rotation speed and also
on the size of the mixer (140). These relationships have been adapted to the rotor-disk
module with modifications, to obtain Equations 5 and 6 that formed the bases for scale-up
in the present studies.
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V=

Fc * R
W

Eqn. 5

Fc =

W *V 2
R

Eqn. 6

Where V is the rotational speed, Fc the centrifugal force, R the plate radius and W the
weight of the powder material.

In addition to the above process variables involved in scale-up, several product
variables have been shown to affect both the spheronization and scale-up processes.
These include the amount of drug present in the system and its mean particle size
diameter, which also affect the drug release of the products.

5. Product Variables and Drug Release

a. Product variables
1. Drug particle size
Drug particle size is an important and challenging factor in the spheronization
process and therefore needs to be optimized for the success of the process (16). Studies
have been performed to describe the effects of interactions observed between powder
particle size and binder viscosity on the mechanisms involved in agglomerate formation
and growth using high shear mixers (52,153). In such systems, agglomeration by
nucleation and coalescence has been shown to dominate when agglomerating small
powder particles and binders with a low viscosity. It was also observed that in order to
produce spherical agglomerates (spheroids), a low viscosity binder has to be chosen when
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agglomerating a powder with a small particle size, and a high viscosity binder must be
applied in the agglomeration of powders with large particles. The latter requirement could
be due to the low agglomerate strength of the large particle sized products that could lead
to agglomerate breakage.
In another report in which three particle sizes of theophylline were used as a
model drug for fluidized rotor granulation, Sienkiewicz, et al. (16), observed that the two
finer grades of the drug were substantially more difficult to spheronize than the coarse
grade of the drug. Only the latter formed the desired spherical product. Additionally, two
MCC grades with different mean particle sizes were used to demonstrate the effect of
their particle sizes on the spheronization process and product qualities (115). Although
both MCC particle sizes gave pellets with good particle size, sphericity, and
compressibility, under a wide range of spheronization conditions, pellet porosity was
greater with MCC of larger particle size. It is therefore necessary that a consideration of
the particle size suitable for the spheronization process should be part of the optimization
studies performed at the developmental part of a project.

2. Drug load
Drug loading has been shown as a major limitation to the usefulness of the
spheronization process and the spheronized dosage form, and as a challenging factor in
the scaling up of fluidized bed processes (16,154). The influence of type and quantity of
drugs on spheronization processes has often been studied by varying the quantity of drug
with respect to the amount of lactose, pure microcrystalline cellulose or different forms of
Avicel (10,155). In a previous report using different loads of lactose, the effects of
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loads applied to agitating powder beds on the particle size distribution was investigated
(156). It was shown that at the light load (6.24 g/cm2), smaller particles were produced
while at the heavy loads (29.2 g/cm2 and 41.9 g/cm2), larger sized particles were
produced after long mix processing. The latter observation was attributed to a quick
increase of fine particles and their subsequent agglomeration to form larger particles due
to the large product load. Consequently, it was assumed that there was a critical fine
particle size and critical load quantity under which the physical properties of the powder
bed change significantly (156).
In another study that used theophylline as the model drug, increasing the drug
loading increased the geometric mean diameter of the microspheres as well as the time
required to release 50% of theophylline microspheres (T50; 157). Moreover, the in vitro
drug release of microparticles with a high drug loading has been shown to be markedly
faster than those with low drug loading (158). The latter was partially attributed to a
more significant initial burst-drug release of the microparticles with a high drug loading.
Consequently, a proper choice of drug levels could lead to a high degree of control over
the physical characteristics of products, including their drug release properties.

b. Drug Release
1. Immediate Release of drugs
Pharmaceutical preparations are formulated to release their actives as immediate
release (IR) or under modified release (MR) conditions. For most immediate release
drugs, including ibuprofen tablet preparations, the United States Pharmacopoeia (USP)
specifies that the formulation must release at least 75% of its drug content at 30 min
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(159). A single time point assessment, called Q20 is also used in which at least 80% of
the drug is expected to be released within 20 min (160). Drug release from conventional
release preparations are often described by Higuchi square root of time relationship
presented in Equation 7:

1

Q = kt 2

Eqn. 7

where Q is the cumulative amount of drug released per unit surface area at time t and k is
a constant.

Drug release is normally intended to be the rate-determining step for absorption of
the drug substance into the systemic circulation (161). The release from dosage forms
and subsequent absorption of the drug are controlled by the physico-chemical properties
of the drug, the delivery and biologic systems. The physiological property of the latter is
also a vital contributive factor. The essential drug properties for the release process
include its concentration, aqueous solubility, molecular size, crystal form, protein binding
and pKa (162). Consequently, it has been shown that drug release rate could be
dependent on the equilibrium solubility of the drug, which in turn is dependent on the pH
of its solution (23,163).
The release of drug from a delivery system involves both dissolution and diffusion
factors. The release mechanisms can be one of the Higuchi matrix, zero, first or second
order types, however, most drugs follow either the Higuchi matrix kinetics, the zero or
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first order release kinetics (164,165). The release kinetics parameters can be calculated
using the following semi empirical (Peppas) equations:
Mt / M = kt n

Eqn. 8

log(Mt / M ) = log k + n log t

Eqn. 9

where Mt/M is the fraction of drug released at time t, k is a characteristic constant of the
drug and n is indicative of release order. Hence, as the k value increases, the release of
drug should occur faster. The n value of 1 corresponds to zero-order release kinetics,
0.5<n<1 means a non-Fickian release model and n = 0.5 indicates Fickian diffusion drug
model (first-order release kinetics). From the plot of log (Mt/M) vs. log t, the kinetic
parameters, n and k are calculated.
Traditionally, delivery systems do not incorporate a means of controlled release of
their actives, such that with each dose of a noncontrolled-release drug (conventional), the
concentration of drug available to the body immediately peaks and then declines rapidly
(Figure 8). At times, the drug concentration is very high, contributing to adverse side

Figure 8. Types of dosage forms (166).
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effects. At other times, the concentration is too low to provide therapeutic benefit (Figure
9). It is desirable to release drugs at a constant rate, thereby maintaining drug
concentration within the therapeutic range and eliminating the need for frequent dosages.
These and other problems have led to a shift in the drug delivery technology towards the
modified/controlled release dosage forms. However, there are some characteristics
associated with drugs used in sustained release formulations, as will be discussed below.

Maximum desired level

Therapeutic range
Drug level

Minimum effective level
Dose

Time

Dose

Figure 9. Drug levels in the blood with immediate ( ) and sustained ( )
release profiles (167).

2. Drugs suitable for sustained drug delivery formulations
i. Drugs with short half-lives.
The extent of fluctuation in drug concentration at steady state is determined by the
relative magnitude of the elimination half-life and the dosing interval. If a drug is given at
an interval equal to the elimination half-life, there exists a two-fold difference between
the maximum and minimum concentrations at steady state, which normally affects its
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effectiveness (166). Drugs with short half-lives and with a clear relationship between
concentration and response, require to be dosed at regular, frequent intervals in order to
maintain the concentration within the therapeutic range. These drugs are therefore
suitable for sustained release delivery, as to reduce the number of daily intakes, and also
maintain a steady state level that is within its therapeutic concentration. The
pharmacological effects of these drugs are maintained by various mechanisms, few of
which will be discussed below. Conversely, drugs with long half-lives can be given at
less frequent intervals, and there is generally no advantage in formulating these drugs as
sustained release formulations.

ii. Drugs with high toxicity and low therapeutic index.
As shown in Figure 8, the conventional oral route of drug administration does not
provide ideal pharmacokinetic profiles. For drugs that display high toxicity and/or narrow
therapeutic windows, the ideal pharmacokinetic profile will be one wherein the drug
concentration reached therapeutic levels without exceeding the maximum tolerable dose,
and maintains these concentrations for extended periods of time till the desired
therapeutic effect is reached (Figure 9; 168). This could be achieved with sustained
release preparations. Several drugs with short half-lives e.g. ibuprofen, must be dosed at
frequent intervals and in high doses to achieve this aim. Such therapeutic measures may
result in higher peak concentrations with the possibility of toxicity. In cases where the
drugs have wide safety margins, this approach may be satisfactory because although very
large fluctuations will occur within a dosing interval, no difficulty is generally
encountered in view of the drugs’ low toxicity (168). However, some side effects might
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be deleterious to health. For this class of drugs, the use of sustained drug delivery could
prevent creating unwanted side effects that occur at very high concentrations and periods
of inefficiency at very low concentrations.
A wide range of drugs is now formulated in a variety of different oral extendedrelease dosage forms. However, only those that result in a significant reduction in dose
frequency (as would apply to ibuprofen) and/or a reduction in toxicity resulting from high
concentrations in the blood or gastrointestinal tract are likely to improve therapeutic
outcomes. Consequently, extended release of a formulation has been broadly defined as
the ability to achieve about two times reduction in dosing frequency usually used for
conventional dosage form (169).
It is also worth noting that in switching a patient from an immediate-release to
sustained release product, the equivalent total daily dose should generally be the same,
although in most cases, an effective response has been shown to be achievable with a
lower dose of the sustained release product (168). Also, in view of the complexity of
extended-release products and the potential for greater variability, both inter- and intrasubject, patients should be monitored at the initial stage to ensure that the anticipated
benefit of switching to such products is actually obtained.

3. Pellets and sustained drug release
Due to the regular spherical shape and the possibility of incorporation of a high
drug level, pellets are often the first choice when a sustained release formulation is
required. In addition, pellets offer flexibility for further release modifications (170). A
membrane coat is usually used to achieve release control. Drug release by coated pellets
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has been achieved by dissolution-control and mostly by drug diffusion, the latter, which is
governed by the intrinsic pore network of the polymeric membrane (171). The film coat
was found to be the major factor controlling the drug release, although both drug and
filler solubility influenced the diffusion of drug through the membrane. In some other
reports, soluble co-excipients such as calcium phosphate and lactose have been
demonstrated to enhance release rates of drugs, including ibuprofen by creating osmotic
forces that may break the membranous barrier, resulting in higher release rates of drugs
(172,173). Such unusual results could only be explained if consideration was given to the
physical characteristics of both powder and pellets (174).
In another study in which diclofenac sodium pellets were coated with Surelease®
polymer, release was dependent on the coating level of Surelease® (175). At low coating
level, diffusion of drug was facilitated due to the presence of more pores at the surface of
the coated pellets, indicating that the rate of dissolution of the drug particles was the ratelimiting step. However, at high coating loads, drug release was mainly diffusion
controlled. It has also been shown that Eudragit® NE 30 D was suitable for coating
diclofenac sodium:alginate (1:1) microspheres (176). However, apart from the effect of
increasing polymer level, the release rate of drug was affected by the size and drug load
of microspheres.

4. Sustained release of drugs
Controlled drug delivery offers an excellent alternative to multiple administrations
obtained with immediate release preparations. These systems are capable of delivering
drugs over longer time periods than conventional formulations (175,177). Drug release is
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controlled by a number of variables including drug content, polymer composition and its
molecular weight, device geometry, and manufacturing process. These variables enable
sustained release formulations to be fitted to the respective drug release model (178).
Modern drug technologies have facilitated the production of dosage forms that
exhibit modified time of release, rate of release, or both. While numerous terms exist for
defining them, the USP recognizes only two types, namely, extended release (also called
sustained-, prolonged- or controlled release) and delayed release (also called modified
release; 168). The delayed release system, e.g. enteric-coated products, involves the
release of discrete amount(s) of drug at some time other than promptly after
administration, and exhibit a lag time during which little or no absorption occurs.
However, they are by definition not extended-release products.
Although both sustained and controlled drug release are generally classified as
extended release preparations, some differences exist between them (168). Controlled
release formulation implies a predictability and reproducibility in drug release kinetics,
and is therefore rate-preprogrammed drug delivery systems. Release of drug molecules in
these systems has been accomplished by system design, which controls the molecular
diffusion of drug molecules. Additionally, they mostly exhibit zero order plasma release
profiles (Figure 8), and Fick’s law of diffusion (Equation 10) is followed (179):
J = −D
b

b

dc

Eqn. 10

dx

where Jb is the bulk diffusion flux, Db is the bulk diffusion coefficient and (c) the
concentration of the species.
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Sustained release products offer several advantages and also some disadvantages.
The use of extended-release products maintains therapeutic concentrations over
prolonged periods, thus reducing the frequency of dosing and fluctuations in blood
concentration (168). In addition, adverse drug effects related to transiently high
concentrations are circumvented (180-182) and patient compliance improved (168,183).
On the contrary sustained release products contain a higher drug load and thus any loss of
integrity of the release characteristics of the dosage form has potential toxicity problems
(168). Moreover, sustained release products should never be crushed or chewed as the
slow-release characteristics may be lost and toxicity may result. This is particularly
important in patients unable to swallow whole tablets, a problem commonly affecting the
elderly or patients with gut motility problems (183). It is therefore of importance that
some drug release devices exist to minimize and/or eliminate these possible adverse
situations, as will be discussed below.

i. Sustained release delivery systems or devices
Several sustained release devices exist and these include diffusion-controlled
products, dissolution-controlled products, erosion products, osmotic pump systems and
ion-exchange resins (168,184). Some of these systems will be discussed below.

1. Dissolution-controlled products
These include encapsulated and matrix dissolution products. In these dosage
forms, the rate of dissolution of the drug (and thereby availability for absorption) is
controlled by coating the dosage form with slowly dissolving polymers or by
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microencapsulation. Once the coating is dissolved, the drug becomes available for
dissolution. Consequently, by varying the thickness of the coat and its composition, the
rate of drug release can be controlled (185,186). In some preparations a fraction of the
total dose is formed as an immediate-release component to provide a pulse dose soon
after administration, thus decreasing or preventing the lag time associated with sustained
release formulations (187). This is followed by slow release of the remaining part of the
formulation.

2. Diffusion-controlled products
In these systems, a water-insoluble polymer controls the flow of water and the
subsequent diffusion of dissolved drug from the dosage form. This mechanism
encompasses both reservoir and matrix systems (Figure 10; 167). In the matrix system
shown in Figure 10A, the drug is homogeneously dispersed throughout a rate-controlling
A

B

Figure 10. Delivery of drug from (A) Typical matrix drug delivery system, (B) Typical
reservoir device (167). Arrows indicate the direction of drug release with time.
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polymer matrix, and the rate of drug release is controlled by diffusion throughout the
polymer matrix. This is described in equation 11:

dC
d 2c
=D
dt
dy 2

Eqn. 11

where y is the dimensional distance, D is the diffusion coefficient of the drug in the
polymer matrix, C is the concentration of the drug at any y position and time (t).
In the reservoir device (Figure 10B) a core of drug (whether solid drug, dilute
solution, or highly concentrated drug) is coated with a film or membrane of a ratecontrolling material, the polymer, and the rate of drug release is controlled by its
permeation through this membrane wall. Thus, because the polymer coating is essentially
uniform, and also possesses a uniform thickness for a specific thickness level, the
diffusion rate of the active agent can be kept fairly stable (zero order kinetics) throughout
the lifetime of the delivery system. This system is described in Equation 12:

F=

DKCs
t
L

Eqn. 12

where F is the flux, D is the diffusivity constant of the drug in the coating membrane, K
the partition coefficient between the coating membrane and the medium, CS is the drug
solubility, t is the time taken to diffuse through the surface area and L is the membrane
thickness through which the drug must diffuse. This equation is used in mathematical
modeling of drug release from controlled drug release formulations where F represents
the cumulative amount of drug released per unit surface area at time, t (188). A plot of F
vs. t yields a regression equation with the slope of DKCs/L, a zero order constant (ko). In
addition to the mathematical modeling of dissolution profiles, some comparison factors
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have been officially stipulated to control changes that could occur between the different
drug release profiles.

ii. Comparison of dissolution profiles
In various guidance documents, the Food and Drug administration (FDA) has
proposed a comparison of dissolution profiles for similarity when data are available for at
least three dissolution time profiles (189-192). The recommendations guiding this
comparison include number of units (12), limit of variability mean dissolution values at
different time points (10 - 20%), dissolution test conditions for different dosage forms
(immediate and modified release), etc. The comparison is achieved either by model
dependent (curve-fitting) or model-independent (statistical) methods. The former
involves linear regression of the percentage dissolved at specific time points while the
model independent analysis involves statistical moment based comparison, repeated
measure split-plot, two way ANOVA, etc. (190), most of which could be very
complicated. The method mostly adopted by the FDA is a simpler model independent
mathematical approach proposed by Moore and Flanner (189) using two factors, f1 and f2
shown in the following equations:

f1 =

{[∑ n Rt − Tt ]
t =1

[∑ n Rt ]}

*100

Eq.13

t =1

1
2
f 2 = 50 LOG{[1 + ( )∑ ( Rt − Tt ) ] −0.5 * 100}
n t =1

Eq.14
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where Rt and Tt are the cumulative percentage dissolved at each n time point for the
reference and test formulations respectively, ∑ is the summation over all time points and
LOG is logarithm to base 10.
The factor f1 is directly proportional to the average difference between the two
profiles, while f2 is inversely proportional to the average squared difference between the
two profiles, and emphasizes the larger difference among all the time-points. The f1 factor
measures the difference, while the f2 factor measures the closeness, between the two
profiles. Because of the nature of measurement, f1 has been described as difference factor,
whereas f2 is the similarity factor (191).
Similarity in product performance is a major factor in dissolution studies and
comparisons. Thus, regulatory interest lies in knowing the extent of similarity between
two curves, and in measuring which curve is more sensitive to large differences at any
particular time point. Consequently, the f2 comparison has been the focus in Agency
guidance documents. When the two profiles are identical, f2 = 50 x log (100) = 100 and
approaches 0 (50 x log {[1 + 1/nΣ (100)2]-0.5 x 100) as the dissimilarity increases. An
average difference of 10% at all measured time points results in an f2 value of 50. FDA
has therefore set a public standard of f2 value between 50-100 to indicate similarity
between two dissolution profiles and a point-to-point difference of not more than 10%.
Although this range is considered wide by some authors, from a public health point of
view, and as a regulatory consideration, f2 comparison metric with a value of 50 or greater
is a conservative but reliable estimate to assure product equivalence. Generally, f1 values
up to 15 (0 – 15) ensure similarity of the two curves being compared.

59

As already discussed, controlled drug release is mostly achieved using the
polymeric reservoir and matrix devices. Cellulose derivatives are commonly used as
polymeric films in the reservoir systems, while the polymeric matrix material may be
plastics, e.g. methylacrylate-methyl methacrylate, polyvinyl chloride, cellulose derivatives
(hydrophilic polymers) or fatty compounds including carnauba wax (a natural wax
product extracted from the leaves of a Brazilian palm tree, Copernica cerifera (192).

6. Polymeric Membranes and Sustained Drug Release

The use of polymeric film membranes has attracted considerable attention in the
development of controlled release drug delivery systems in recent years. There has been a
drastic shift from the originally used solutions of polymeric materials in organic solvents
to the use of aqueous polymeric dispersions with different commercial names and
potential applications in sustained release preparations (23). There is also considerable
shift form the originally coated tablets to the use of sustained release
multiparticulate/pellet delivery systems (193) using fluid-bed film coating and drying
equipment.
Film coatings are applied to pellet and tablet formulations for several reasons
including controlled release, taste masking, and improved stability (194). Pellet qualities,
especially the shape of pellets, have been shown to influence the deposition of film
coatings in a fluid-bed process. In a previous report, eight pellet batches were used to
monitor the pellet shape as a function of the film thickness formed (194). Four of these
were spherical visually, and the other four batches can be described as ovoids, dumbbells,
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long dumbbells, and cylinders respectively. The average coat thickness of the pellets
assessed by cross-sectional measurements did not appear to be influenced by the initial
shape of the pellets.
Among the aqueous polymeric films used in the manufacturing industries, the
ethylcellulose and polymethacrylic acid based films have been widely employed. This is
due to their inertness, solubility in relatively non-toxic solvents and availability in resins
with different properties (195). Surelease and Eudragit NE 30D are typical examples
of this class of coating materials.

a. Surelease
Surelease is an aqueous polymeric dispersion of ethylcellulose. It is a latex
coating system of fully plasticized ethylcellulose dispersions with 25% weight/weight
(w/w) solids content (23). The dispersion contains dibutyl sebacate and oleic acids as
plasticizers and fumed silica as an anti-adherent, in ammoniated water. Plasticizers
reduce the minimum film forming temperatures as well as the glass transition
temperatures, and consequently, increase the flexibility of the film coatings. Surelease
has been shown to be superior to several other polymers when sustained release (pellet
and tablet) delivery is required, as well as with the use of the rotor-disk module (175).
Although some studies have been reported on controlled release forms of
ibuprofen tablets (22-25,196) only one such formulation, namely, Brufen Retard, is
available in the market (26). A study using ibuprofen tablets compressed from ibuprofen
granulated with different concentrations of Surelease showed that the tablets made from
polymer-containing granules demonstrated more prolonged release profiles than control
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tablets that contained no polymer (23). It was also observed that increasing the amount of
Surelease in the tablets resulted in a reduction in ibuprofen release rate and a
linearization of the drug release curves. This was reported to be due to the higher degree
of imperfection in the formation of the film membrane around ibuprofen by these low
polymer levels, which might have caused increased diffusion of the drug from the dosage
forms. In addition, at lower polymer concentrations (1.2 - 3.5%), the release of this acidic
drug (pKa 4.8) was affected by the pH of the dissolution medium, hence, the release was
considerably lower at pH 1.2 than at pH 7.5 (Figure 11). The latter results resembled

Figure 11. Release profiles of ibuprofen from tablets granulated with water (control) and
different levels of Surelease® in pH 1.2 (Upper) and 7.5 (Lower) dissolution media (23).
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those obtained with both unprocessed pure ibuprofen and processed uncoated drug at both
pH values used in the study. These studies indicate that drug release rate from Surelease
is dependent on the thickness of the coating material, and the equilibrium solubility of the
drug, which in turn is dependent on the pH of its solution (23).
From these and other studies, drug release mechanisms at both pH values were
reported to be both diffusion and dissolution controlled. However, at the high pH (≥ 7.5),
the release rates of pellets and tablets coated with higher Surelease levels depended not
only on the solubility of the drug, but also on the polymer/dissolution medium partition
coefficient.

b. Poly(ethylacrylate-methylmethacrylate (Eudragit NE 30D)
In processing sustained release preparations, usually additional excipients like
plasticizers and glidants may be required. Modern sustained release dosage forms require
reliable and minimized number of excipients to ensure a release rate of the active drug
that is reproducible within a narrow range. Eudragit® polymers fulfill these requirements
to a very high extent (197), thereby enabling research and development to create tailormade solutions. These products are used in the pharmaceutical industry for the
development of formulations for enteric and controlled-release oral products, as well as
for providing protective coatings and taste masking for bitter oral dosage forms (194).
The Eudragit® RL- and RS-types are based on copolymers of acrylate and
methacrylates with quaternary ammonium groups as functional groups. The latter
determine the permeability and swellability of the films in water. The Eudragit® RLtypes contain higher amount of the quaternary ammonium groups and therefore form
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highly permeable films with little delaying action. The RS-types that contain lesser
amount of the quaternary ammonium functional groups are poorly permeable, swell less
easily but slow down drug diffusion very noticeably. The Eudragit® NE-types that
include the NE 30 grade contain no functional groups but are ethylacrylate
methylmethacrylate copolymers with a neutral ester group. They are both permeable and
swellable in water, and are used for granulation processes and sustained release coatings
(198). For the sustained release applications, their usual formulation amounts are 5 - 20%
calculated on the drug weight, although sufficient release is usually obtained at 14%
polymer addition (Figure 12).

Figure 12. Coating of potassium chloride crystals with aqueous dispersion of
Eudragit NE 30 D (199).

Eudragit® NE 30D [poly(ethylacrylat-methylmethacrylat)] is an aqueous
dispersion of a neutral copolymer based on ethyl acrylate and methyl methacrylate
polymers, and containing 30% w/w dry polymer substance. Eudragit® NE 30D polymer
film is water insoluble, permeable, swellable and pH independent (200,201). The water
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permeability of the polymer film is critical to drug dissolution profiles; it determines both
the onset of drug release and the release rates of the drug products. The release profiles
can be determined by varying mixing ratios and/or film thickness of the product. As
shown in Figure 12, increasing amounts of polymer has been shown to decrease release
rate in vitro.
Besides ethyl acrylate and methyl methacrylate, the only component in the
polymer latex dispersion is about 1.5% (on the dry polymer basis) surfactant, nonoxynol
100 (202). At higher concentrations, this surfactant has been shown to crystallize out
from polymer films during storage, and to decrease drug release during aging. Therefore,
drying of the moistened drug/polymer mixture to a residual water content of <2% is
necessary to avoid changes on the release profile during storage.
For the coating process, Eudragit® NE 30D neither contains nor needs any
plasticizer, however, stickiness shown by this product can be improved by using glidants
such as talc or glyceryl monostearate. It is used in the coating of small particles for
directly compressed and wet granulated products. If the coating with this polymer is
complete, the model represented in Equation 12 (reservoir delivery system) is expected. If
the coating is not complete (i.e. a more porous membrane exists), a mixed release
mechanism with both square root of time (Equation 7) and zero order (Equation 12)
release components, which has recently been proposed (177) could be operating. This is
represented in Equation 15:
1

Q = Kt 2 +

DKCs
t
L

Eqn. 15
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The pellet dosage forms of diffusion- or dissolution-controlled products can be
encapsulated using hard gelatin capsules, or prepared as a tablet. In most cases where
gelatin encapsulation were used, the physical characteristics evaluated included bulk and
tapped densities, Carr’ s compressibility index, and drug release properties (203,204). The
release profiles can be assessed as a mean dissolution time (MDT) and its variance (VDT)
or by comparison using the similarity factor. The mechanism of dissolution could be
assessed from the value of the relative dispersion (RD) of the mean dissolution time. In
some cases where the pellets are tableted, the possible relationship between the properties
of the pellets and those of the tablets is evaluated by canonical analysis followed by
multiple regression analysis (205). In the latter studies, it was found that only about 51%
of the tablet properties could be predicted from the properties of the pellets.
One of the advantages of encapsulated pelleted products is that the onset of
absorption is less sensitive to stomach emptying (206). Additionally, because of their
small size the entrance of the pellets into the small intestine (where the majority of drug
absorption occurs) is expected to be more uniform than with non-disintegrating extendedrelease tablet formulations.

7. Hard Gelatin Encapsulation and Technology

a. Hard Gelatin Encapsulation
Most capsules are made from gelatin that is also widely used in many food
products. Gelatin is a mixture of water-soluble proteins derived primarily from collagen,
the main naturally-occurring protein constituent of connective tissue (207). Gelatin is
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defined as a versatile container that can encapsulate powders, pellets, liquids, semi-solid
formulations, caplets, tablets and even combinations of these (Figure 13).

Figure 13: Capsules as versatile container for different pharmaceutical
dosage forms (208).

Capsules are made from pharmaceutical grade gelatin that has met the stringent
requirements of the United States Pharmacopoeia and other international organizations
that set standards for products used in medicines. In the body, the water-soluble gelatin
shell dissolves in the stomach, releasing its contents within the first few minutes of
swallowing.
Both tablets and capsules are well-proven and well-accepted dosage forms.
However, capsules have the added advantages of masking the taste and/or odor of specific
medicinal compounds, are easy to swallow, have attractive appearance, color, and can
also be easily filled and processed (209). The capsule provides a simple way for the
patient to take medications or supplements, and many pharmaceutical companies use
capsule-filling machines as a convenient way to package a pharmaceutical product for
single or multiple doses. Additionally, capsules require fewer excipients and have been
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shown to be more suitable for sustained release dosage forms. Therefore, capsules can
promote patient compliance (210).

b. Hard Gelatin Capsule Technology
A detailed step-by-step description of hard gelatin capsule production has been
given (211). These are manufactured from melted gelatin in demineralized water with the
addition of any needed additives like dyes and opacifants, in feed tanks that gravity-feed
the mixture into a dipper section. Herein, the capsule cap and body are molded onto their
respective stainless steel pin bars dipped into the gelatin solution. Once dipped, the pin
bars rise to the upper deck allowing the cap and body to set. Then, gently moving air that
is precisely controlled for volume, temperature, and humidity, dries the capsule halves up
to a stipulated amount of moisture, while precision controls constantly monitor humidity,
temperature, and gelatin viscosity throughout the production process. Once drying is
complete, the pin bars are moved to an automatic table section where the capsule halves
are stripped from the pins. The cap and body lengths are then precisely trimmed to an
acceptable tolerance, and joined automatically in joiner blocks. The finished capsules are
pushed onto a conveyer belt, which empties them into a container.
Throughout the production process, capsule qualities, size, moisture content, wall
thickness, and color, are monitored. Capsules are sorted and often visually inspected on
specially designed inspection stations. Perfect capsules are imprinted with a particular
logo on high-speed capsule printing machines, and thereafter sterilized and packaged as
required.
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The most commonly used capsule sizes range from 000 to 5, largest to smallest
size respectively, and have corresponding fill powder volumes and weights (Figure 14). If
a greater extent of compression is required in order to fill large dose drugs or to use a
smaller capsule size, the dosator nozzle principle discussed in a later section usually
works more successfully for granules, but not necessarily for pellets that do not require
the formation of firm plugs for filling.

Figure 14. Capsules showing approximate sizes and typical fill weight (212).

c. Capsule Filling Machine Instrumentation
Capsule-filling machines generally consist of a through-hole for accommodating
the cap of a capsule and a body transport member having a body pocket for
accommodating a body of the capsule (213). It also comprises of a filling system for
filling the capsule contents. The contents are typically pharmaceutical products (powders,
pellets, oils) and foods. The filling system includes a force-feeding screw disposed in a
chamber, and has a lower end opening above the body transport member. Thus,
powders/pellets supplied into the chamber are compulsorily force-fed into the capsule
body by the force-feeding screw. Consequently, even if the substances to be filled into a
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capsule have low bulk density and inferior formability and fluidity, they can be
compulsorily force-fed into the capsule body by the screw system. By so doing, filled
capsule in which a predetermined amount of the contents is filled can be produced with
certainty. The cap transport part includes a plurality of segments that includes the cap
pocket. These segments are individually vertically movable with respect to one another
and also in a vertical direction away from the body transport member.
A modern and ideal capsule-filling machine is designed to fill the material which
could be very low in bulk density and very inferior in fluidity or formability. These could
include crushed substance of weeds, grass or tea leaves or silicon dioxide. Most of these
are difficult for a conventional filling machine because of the uncertainty of the expected
fill amount. The machines typically form the capsule contents (plugs, pellet dose, etc.)
once and charge them as such into the capsule body. Alternatively, vibrations are applied
to the substances that facilitate their flowing into the capsule body. It is expected that for
every capsule filling machine, various products of different qualities could be filled well
into a capsule reproducibly.
There are basically two types of automatic capsule filling machines that are
commonly used in the pharmaceutical field, based on their mechanisms of filling. These
are the dosator and the tamping and dosing disk (tamp filling) machines.

d. Types of Automatic Capsule Filling Machines
1. Tamp filling machine
The dosing disk consists of a rotating steel plate with precisely bored holes that
form the dosing chamber. This machine depends on pushing pins through a powder bed
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so that a unit dose is transferred into a dosing disk cavity. This dose is then ejected into
the capsule body. The important process variables of the tamping capsule filling machine
include the fill weight, the tamping force, the number of tamps, the operational speed,
powder bed height, and formulation variables such as the presence or absence of
lubricants and disintegrants. These variables have been widely studied and their
requirements at various filling conditions validated (214,215). It has also been reported
that substance flowability affects the filling weight adversely.
The operational speed is the operating rate of the machine that has been shown to
relate strongly with the filled capsule characteristics, especially, the average capsule fill
weight (216). Variability in the latter is expressed as standard deviation and coefficient
of fill weight variation.
Recent adaptations of the tamp-filling machine for pellet filling include gravityfeeding of the pellets from a hopper into main pellet housing. A male and a female gates
control the amount of pellet that could be filled into the capsules (Figure 21). In this case,
the shuttle speed, which regulates the length of time the gates could remain open, is an
important variable that affects the capsule fill weight (217).
The instrumentation of tamp-filling capsule machine is normally described in
different ways. In some studies, it was described using strain gauges, by moving an
instrumented piston from one compression station to the next (218). These revealed
important relationships between compression force, piston setting, and final fill weight,
with the latter being a complex interaction of all compression stations. In another report,
the instrumentation of a Bosch GKF 400S tamp-filling machine was described using a
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prototype of a pneumatic tamping head equipped with a piezoelectric force
transducer (219).
During continuous capsule filling, feedback control of capsule fill weight can be
achieved. Podczeck (219) established this mechanism by replacing the springs of a
conventional tamping machine situated between tamping pins and the upper part of the
tamping head with a pneumatic system. He reported that the air pressure inside the
pneumatic chamber can be regulated through a feedback switch valve, and that the use of
the pneumatic tamping head is limited to the control of fill weight during tamping.
Therefore, major adjustments of fill weight at the set-up stage of the machine should be
made by alteration of the tamping pin and powder bed height settings. Although the
principles of capsule fill weight control by continuous monitoring of tamping forces have
been established, the transfer of the system to full industrial use requires further
development by every machine manufacturer.
A trend has been observed toward slower dissolution rate with increasing number
of tamps due to increased compactedness, and also depending on the type of filler used
(220). The inclusion of a disintegrant tends to nullify the effects of number of tamps or
tamping force and enhances drug dissolution markedly. Insoluble fillers appear to cause
some drugs to follow a diffusion mechanism from insoluble matrix model regardless of
the number of tamps or their intensity. Using drug plugs, mercury intrusion pore size
distribution data and other studies suggest that for tamp forces 100 or 200 N, only two
tamps are sufficient for a good powder consolidation. However, the tamp filling machine
has also been reported to be very suitable for pellets that do not require plug formation in
order to be properly filled (215).
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2. Dosator filling machine
The dosator principle is used by numerous intermittent-motion and continuousmotion capsule-filling machines. Its instrumentation has been likened to that of tablet
machines because they both rely on compression process (215). The compressibility is
related to the tapped density of the materials, thus, it is suitable for powders that require
high compressibility for encapsulation. Very flowable powders and consequently pellets
have been found difficult to densify and fill using this machine leading to greater
variation in fill weight.
The important variables for this system include the type and level of lubricant and
the ejection force, powder bed height, piston height, and compression force on the
ejection forces generated during the filling process. It has been observed that the ejection
force increased with increasing the powder bed height, piston height and compression
force (219). In a study using a Zanasi LZ 64 machine with intermittent operation, the
effect of the excipient- and machine parameters on the filling of the capsule and the
dissolution rate using caffeine as model substance was determined (221). Sufficient
lubrication of the capsule powder mixture measurable by low ejection forces is critical for
a uniform fill weight. However, addition of too much lubricant prevented the compact
from forming and increased the standard deviation of the fill weight (222). Another
report also showed that for an effectively lubricated formulation, a lubricant film is
formed and maintained on the inside of the dosator nozzle during a run, which maintains
the ejection force of the process (223). However, for a less effectively lubricated film,
where the lubricant film is not formed and maintained, the ejection force increases
slightly as each slug is ejected.
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3. Comparison of the tamp and dosator capsule filling machines
A comparison of the effectiveness of the above two commonly used capsulefilling mechanisms have been made by several authors (204,224). In one of the studies,
four different granule size fractions of Sorbitol instant® were filled into hard gelatin
capsules on a tamp filling (Bosch) and a dosator nozzle machine (Zanasi). An acceptable
filling performance was always observed and was independent of the machine type
employed. A direct relationship between the angle of internal flow and the coefficient of
fill weight variation has also been recorded for both systems (224). However the tamp
filling machine was found to be slightly better for the coarser granule size fractions,
because it does not require the formation of a firm plug.
It has therefore been concluded that in situations where a low plug density is an
essential prerequisite for product qualities including drug dissolution and bioavailability,
the tamp-filling machine is more suitable. The dosator machine is preferred when higher
compressiblity is required as to fit large drug doses into small capsule sizes. The
compressibility issue is however not applicable to the filling of pharmaceutical pellets
that are normally ≥ 400 µm, especially as it has been shown that particles larger than
40 µm do not efficiently form a plug (215). Additionally, the dosator machine is not
suitable for the filling of pellets since their inability to form plugs will lead to loss of
metered doses from the nozzle during its passage from the hopper to the capsule body.
In a previous report, a dosator and a tamping capsule filling machines were used
to study the relation between variation of filling weight and powder flowability in
connection with filling mechanism (225). The angle of repose, the minimum orifice
diameter and the discharge rate through orifices were measured. The orifice diameter is
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the length of a straight line which passes through the center of the orifice, and terminates
at the circumference. The minimum orifice diameter was closely related to the discharge
rate through orifices. The angle of repose was used as an index of flowability representing
the mobility of the particles on the surface of a powder bed, while the minimum orifice
diameter was used as one representing the mobility of the particles in a powder bed under
dynamic conditions. In both systems, no good correlations were found between the angle
of repose and the minimum orifices. However, a good correlation was found between the
variation of filling-weight and the minimum orifice diameter in a dosator system. In
tamping system, the variation of filling-weight was closely related to the angle of repose.
In this system, a minimum point appeared in the plots of the angle of repose versus the
coefficient of variation of filling-weight. This indicated that as the angle of repose
increases, the variation of filling-weight is governed by both the variation of the powderbed-height (an increasing factor) and the amount that escapes the filled capsule (a
decreasing factor).
Consequently, the tamp filling machine (Figure 15), which has been shown to

Figure 15: Tamp capsule filling machine with color touch-screen control (left; 226).
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posses the ability of handling a wider range of products than a dosator machine, including
medicinal herbs, will be used in our study.

e. Stages of Hard Gelatin Encapsulation Process
All capsule-filling machines rectify, separate, fill and join empty capsules that are
thereafter ejected from the system (227). Modern capsule fillers are designed to offer
precise dosing, high speed, and easy changeover and cleanup.

1. Rectification
In order to obtain a capsule product as described above, the cap transport portion
is placed on the body transport member such that the cap and body pockets are aligned
with each other. This arrangement can accommodate an empty capsule in which the cap
and the body are temporarily coupled to each other.

2. Separation
The empty capsule is transported in the formed capsule pocket in an erected
position, with the cap directed upward. During transportation of the empty capsule, the
cap and the body are separated from each other inside the capsule pocket, the cap is held
in the cap pocket while the body is held in the body pocket. Thereafter, the cap and body
transport members are separated from each other.
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3. Filling
The material or medicament is directly force-fed and filled into the body by the
force- feeding screw.

4. Joining and ejection
Finally, the cap transport member is placed onto the body transport member such
that they are once more aligned with each other, and then coupled to each other within the
capsule pocket, to produce a filled capsule product.

f. Comparison of Hard Gelatin Encapsulation of Various Dosage Forms
1. Powder
The filling of powders in capsules demands a powder with good
pharmacotechnological properties for samples to be constant, and to facilitate its transfer
into the capsule (228). Thus the powder bulk and tapped densities, its various flow
angles: repose, internal flow, and friction, as well as some machine variables are of great
importance (229). The range of powder combinations that can be filled on the tamp
filling machine exceeds that applicable to a dosator nozzle system. However, the latter is
used very extensively because large doses of highly compressible drugs can be filled into
smaller capsule sizes. Microcrystalline cellulose (MCC) and silicified microcrystalline
cellulose (SMCC) powdered formulations are mostly used as fillers in powder capsule
technology (230), while lactose, Mg stearate, and sodium lauryl sulfate are mostly used as
lubricants (231,232).
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The problems encountered with powder filling are numerous and depend on the
type of material. Filling problems due to powder flooding could be solved by increasing
the powder bed height in the powder bowl. Inappropriate powder bed height adversely
affects the capsule fill weight, an effect which increases with decreasing powder flow.
Tamping pin setting and powder bed height influence capsule fill weight of powders and
even granulated products having poor flowability. However, for moderate flowing
powders and granules, the coefficient of fill weight variation, an attribute of the powder
distribution into the capsules, appeared to be nearly independent of powder bed height or
tamping pin setting. The filling performance of powders with poor flow properties could
therefore be adjusted by optimizing both machine settings.

2. Liquids and semi-liquids
Liquid and semi-solid formulations in hard gelatin capsules provide alternate
choice over soft gelatin capsules for improving bioavailability and stabilizing moistureor oxygen-sensitive drugs, processing for low melting point drugs and achieving good
content uniformity for low-dose drugs. They are also convenient delivery route for
administering high potency compounds. In addition to high patient acceptability, they can
also improve product stability (233). Other advantages of this technology over soft
gelatin capsules have been demonstrated, especially the flexibility of developing solid
dispersion and controlled-release formulations. These products include oils, waxes,
polyethylene glycols, pluronics, surfactants, self-emulsifying system and polyglycolyzed
glycerides (Gelucire®) with a range of melting point and hydrophilic-lipophilic balance
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(HLB) values and. Important processing variables include filling temperature, cooling
rate, and shear rate and should be carefully evaluated (234).

3. Tablets
Tablets are encapsulated for various purposes, including improved stability and
taste. A fiber-optic probe or an electrochemical device is usually incorporated in the
system to verify the dosing (226,235). This is coupled with a reject mechanism that
rejects capsules with missing tablets. It is recommended that tablet dimensions and
hardness specifications be maintained within strict tolerance, to assure proper tablet feed.
Spherical tablets are most suitable for this technology.
It has however been shown that in comparison with tablets, pellet encapsulation is
the technology of choice both for immediate and sustained release formulations.
Moreover, it is not plausible to compress coated pellets into tablets due to cracking of the
protective and sustained release coatings. In order to maintain the geometry of pellets,
coated and uncoated, encapsulation is therefore the preferred method.

4. Pellets
Pellets are very suitable for hard gelatin encapsulation because of their regularity
of shape, good flowability and other physiological and mechanical qualities. Pellets can
be filled into hard gelatin capsules using different methods that include feed-frame,
dosing chamber and vacuum dosator methods. In the feed frame method, most pellet
formulations are designed with a bulk density to fill the capsule body completely. The
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vacuum dosator method maintains strictly the dosator mechanism already discussed. The
dosing chamber method (Figure 16) is widely utilized by many machine types including
the tamp filling machines, because it allows for partial dosing of the capsule, as well as
for dosing capsules with two types of pellets or beads. These pellet formulations must be
free flowing and free from agglomerations or electrostatic charge that interfere with pellet
discharge into the capsule body from the dosing chamber. Narrow to uniform particle
sizes also facilitate accurate dosing.

Figure 16: Tamping pellet filling system (227).

A new automatic ultrasonic control system has been developed for the
determination of the filling height in pellet encapsulation, and integrated into an
intermittently operating high output capsule filling machine (236). Measurement of the
time required for transmission of several ultrasonic impulses determines the height to
which each capsule has been filled. Utilizing this in-line measuring system, it is possible
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to monitor the fill mass of all capsules without a reduction in throughput. Furthermore,
the sporadic occurrence of overfilled or under filled capsules can be detected with a high
probability and such capsules rejected, contrary to manual in process control methods.
This new filling monitoring system has been successfully validated and also used
successfully in routine operation.

In a previous study (209), film coated and uncoated pellets of different shapes,
varying from spherical to cylindrical, were filled into hard shell capsules. It was observed
that when no film coat was applied, the pellets needed not be perfectly spherical in order
to be filled reproducibly. Thus, an aspect ratio (i.e. the ratio of the maximum and
minimum dimensions of a particle) of ≤ 1.2 was suitable for encapsulating the pellets into
hard gelatin capsules, and only very pronounced surface roughness hindered the filling
process. After coating of the pellets with an ethylcellulose film, none of the batches could
be filled to an acceptable standard, because electrostatic loading led to a blockage of the
filling mechanism. The addition of 1% talcum powder was sufficient to remove all
charges. It is therefore necessary to monitor the surface roughness and pellet shape/aspect
ratio for efficient encapsulation of coated and uncoated pellets respectively.
Pellet encapsulation also leads to reproducible gastrointestinal transit times that
result in increased efficacy and safety of these dosage forms compared to single unit
dosage forms or tablets (70). Furthermore, predictable concentration/time profiles can be
achieved and local mucosa irritations reduced. Using traditional extrusion/spheronization
process for theophylline, it has been shown that several process steps are necessary to
obtain the finished encapsulated dosage form. However, the pharmacokinetic and clinical
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advantages already mentioned compensated the increased investment necessary for this
pellet development (70). The use of the rotor-disk module in both spheronization and
coating processes will eliminate the several steps involved in the traditional
spheronization process, thereby leading to a reduction in processing time and cost.
To confirm these advantages, two sustained-release (pellets in hard gelatin
capsules) forms of propranolol have been compared with ordinary sustained release
propranolol tablets (237). The bioavailability of the capsules was more acceptable than
that of the tablets due to improved absorption and efficacy.
Despite the several advantages of microparticulate dosage forms and capsules
over tablets, there are no ibuprofen pellet formulations in the market in both immediate
and sustained release forms. Additionally, elaborate studies have not been done to
elucidate the advantages and drawbacks of the fluid-bed rotor-disk machine. Therefore,
the specific aims of this research are as follows:
1) Development of ibuprofen spheroids from different drug particle sizes and
different drug loads using the rotor-disk fluid-bed technology and Avicel as the major
excipient and spheronization enhancer, sodium lauryl sulfate as lubricant and water as the
granulating liquid.
2) Optimization of the developed process and product variables using statistically
designed factorial experiment.
3) Scale-up of process and batch size from development to pilot and eventually to
semi-production sizes.
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4) Polymer coating and encapsulation of coated and uncoated microparticulates
using hard gelatin capsules for comparative evaluation of controlled and immediate
release delivery systems.
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II. EXPERIMENTAL

A. Materials and Equipment

The materials and equipment used in the study are shown in Tables II and III
respectively.

Table II: List of Materials

Ibuprofen (20 µ)

Lot/Batch
Number
LPL-4814

Ibuprofen (40 µ)

LPL-5810

Albemarle Corp., Baton Rouge, LA

Avicel RC-581

B106C

FMC Biopolymer, Princeton, NJ

Avicel CL-611

A178N

FMC Biopolymer, Princeton, NJ

Sodium lauryl sulfate

S0180

Spectrum Chemicals, Gardena, CA

HPMC (Methocel)

E5LV

Dow Chemical Co., Midland, MI

Talc

W47835P09

Spectrum Chemicals, Gardena, CA

Surelease®

E-7-19010

Colorcon, West Point, PA

Eudragit® NE 30D

1290112016

ROHM Technical Inc., Malden, MA

Hard gelatin capsules

619067

Capsugel, Greenwood, SC

Sodium hydroxide

S3183

Fisher Scientific, Pittsburgh, PA

Acetonitrile (HPLC grade)

943286

Fisher Scientific, Pittsburgh, PA

Glacial acetic acid

903092

Fisher Scientific, Pittsburgh, PA

Potassium phosphate monobasic 966500

Fisher Scientific, Pittsburgh, PA

Methanol (HPLC grade)

970703

Fisher Scientific, Pittsburgh, PA

Triethylamine

920412

Fisher Scientific, Pittsburgh, PA

Polysorbate 80

A38-500

Fisher Scientific, Pittsburgh, PA

Material

Manufacturer/Supplier
Albemarle Corp., Baton Rouge, LA
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Table III: List of Equipment
Equipment

Model Number

Manufacturer/supplier

Fluid-bed Granulator

FL-MULTI-1

Vector Corporation, Cranbury, NJ

Fluid-bed Granulator
Fluid-bed Granulator
Glatt Fluid-bed
Capsule filling machine

FL-MULTI-15
FLN-120
WSC-5
K150i

Vector Corporation, Cranbury, NJ
Vector Corporation, Cranbury, NJ
Glatt, Binzen, Germany
Romaco/Index, Pompton Plains, NJ

Liquid Chromatography system

LC-10AS

Auto Injector

SIL-10A

UV-VIS Detector

SPD-10A

System Controller

SCL-10A

Precolumn

LUNA 5 C18

Shimadzu Scientific Instruments,
Columbia, MD
Shimadzu Scientific Instruments,
Columbia, MD
Shimadzu Scientific Instruments,
Columbia, MD
Shimadzu Scientific Instruments,
Columbia, MD
Phenomenex, Torrance, CA

Column

IB-SIL 5 C18

Phenomenex, Torrance, CA

Ezchrom® Software

Version 3

Shimadzu Scientific Instruments,
Columbia, MA

Vander Kamp Tap Density
10705
tester
Computrac® Moisture Analyzer Max 200
Image analyzer
Quantimet 500

Van-Kel Industries, Edison, NJ
Arizona Instrument, Las Vegas, NV
Leica Cambridge LTD., Cambridge, UK

Image analysis software

QWIN

Leica Cambridge LTD., Cambridge, UK

Microscope

Microstar IV

Bordersen Instrument Co., Valencia, PA

Sieve Shaker

18480

CSC Scientific Co., Inc., Fairfax, VA

Mettler moisture analyzer
Denver Instruments balance

Mettler Pm 100
B077193

Dissolution Apparatus

VK-600

Mettler Toledo Inc., Columbus, OH
Denver Instruments Company,
Arvado, CO
VanKel Industries, Inc., Edison, NJ

JMP® software

Versions 3.0 & 4.0

SAS Institute, New York, NY

Scanning electron microscope

Hitachi S510

Hitachi, Tokyo, Japan

Scanning electron microscope

Philips XL 30 FEG Holland, Nederlands

Cressington Sputter Coater

108

Franklin Electric, Bluffton, IN

Hummer Sputtering System

LO.2

ANATECH Ltd., Alexandria, VA
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B. Methodology

The methodology is divided into four phases:
1. Feasibility studies in the spheronization and scale-up of ibuprofen microparticulates
using the fluid-bed rotor-disk technology and also using only Avicel® as spheronization
enhancer, sodium lauryl sulfate as lubricant and water as binder.
2. Optimization of the developed process and product variables using statistically
designed factorial experiment.
3. Evaluation of the effects of drug loading, particle size and intermediate size scale-up
using the fluid-bed rotor-disk technology.
4. Coating of spheronized ibuprofen microparticulates and encapsulation of coated and
uncoated formulations using hard gelatin capsules for sustained and immediate release
delivery systems.

Phase 1
Feasibility Studies To Evaluate the Spheronization and Scale-up of Ibuprofen
Microparticulates

a. Blending and spheronization

1. Spheronization of 0.75 kg trial batch
Preliminary spheronization was performed in FLM-1 fluid-bed granulator, VPS
Corporation, Cranbury, NJ (Figure 17) using a teflon plate (9”) and 0.75 kg batch of
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ibuprofen and Avicel® RC-581 (1:1), with 1% SLS. Spheroids were successfully made.
The moisture content of the powder bed was checked at regular intervals using a Mettler
moisture balance (Mettler Pm100 and LP16, Mettler Toledo Inc., Columbus, OH).

Figure 17. Components of Vector FL-Multi 1 fluid-bed granulator. (1) Pulse
valve, (2) Cartridge filters, (3) Sample port, (4) Process air heater, (5) Exhaust blower, (6)
Air flow station, (7) Inlet air filter, (8) Interchangeable processing inserts, (9) Spray gun,
(10) Control panel, (11) Solution pump, (12) High Efficiency Particle Arresting
(HEPA) filters (97).

It was observed that, the amount of water needed to provide appropriate
consistency was between 50 and 52% of the dry powder blend. Based on this
observation, FLM-15 (Figures 4 and 18; 12" plates), together with the conditions stated
on Table IV were used for initial batches of 1 kg, which were later scaled up to 5 kg and
10 kg pilot batches using 19" plate.
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Table IV. Spheronization Conditions and Process Parameters

Equipment

FLM-15

Parameters
Batch size

1 kg

5 kg

10 kg

Plate size

12”

19”

19”

Centrifugal force

41,667

41,667

41,667

Plate material

SS/smooth

SS/smooth

SS/smooth

type/contour

Tef./waffle

Tef./waffle

Tef./waffle

50

90

140

Plate gap (mm)

0.8

3.5

6

Spray rate (g/min)

50

90

140

Rotor speed (rpm)

500

300

200

Inlet air temperature (oC)

25-30

25-30

25-30

Product temperature (oC)

18-22

18-22

18-22

Atomization air pressure

45

45

45

Air volume (cfm)

85

145

220

Plate gap (mm)

1.3

5.0

8

Rotor speed (rpm)

150

124

124

(N)

Spraying
Air volume (cfm) A1
and A2 values

B1 and B2 values

(psi)
Drying

SS/smooth: Stainless steel smooth; Tef./waffle: Teflon waffle
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Figure 18. Components of the Vector FLM-15 equipment. (1) Top exhaust vent
(2) Filter chamber (3) Filter access doors (4) View windows (5) Temperature probe
(6) Product container (7) Spray gun ports (8) Sample port (9) Inlet air plenum
(10) product container cart (11) Support frame (12) Inspection light windows (97).

2. Spheronization of 1 kg batches
Several formulation (Table VA) and process (Table VB) variables resulting in the
development of eleven different batches were used to determine those parameters that
will yield spheroids with acceptable characteristics. These preliminary parameters are
shown in Table VI.
Ibuprofen (20 µm) and Avicel RC-581 or CL-611 were sieved through a size 16
(1,180 µm) mesh sieve. Weighed amounts (1:1) of the sieved ibuprofen and Avicel

89

Table VA. Formulation Variables

Variables
Avicel type

Batch size
1 kg

5 kg

10 kg

RC-581

RC-581

RC-581

Water

Water

Present

Present

Absent

Absent

Absent

Absent

CL-611
Binder

Water
HPMC

SLS (1%)

Present
Absent

Talc (3%)

Present
Absent

PEG (25%)

Present
Absent

Table VB. Process Variables

Variables

Stainless steel/Waffle plate

Batch size
1 kg

5 kg

10 kg

Used

Not used

Not used

Used

Used

Used

Used

Used

Used

Not used

Not used

Not used
Stainless steel/Smooth plate

Used
Not used

Teflon/Waffle plate

Used
Not used

500 rpm

Used
Not used

650 rpm

Used
Not used
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RC-581 or CL-611 were blended with and without 1% SLS, and spheronized in FLM-15
using water or HPMC solution as binders. The other formulation and process variables
are shown in Tables VA and VB. The inlet and exhaust flaps were kept open and a
frequency drive device was used to adjust the control of the air-flow. Fluidization of
powder blend was achieved by centrifugal, vertical and gravitational forces, as well as
heated air drawn through a gap around the rotor-disk and also by the nozzle
pressure (47,95).
The air volume and velocity of air can be adjusted with the gap-adjustment ring
below the disk. This aids in air distribution while the rotor-disk is spinning in a
clockwise direction. The fine powders lifted up by the fluidization air are restricted by
polyester air filters (in the upper part of the equipment chamber) that are intermittently
cleaned or cleared by a pulsating jet of air, enabling them to be returned to the batch (98).
Spheronization end point was visually assessed, based on experience and the fluidization
pattern that has been observed to correspond to moisture content of 50 - 52%.
Drying was performed at gradual inlet temperature increases of 10 °C every 5 min
up to 60 °C. This staged drying was done to prevent case hardening of the spheroids. The
end point for drying was achieved when the product temperature reached 50 °C. The
moisture content at the end of spheronization and drying periods were measured to
determine loss on drying (LOD; 139) using the moisture balance at 85 °C and the result
was recorded when the value became constant. The 85 °C was chosen to achieve optimal
moisture loss with the product remaining intact.

91

Table VI. Variables Involved in the Preliminary Trial Batches
Trials
Variables

1

2

Standard No

3

4

Avicel® Smooth

SLS CL-611 disk

*Standard formulation
1 % SLS: surfactant and wetting agent
Avicel® RC-581: filler, binder
Plate material type: stainless steel
Plate contour: waffle
500/SS: rotational speed/stainless steel
Water: granulating liquid
PEG: Polyethylene glycol.

5
650/SS

6

7

8

9

HPMC 500/tef 650/tef 650/SS

Smooth (5%)

Waffle Waffle Waffle

disk

disk

disk

disk

10

11

PEG

Talc

(25%)

(3%)
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Consequent to data analyses of the eleven spheronized batches and the resultant
product characteristics (yield, particle size, size distribution, sphericity, etc.), eight of
these 1 kg batches were replicated twice and analyzed further (Table VI, trials 1-8). Two
of the replicated formulations (trials 4 and 7) were used to make two batches each of 5
kg, 10 kg pilot scale-up trials (trials 12 - 15).

3. Spheronization of Pilot scale batches (5 kg and 10 kg batches)
Scale-up was based on geometric similarity using the plate radius (R) and
centrifugal force (Fc) as similarity factors, as shown in equations 5 and 6 for rotational
speed (V) and centrifugal force (Fc) respectively. These equations are modifications of
the Froude’s number equation as reported by Horsthuis, et al. (137).
V=

Fc * R
W

Eqn. 5

Fc =

W *V 2
R

Eqn. 6

Using known values of weight (1 kg), rotational speed (500 rpm) and plate radius
(6"), the centrifugal force was calculated to be 41,667 Newtons. Using this value, the
rotational (rotor) speeds during spheronization phase for 5 kg and 10 kg batches were
calculated from equation 6 to be 300 and 200 rpm respectively (Table IV). The Froude’s
numbers for 1 kg, 5 kg and 10 kg batches were of 72.00, 41.04 and 18.24 respectively.
For drying of the scale-up batches, a reduced rotor speed was used. The two plate
types and contours used for these two batches are shown in Figure 19. The principle of
geometric similarity was also applied to other process variables using the results of the
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1 kg batches as well, and also using the air volume indicator present on the equipment
(101). The air volume that gave the desirable fluidization for the scale-up batches was
obtained visually by tuning the frequency drive of the exhaust blower in order to balance
the air volume and velocity. This correlated with an increased air volume of 10 cfm for
each additional kilogram powder (Table IV). The spray rate multiplier for the scale-up
batches was determined as the ratio of the two air volumes needed for fluidization of both
batches, and was calculated from known values using Equation 4.
B2 =

A2 * B1
A1

Eqn. 4

A

B

Figure 19. Rotor-disk plates for fluid-bed machines, stainless steel/smooth (A);
teflon/waffle (B) (97).
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b. Physical Characteristics of Developed Microparticulates
Acceptance criteria were set for the physical qualities of the spheroids based on
literature (6,9) and FDA guidance for immediate release dosage forms (147). These
included high product yield: ≥ 85%, adequate sphericity: ≥ 0.85, high drug content:
≥ 90%, good dissolution profile: Q20 ≥ 80JRRGIORZDELOLW\ ≤ 30o, granule size
distribution in the range between 250 and 850 µm [(20/60 mesh) chosen as our usable
fraction]: ≥ 85 % of the total product. This tight fraction was chosen to achieve
homogenous surface area, in order to account better for any differences in drug
dissolution profiles.

1. Yield of microparticulates
The yield of the granules was taken as a percentage of the ratio of the total output
obtained from batch processing and the initial weight of the powder blend (1 kg).

2. Particle size distribution
The particle size of ibuprofen was determined using an image analyzer
(Quantimet 500, Leica, USA) interfaced with a microscope (Reichert, Bordersen
Instrument Co., Inc., Valenca). This is based on transfer of a two-dimensional image of
the representative pellet sample to a video screen and computation of the area and
equivalent circle diameter (µm) of the individual particles (78). The ibuprofen powder
was dispersed in water by gentle vortexing for adequate dispersion and accurate analysis.
The computed equivalent circle diameter represents the particle size of the mounted
sample. An average of 30 particles was taken.
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Microparticulate size distribution was determined using conventional sieve
analysis performed once per replicate batches of each formulation. Spheroids weighing
100 g were placed on the uppermost of nested sieve with mesh sizes 16, 20, 40, 60, 80,
and corresponding to mean pore sizes of 1,180, 850, 425, 250, 180 µm, respectively. The
sieve-nest was vibrated in a shaker for 5 min and the weight of each sieve was measured
before and after, to calculate the weight of granules retained on each sieve. The frequency
is the percentage of granules obtained in the different sieves to the total weight (100 g) of
the particles used for the analysis. Using the frequency data, the log-normal distribution
on a probability scale was plotted and the geometric mean diameter dg, and the geometric
standard deviation δg were calculated. The results reported are the means of two replicate
batches and their corresponding geometric standard deviations (Tables XXA and B).
The usable fraction (UF) is the percentage of the total fraction of spheroids
obtained from the 20 - 60 (granules with size ranges between 250 and 850 µm) mesh
sizes and the initial weight used for particle size analysis (100 g).

3. Density of the granules
7UXHGHQVLW\

ZDVGHWHUPLQHGIURPWKHVDPSOHPDVVDQGYROXPHXVLQJD

Quantachrome multipychnometer® (Vincentown, NJ). The system and samples of known
weight were purged of contaminated gas, moisture and vapor for a minimum of 20 min by
placing the latter in the instrument using helium gas. Sample volume (Vs) was calculated
from cell and reference volumes (Vc and Vr respectively) obtained by calibration of a
reference spherical material, using the manufacturer’ s protocols which includes
Equation 16:
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Vs = Vc − Vr [(

P1
P2

) − 1]

Eqn.16

where P1 and P2 are the pressures obtained from the reference and cell volumes
respectively.

4. Drug content and HPLC assays
i. Sample preparation
Standards were prepared in triplicates using a concentration range between 2.5
and 300 µg/ml of methanol. The determination of ibuprofen in the granules was
conducted by extracting the drug twice from known sample weight of the product using
3 ml methanol.

ii. HPLC assay
Fifty microlitre of standards was directly injected into the HPLC (Shimadzu
Scientific Instruments, Inc., Columbia, MD), consisting of C18 reverse phase column (100
x 4.6 mm, 5 µm, Phenomenex, MD). The HPLC method (238) is a modification of Tsao
and Savage (239), in which the mobile phase consisted of acetonitrile:water:glacial acetic
acid:triethylamine (600:400:1:0.2). The mobile phase was vacuum filtered and degassed
simultaneously using a Branson 3200 ultrasonicator (Branson cleaning equipment, CT).
Ibuprofen was monitored by UV detector at 265 nm wavelength, and the results were
reported as the means of data from nine replicates of standards analyzed on three different
days. A calibration curve was set up and the method was validated for both accuracy and
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inter-day reproducibility, namely, coefficient of variation, using Equations 17 and 18. The
regression equation was linear with a correlation coefficient (R2) of 0.9996.
% Accuracy =

Measured concentration
x 100
Expected concentration

% Interdaycoefficient of variation (CV) =

Standard deviation
x 100
Mean concentration

Eqn.17

Eqn. 18

The samples were also analyzed as stated for the standards, however, known
concentrations of ibuprofen standard were injected separately and analyzed
simultaneously with them. The results were reported as the means of data from six
replicates obtained from two different batches.

5. Dissolution
The dissolution of the produced microparticulates was carried out using the USP
apparatus I at a rotation speed of 100 rpm. Known amount of sample was weighed into
3x2-cm diameter stainless steel minibaskets with 40-mesh screens that held each sample
in the six flasks. Simulated intestinal fluid (USP) containing 0.02% Tween 80 (enzyme
grade) at pH 7.4 ± 0.05 was used as the dissolution medium with a temperature of 37 ±
0.1 °C. One milliliter sample was collected at specific intervals and filtered immediately
using a 5 micron hydrophilic nylon filter membrane (B. Braun Medical Inc., PA, USA).
The removed volume was not replaced in the dissolution vessel, but was factored into the
calculation during the data analysis. Fifty microlitres of the samples and known standard
concentrations were analyzed by HPLC with ibuprofen concentration monitored by UV
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detector at 265 nm, as already stated. The results were reported as the means of data of
9 - 12 dissolution vessels from replicate batches.

6. Flowability
7KHDQJOHRIUHSRVH

DQG&DUU VFRPSUHVVLELOLW\LQGH[ 40) were used to

GHWHUPLQHWKHIORZDELOLW\RIWKHVSKHURLGV9DOXHVRI OHVVWKDQo as well as values of
Carr’s index below 15% were considered good product flowability.

i. Angle of repose
Weighed amount of granules was gently poured into an 8 oz funnel that was
mounted on a stand and with the orifice covered. The covered end was gently opened so
that the granules flowed freely on a dark surface. The diameter and height of the granules
were measured and the angle of repose calculated using the following Equation:
−1
θ = (H
R ) tan

Eqn.19

where H and R are the height and radius respectively formed by the granules. The results
reported are the means of six replicates of two batches.

ii. Carr’s index determination
The bulk and tap densities of the pellets were determined with Vanderkamp Tap
density tester (Van-Kel Industries Inc., NJ). The Carr’ s compressibility index was
calculated using the following Equation:
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%C =

DT − DB
DT * 100

Eqn. 20

where C is the compressibility index while DT and DB are tap and bulk densities
respectively.

7. Granule friability test
The friability tester of tablets was used to test the resistance of the pellets to
abrasion. Size fraction of 250-850 µm placed in the Roche friabilator was subjected to a
falling shock for 15 min at 30 rpm, sieved for 10 min and the weight loss was recorded.

8. Sphericity and roundness of granules
Sphericity and roundness were determined using a Quantimet image analyzer 500
interfaced with a microscope in which the roundness, perimeter (Pm) and the particle
projected area (A) were measured (78). These were used to calculate sphericity (S), a
reciprocal of the roundness factor, as shown in the equation 21 below (241):

S = 4 A∗3.142
Pm2

Eqn. 21

A perfectly spherical particle will have a value of 1.0 while non-spherical particle will
have a value of 0.1.
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9. Scanning electron microscopy (SEM)
The samples were placed on a sample stub containing double-sided transparent
adhesive tapes. They were then coated under reduced pressure (~0.8 mbar) with gold for
2 min using a Cressington Sputter Coater 108 (Franklin Electric, Bluffton, IN) and
observed under a scanning electron microscope (Hitachi S510, Tokyo, Japan) at 10 kV.

c. Statistical analysis
The influence of the independent variables on the pellet characteristics was
analyzed by standard deviation and relative standard deviation, while the yield variable
was also analyzed by one-way ANOVA and student’s t-test techniques using the JMP IN
version 3.2 statistical software.

Phase 2
Optimization of the Developed Process and Product Variables Using Statistically
Designed Factorial Experiment.

a. Experimental Design
The results of the feasibility studies showed that two formulation (binder and
surfactant levels) and one process (plate type-contour) variables were critical to the
quality of the spheroids prepared in the rotor-disk fluid-bed equipment (47). Based on
these results, a 2x2x3 full factorial design was generated using a JMP IN based software
and consisting of two binder levels (X1), two surfactant levels (X2), and a three level
plate type (X3) in which two-two level factors were collapsed into a single three level
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factor. An additional blocking effect was studied in which every experiment in each
block was randomly replicated, to access the effect of batch replication on the chosen
product qualities and on the main factors. This increased the statistical power of our
design in that the experimental runs were increased from twelve to 24 and the
randomization ensured that each of the experiments had one over twelve (within each
block) chances of being run at any given time. This design allows the estimation of
statistical significance of the effect and interactions of the three product and process
variables (X1 - X3) on several spheroid qualities in the generated experimental runs. The
experimental design matrix is shown in Table VII, and the different levels of the three
factors shown in Table VIII. In Table VII, the levels for each of the formulation
parameters are represented by a (-) sign for the low and a (+) sign for the high levels.
In the matrix of the factorial design shown in Table VII, each line identifies the
experimental condition for each batch (X1 - X3), and each experiment gives a result (Y).
From these, and applying factorial design mathematical model, one obtains a general
linear analysis (242,243):
Yijkl = µ + ai + b j + ab ij+ ck + ac ik+ bcjk + dl + ad il+ bd jl + cd kl+ eijkl

Eqn. 22

where Yijkl is the response variable, µ is the mean value, ai, bj, ck and dl are the main effect
coefficients (binder level, surfactant level, plate type and block respectively), while abij,
acik, bcjk, adil, bdjl, and cdkl are the second level coefficient of interactions, and eijkl the
error value.
Previous studies have shown that higher order interactions are generally not likely
to exist, and also are uninterpretable even when they are significant (112,244).
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Table VII: Experimental Design Matrix for Optimization Studies

X 1
- 1
- 1
1
1
- 1
1
- 1
1
- 1
1
1
- 1

B lo c k 1
X 2
1
-1
1
-1
1
1
-1
-1
1
1
-1
-1

X 3
-1
0
0
1
0
-1
1
-1
1
1
0
-1

X 1
- 1
- 1
1
- 1
1
1
- 1
- 1
- 1
1
1
1

B lo c k 2
X 2
-1
1
1
-1
-1
-1
1
1
-1
-1
1
1

X 3
0
-1
-1
1
0
1
0
1
-1
-1
0
1

X1: Binder level; High (1), Low (-1)
X2: Surfactant level; High (1), Low (-1)
X3: Plate type; Stainless steel waffle (-1), Stainless steel smooth (0), Teflon waffle (1)

Consequently, interactions of three or more factors were confounded with
two-factor interactions and were assumed to be insignificant for the purposes of this
design. Moreover, because blocking (dl) had no statistically significant effect on eleven
out of the twelve response variables (Y), and consequently yielded statistically
insignificant interactions with the main effects [(ai, bj, ck) results not shown] their
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Table VIII: Experimental Design for Optimization Studies
Runs

Batch name*

Binder level

Surfactant level

Plate type

1

Formulation 1a

1200

20

SS-Waf

2

Formulation 2a

1200

10

SS-Sm

3

Formulation 3a

1350

20

SS-Sm

4

Formulation 4a

1350

10

Tef-Waf

5

Formulation 5a

1200

20

SS-Sm

6

Formulation 6a

1350

20

SS-Waf

7

Formulation 7a

1200

10

Tef-Waf

8

Formulation 8a

1350

10

SS-Waf

9

Formulation 9a

1200

20

Tef-Waf

10

Formulation 10a

1350

20

Tef-Waf

11

Formulation 11a

1350

10

SS-Sm

12

Formulation 12a

1200

10

SS-Waf

13

Formulation 2b

1200

10

SS-Sm

14

Formulation 1b

1200

20

SS-Waf

15

Formulation 6b

1350

20

SS-Waf

16

Formulation 7b

1200

10

Tef-Waf

17

Formulation 11b

1350

10

SS-Sm

18

Formulation 4b

1350

10

Tef-Waf

19

Formulation 5b

1200

20

SS-Sm

20

Formulation 9b

1200

20

Tef-Waf

21

Formulation 12b

1200

10

SS-Waf

22

Formulation 8b

1350

10

SS-Waf

23

Formulation 3b

1350

20

SS-Sm

24

Formulation 10b

1350

20

Tef-Waf

*: The "a" and corresponding "b" of each number are random replicates of the same
formulation and give the mean of the dependent variables presented in Table XX below.
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interaction factors (adil, bdjl, and cdkl) were eliminated while their degrees of freedom
were added to that of the error factor, thereby increasing the statistical power of the
design. The new linear equation is represented in Equation 23:
Yijkl = µ + ai + b j + abij + c k + ac ik + bc jk + d l + eijkl

Eqn. 23

b. Blending and spheronization
This was performed as already described above (pp 88 - 92) and also in our
published report (47), except that both 1 and 2% SLS were used, and spheronization was
performed using fixed amount (120 or 135% of the starting material) of water as binder
solution (Table VIII). Drying was performed till 50 °C product temperature was reached
and moisture content was used as a measure for loss on drying (LOD). The granulation
end-point was obtained at the set binder content values (Table VIII).

c. Physical characterization of spheroids
These were performed as already described in the feasibility studies. The yield of
the granules was taken as a percentage of the ratio of the final weight obtained after the
production processes and the initial weight of the powder blend. Microparticulate size
distribution was determined using conventional sieve analysis and the geometric mean
diameter and geometric standard deviations calculated. Usable products were considered
as granules with size ranges between 250 and 850 µm (20/60 mesh size), and were used
in the different analyses to obtain the response variables (Y). The drug content and the
dissolution assays were analyzed using the HPLC reversed phase column and ibuprofen
was monitored by UV detector at 265 nm wavelength. However, the samples were
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filtered using 0.45 micron hydrophilic wolven nylon filter membrane (B. Braun Medical
Inc., PA, USA). The sphericity and roundness of the spheroids were determined using an
image analyzer (Quantimet 500, Leica, USA) interfaced with a microscope (Reichert,
Bordersen Instrument Co., Inc., Valenca). Spheroid friability, flowability, Carr’s index,
tap and bulk densities were performed exactly as described earlier.

Scanning electron microscopy (SEM)
The samples were placed on a sample stub with double-sided carbon tapes,
evacuated, back-filled with argon under reduced pressure (0.1 torr). They were then
coated with palladium using a Hummer Sputtering System LO.2, (ANATECH Ltd.,
Alexandria, VA), and observed under a scanning electron microscope (Philips XL 30
FEG CDUTM LEAPTM, Holland, Nederlands) at 1 kV.

d. Statistical analysis
The influence of the independent variables on the characteristics of microparticulates was
analyzed by the ANOVA method using the JMP software. Pareto charts were used to
show the scaled estimates of the effects of the studied product and process variables on
the physical characteristics of spheroids (245). The effect of a factor or an interaction is
considered significant as long as it is superior to the experimental error (246,247).
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Phase 3
Drug Loading, Particle Size Effects. Scale-up to Intermediate Scale Using the
Fluid-bed Rotor-disk Technology

The results from the optimization studies indicated that higher binder content
caused higher yield of the spheroids while stainless steel smooth plate gave more
consistent product quality especially with respect to yield, drug content, sphericity and
usable fraction. Additionally, higher binder content in combination with the lower
surfactant level yielded more acceptable spheroid characteristics as specified in the set
acceptance criteria (page 94). The formulation consisting of high binder level, low
surfactant level (1%), and made with stainless steel smooth plate was therefore chosen for
the studies in this section.

a. Effects of drug particle size and drug loading on the characteristics of ibuprofen
microparticulates

1. Experimental design
Drug particle size and drug load have been shown as among the limitations of the
rotor-disk fluid-bed technology (15,154). In order to investigate these observations, a 2x3
full factorial design was generated using a JMP IN based software and consisting of two
drug particle sizes (X1) and three drug loads (X2). The experimental runs were replicated
to access the effect of batch replication on the chosen product qualities and on the main
factors. The replication also increased the statistical power of our design by increasing the
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experimental runs from six to twelve. Additionally, this design allows the estimation of
statistical significance of the effect and interactions of the two product variables (X1 and
X2) on several spheroid qualities in the generated experimental runs. The experimental
design matrix is shown in Table IX, and the different levels of the two factors shown in
Table X. In Table IX, the levels for each of the formulation parameters are represented by
a (-) sign for the low, and a (+) sign for the high levels.

Table IX: Experimental Design Matrix for Drug Particle Size and Drug Load
Effects on Spheroid Characteristics
Number of runs

Replication

X1

X2

1

-1

-1

-1

2

1

-1

-1

3

-1

-1

0

4

1

-1

0

5

-1

-1

1

6

1

-1

1

7

-1

1

-1

8

1

1

-1

9

-1

1

0

10

1

1

0

11

-1

1

1

12

1

1

1

X1: Drug particle size (µm); 20 (-1), 40 (1)
X2: % drug load; 50 (-1), 65 (0), 80 (1)
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In the matrix of the factorial plan represented in Table IX, each line identifies the
experimental condition for each batch of the factors (X1 and X2), and each experiment
gives a result (Y) that will be applied to a general linear model based on the algorithm of
Yates, as shown in equation 24:
Yijk = µ + ai + b j + ab ij+ ck + ac ik+ bcjk + eijk

Eqn. 24

where Yijk is the response variable, µ is the mean value, ai and bj are the main effect
coefficients (drug particle size and drug load) respectively, while ck is the replication

Table X: Experimental Design for Drug Particle Size and Drug Load Effects
on Spheroid Characteristics
Number of runs

Batch name

Drug Particle Size (µm)

% Drug Load

1

Ibu 20-50a

20

50

2

Ibu 20-50b

20

50

3

Ibu 20-65a

20

65

4

Ibu 20-65b

20

65

5

Ibu 20-80a

20

80

6

Ibu 20-80b

20

80

7

Ibu 40-50a

40

50

8

Ibu 40-50b

40

50

9

Ibu 40-65a

40

65

10

Ibu 40-65b

40

65

11

Ibu 40-80a

40

80

12

Ibu 40-80b

40

80

*: The "a" and corresponding "b" of each number are replicates of the same formulation
and give the mean of the dependent variables presented in Table XXV below.
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effect. The parameters abij, acik, and bcjk are the second level coefficient of interactions,
and eijk is the error value.
As already mentioned, previous studies have shown that higher order interactions
are generally not likely to exist, and also are uninterpretable even when they are
significant (93,244). Consequently, interactions of three or more factors were confounded
with two-factor interactions and were assumed to be insignificant for the purposes of this
design. Moreover, because replication (ck) had no significant effect on ten out of the
twelve response variables, and also yielded statistically insignificant interactions with the
main effects (ai, bj), their interaction factors (acik and bcjk) were eliminated while their
degrees of freedom were added to that of the error factor, thereby increasing the statistical
power of the design. The new linear equation is represented in Equation 25:
Yijk = µ + ai + b j + ab ij+ ck + eijk

Eqn. 25

2. Blending and spheronization
This was performed as already described in the feasibility studies (pp 88 - 92) and
also in our published report (47). Spheronization end point was visually assessed, based
on experience and the fluidization pattern that gave the most acceptable product qualities.
This has been observed to correspond to moisture content of 50 - 55% for the
drug:Avicel® 50:50 ratios, 45 – 48% for the 65:35 ratios, and 37 – 41% for the 80:20%
ratios, for both drug particle sizes (Table XI). These amounts of water did not yield much
oversized spheroids, and were recorded with regard to both the drug particle size and
thedrug load. Drying was performed as previously reported, with the end point achieved
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Table XI. Binder and Time Conditions During Spheronization and Drying Processes

20 micron ibuprofen
65

40 micron ibuprofen

% ibuprofen

50

80

50

65

80

Binder added during

1.525 ± 0.04 1.265 ± 0.08 1.085 ± 0.16 1.394 ± 0.02 1.189 ± 0.02

0.910 ± 0.03

67.5 ± 0.95

53.1 ± 0.41

spheronization (kg)
Total time [(spheronization

54.5 ± 2.12

46.5 ± 2.12

75.0 ± 1.14

66.0 ± 2.83

and drying) mins]
Moisture content at end of
spheronization

50.69 ± 0.27 45.21 ± 0.02 37.27 ± 1.05 55.81 ± 0.56 48.45 ± 0.47

41.44 ± 0.07
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when the product temperature reached 50 °C. The plate gap was adjusted from 0.8 –
1.0 cm and the air volume from 85 - 90 cfm, to ensure proper fluidization of the pellets.

3. Physical characterization of spheroids
These were performed as already described in the feasibility studies (pp 94 - 99).
The yield of the granules was taken as a percentage of the ratio of the final weight
obtained after the production processes and the initial weight of the powder blend. The
moisture content was measured as a function of time for all the batches, and the values at
the end of spheronization process are shown in Table XI and Figure 36. Microparticulate
size distribution was determined using conventional sieve analysis. Usable products were
considered as granules with size ranges between 250 and 850 µm (20/60 mesh size), and
were used in the different analyses to obtain the response variables. The drug content and
the dissolution assays were analyzed using the HPLC reversed phase column with
ibuprofen monitored by UV detector at 265 nm wavelength. The samples were filtered
through 0.45 micron hydrophilic wolven nylon filter membrane (B. Braun Medical Inc.,
PA, USA). The sphericity and roundness of the spheroids were determined using an
image analyzer (Quantimet 500, Leica, USA) interfaced with a microscope (Reichert,
Bordersen Instrument Co., Inc., Valenca). Spheroid friability, flowability, Carr'
s index,
tapped and bulk densities were performed exactly as already described. The scanning
electron microscope analysis for studying the morphology of the spheroids was performed
exactly as described in phase 2 (page 105).
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4. Statistical analysis
The influence of the independent variables on the characteristics of
microparticulates was analyzed by the ANOVA method using the JMP software. Pareto
and interaction plots were also used as described earlier (245).

b. Effects of Intermediate Size Scale-up on the Characteristics of Ibuprofen
Microparticulates
Results from the drug load and drug particle size effects showed that the three
drug loads were spheronizable, however, drug loads of 50% and 65% had similar
characteristics and significantly affected most of the physical characteristics studied. As
was previously observed (157), the 80% drug load was more difficult to spheronize and
also had high standard deviations between most of the obtained replicate values, and was
therefore difficult to replicate. Additionally, drug particle size of 20 µm had the most
significant effects on the spheroid qualities studied. Therefore, 50% and 65% drug loads
as well as 20 µm sized ibuprofen were used for further studies.

1. Experimental design
In order to study the scalability of the optimized product and process variables to
semi-production size, a 2x2 full factorial design was generated using a JMP IN based
software and consisting of two batch sizes (X1) and two drug loads (X2). The
experimental runs were replicated for the reasons already mentioned in the previous
experiments. The experimental design matrix is shown in Table XII and the different
levels of the two factors are shown in Table XIII. The general linear model and the
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model deduced to increase the statistical power of the experiments are as shown in
Equations 26 and 27 respectively. However, ai and bj are the main effect coefficients
(batch size and drug load) respectively.
Yijk = µ + ai + b j + ab ij+ ck + ac ik+ bcjk + eijk

Eqn. 26

Yijk = µ + ai + b j + ab ij+ ck + eijk

Eqn. 27

Table XII: Experimental Design Matrix for Intermediate Size Scale-up Effect on the
Characteristics of Ibuprofen Microparticulates

Number of runs

Replication

X1

X2

1

-1

-1

-1

2

1

-1

-1

3

-1

-1

1

4

1

-1

1

5

-1

1

-1

6

1

1

-1

7

-1

1

1

8

1

1

1

X1: Batch size (kg); 1 (-1), 50 (1)
X2: Drug load (%); 50 (-1), 65 (1)
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Table XIII: Experimental Design for Intermediate Size Scale-up Effect on the
Characteristics of Ibuprofen Microparticulates
Number of runs

Formulation name

Batch Size

% Drug Load

1

1kg-50%-a

1

50

2

1kg-50%-b

1

50

3

1kg-65%-a

1

65

4

1kg-65%-b

1

65

5

50kg-50%-a

50

50

6

50kg-50%-b

50

50

7

50kg-65%-a

50

65

8

50kg-65%-b

50

65

*: The "a" and corresponding "b" of each number are replicates of the same formulation
and give the means of the dependent variables presented in Table XXVII below.

2. Blending and spheronization
This was performed as already described in the feasibility studies (pp 92 and 93)
and also in our published report (47). The FLM-15 was used for the 1 kg batches, while a
FLN-120 having the same geometric similarities was used for the 50 kg batches. The
specifications of both equipment are shown in Figures 18 and 20 respectively. For the
large-scale equipment and process, the principles of dynamic geometric similarity as well
as trial and error (137,138) were applied to obtain fluidization air volume that efficiently
fluidized the powder bed throughout the wetting and drying periods (Equations 4 – 6;
102). The obtained spheronization conditions, compared to those used for the pilot
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Figure 20. Components of the Vector FLN-120 fluid-bed machine with the numbers
corresponding with the same equipment parts as were specified in Figure 18 (97).

scale batches are shown in Table XIV. The range of the rotor speed used during the
spheronization period corresponded to Froude’s numbers of 6.02 -17.28. Spheronization
end point was also determined as previously reported, based on experience and acceptable
fluidization pattern, and the results are shown in Table XV. Drying was performed as
previously reported, with the end point achieved when the product temperature
reached 50 °C.
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Table XIV: Spheronization Conditions of Scale-up Batches

Parameters
Batch size

1 kg

5 kg

10 kg

50 kg

Plate size

12"

19"

19"

39.5"

41,667

41,667

41,667

41,667

Centrifugal force (N)
Plate material type/contour

SS/smooth SS/smooth SS/smooth SS/smooth
Teflon/waf. Teflon/waf. Teflon/waf.

NA

Spraying
Air volume (cfm) A1 and A2

50

90

140

500-1500

Plate gap (mm)

0.8

3.5

6

NA

Spray rate (g/min) B1 and B2

50

90

140

470 - 500

Rotor speed (rpm)

500

300

200

130 - 135

o

25 - 30

25 - 30

25 - 30

25 - 30

o

18 - 22

18 - 22

18 - 22

18 - 22

Atomization air pressure (psi)

45

45

45

45

Air volume (cfm)

85

145

220

1100 - 1300

Plate gap (mm)

1.3

5

8

NA

Rotor speed (rpm)

150

124

124

75

Inlet air temperature ( C)
Product temperature ( C)
Drying
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Table XV. Binder and Time Conditions for Spheronization and Drying Processes of
Intermediate Size Scale-up Ibuprofen Microparticulates

Batch sizes

1 kg

50 kg

% ibuprofen
Binder added during
spheronization (kg)

50
1.525

65
1.265

50
55.22

65
53.00

± 0.04

± 0.08

± 1.11

± 1.41

Total time [(spheronization
and drying) mins]

67.50

54.50

246.50

198.00

± 0.95

± 2.12

± 5.66

± 2.83

Moisture content at end of
spheronization

50.69

45.21

47.55

40.59

± .0.27

± 0.02

± 1.74

± 0.01

3. Physical characterization of spheroids
These were performed as already described in the feasibility studies (pp 94 - 99).
The yield of the granules was taken as a percentage of the ratio of the final weight
obtained after the production processes and the initial weight of the powder blend.
Microparticulate size distribution was determined using conventional sieve analysis.
Usable products were considered as granules with size ranges between 250 and 850 µm
(20/60 mesh size), and were used in the different analyses to obtain the response variables
(Y). The drug content and the dissolution assays were analyzed using the HPLC reversed
phase column with ibuprofen monitored by UV detector at 265 nm wavelength. The
samples were filtered using 0.45 micron hydrophilic wolven nylon filter membrane (B.
Braun Medical Inc., PA, USA). The sphericity and roundness of the spheroids were
determined using an image analyzer (Quantimet 500, Leica, USA) interfaced with a
microscope (Reichert, Bordersen Instrument Co., Inc., Valenca). Spheroid friability,

118

flowability, Carr’s index, tapped and bulk densities were performed exactly as already
described. The scanning electron microscope analysis for studying the morphology of the
spheroids was also performed exactly as described in phase 2 (page 105).

4. Statistical analysis
The influence of the independent variables on the characteristics of
microparticulates was analyzed by the ANOVA method using the JMP software. Pareto
and interaction plots were also used as described earlier (245).

Phase 4
Coating and Encapsulation of Spheronized Ibuprofen Microparticulates Using
Hard Gelatin Capsules

The results of the scale-up experiments showed that replication did not affect the
physical characteristics of both spheroid batch sizes and that both the drug loads used and
the rotor-disk spheronization process are scalable. Therefore, 1 kg batch size with 65%
drug load (Table XIII, Runs #7 and 8) were pulled and used to study the effect of polymer
film coating and hard gelatin encapsulation on the qualities of the spheroids.

a. Polymer Film Coating of Spheroids
1. Preliminary studies using Glatt fluid-bed
To investigate the feasibility of coating the spheroids, the Glatt fluid-bed (Glatt
WSG-5 Wurster column/Fluid-bed) was first used to coat 6 x 1 kg batches using three
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coating levels each of Surelease (5, 10 and 15%) and Eudragit (8, 14 and 20%)
polymers. The fluid-bed conditions used were almost the same for both polymers and are
as follows: inlet air temperature (26 oC), outlet air temperature (24 - 28 oC), air of
operation (2 mbar), air of atomization (2 - 4 mbar), flow rate (40 g/min). The batches
were pre-warmed for 10 min before applying the film coats. Moisture content was
analyzed before and after the pre-warming, after the polymer application and at the end of
the process. The products were analyzed for yield, usable fraction and drug release.
Based on the obtained results (not shown), the coating conditions and the rotor-disk
conditions from previous studies (47,199), the levels and conditions for our rotor-disk
fluid-bed coating were selected. These are shown in Tables IX (page 107) and XVI.

2. Experimental design for rotor-disk fluid-bed coating
A 2x3 full factorial experimental design was generated using the JMP software,
consisting of 2 levels of polymer film type (X1) and three coating levels (X2). The
polymer levels were chosen based on manufacturer’ s technical literature (of the
polymers). Consideration of the coating levels that would allow for rotor-disk processing
in the equipment was also made. The generated design was replicated to study the
reproducibility of the rotor-disk coating process and also to increase the statistical power
of the design. The experimental design matrix and the different levels of the two factors
are shown in Tables IX (where, in this case, X1 is the polymer type and X2 the coating
level; page 107) and XVI respectively. A stainless steel plate (12") was used with a batch
size of 700 g.
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Table XVI: Experimental Design for the Coating of Spheronized Ibuprofen
Microparticulates

Number of runs

Batch name

Polymer type

Polymer level (%

1

SR-7.5a

Surelease

Low (7.5)

2

SR-7.5b

Surelease®

Low (7.5)

3

SR-10a

Surelease®

Medium(10)

4

SR-10b

Surelease®

Medium(10)

5

SR-12.5a

Surelease®

High (12.5)

6

SR-12.5b

Surelease®

High (12.5)

7

EUD-12.5a

Eudragit® NE 30D

Low (12.5)

8

EUD-12.5b

Eudragit® NE 30D

Low (12.5)

9

EUD-14a

Eudragit® NE 30D

Medium(14)

10

EUD-14b

Eudragit® NE 30D

Medium(14)

11

EUD-15.5a

Eudragit® NE 30D

High (15.5)

12

EUD-15.5b

Eudragit® NE 30D

High (15.5)

*: The "a" and corresponding "b" of each number are replicates of the same formulation
and give the mean of the dependent variables presented in Table XXIX below.

3. Rotor-disk fluid-bed coating
i. Coating of spheroids with Surelease polymer
The Surelease product containing 25% dry polymer weight was mixed with
appropriate amount of distilled water to bring it to 15% total solids content (174). The
spheroids (700 g) were pre-warmed to ~ 30 oC product temperature. The coating
conditions and formulations are shown in Tables XVII and XVIII respectively. The
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Table XVII. Conditions and Process Parameters Used for the Coating of 700 g Ibuprofen Spheroids

Surelease
Coating level (%)

7.5

10

Eudragit NE 30D
12.5

12.5

14

15.5

Coating
Air volume (cfm)

60 - 85

Plate gap (mm)

1.0 – 1.5

Rotor speed (rpm)

200 -250

Inlet air temperature (oC)

40 - 50

Spray rate (g/min)

5.5 -7.5

5.5 -10.0

5.5 – 10.0

5.5 -7.5

5.5 -10.0

5.5 – 10.0

Air volume (cfm)

80 - 90

80 - 100

80 - 150

80 - 90

80 - 100

80 - 150

Drying

Plate gap (mm)

1.5

Rotor speed (rpm)

250
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Table XVIII. Formulation of the Aqueous Dispersions Used for the Coating of 700 g Ibuprofen Spheroids

Surelease

Polymer type
Coating level (%)

Eudragit NE 30D

7.5

10

12.5

Surelease polymeric solution (g)

210

280

350

Surelease polymer (solids; g)

52.5

70

87.5

Water ad (to dilute to 15% solids; g)

350

466.67

583.33

12.5

14

15.5

Formulation

NA

Eudragit polymeric solution

291.67

326.67

361.67

Eudragit polymer (solids; g)

87.5

98

108.5

17.5

19.6

21.7

420

470.4

520.8

Talc (20% of dry polymer; g)

NA

Water ad (to dilute to 25% solids; g)

Solid content (% w/w) of the
dispersion

15

25
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coating conditions were adjusted to ensure that spraying was performed continuously
during a greater period of the process. The product temperature was maintained between
35 and 40 oC. Spraying was intermittently interrupted to ensure proper fluidization of the
spheroids, avoid agglomeration and minimize attrition problems. The total amount of the
polymer shown in Table XVIII was used to obtain the theoretical percentage weight gain
required for each of the batches.

ii. Coating of spheroids with Eudragit NE 30 D polymer
A known weight of talc (20% w/w of the total dry polymer weight) was dissolved
in an appropriate amount of distilled water with constant stirring. The talc solution was
passed through a 60 mesh sieve (250 µm) to remove any undissolved particles. Eudragit
(30% w/w) was diluted in the talc solution to obtain 25% total solid content (Table
XVIII), which was constantly stirred. The spheroids (700 g) were pre-warmed to ~ 30 oC
product temperature in the rotor-disk fluid-bed. The coating conditions are as shown in
Table XVII, and were adjusted to ensure that spraying was performed continuously during
a considerable period of the process. The product temperature was maintained at 30 oC.
Although talc was added in the spraying solution to prevent agglomeration, spraying was
intermittently interrupted to ensure proper fluidization of the spheroids. The formulation
contents are as shown in Table XVIII.

4. Physical characterization of the coated spheroids
Particle size analysis was performed by the traditional sieve analysis method and
the usable fraction was calculated as has been previously described. The geometric mean
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and standard deviations were also calculated. The yield of the coated products was
calculated as a percentage of the product output and the total weight of the solid content
of the starting material [spheroids (700 g), talc, Surelease® and Eudragit®] as applied to
specific batches (Table XVIII). The true and bulk densities, flowability, friability,
scanning electron microscope were performed as already explained in the previous
sections. The compressibility index was also calculated. However, there was little to no
volume change after several taps of the spheroids. This conforms with the reports that the
bulk and not the tapped densities is used as a measure for calculating capsule fill weight
and size for pellets (227). It also supports the results that compressibility is not required
for pellet filling, thus the preference for tamp filling machine for these products over the
dosator machines. Drug content testing was performed as already described and the
weight of the polymer was accounted for in the calculations. Drug release studies were
also performed as already reported, however, the time taken for 50% (T50) of the drug to
be released was used to measure the coating efficiency and duration of release instead of
the Q20 used for the immediate release preparations (160,248).

i. Comparison of dissolution profiles
Model-independent methods (Equations 13 and 14 previously shown), difference
and similarity (f1 & f2) factors respectively, were used to compare dissolution profiles for

f1 =

{[ ∑ n Rt − Tt ]
t =1

[ ∑ n Rt ]}

* 100

Eq.13

t =1

1
2
f 2 = 50 log{[1 + ( )∑ n( Rt − Tt ) ] −0.5 * 100}
n t =1

Eqn.14
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similarity. An f1 value up to 15 (0 – 15) and an f2 value between 50 and 100 showed that
the two dissolution profiles were similar.

ii. Mathematical modeling of drug release
The drug release data from uncoated and coated pellets were analyzed with
square-root of time equation (Higuchi equation, Equation 7), Peppas equation (Equation
9), zero-order kinetic (Equation 12), and first-order kinetic (Equation 28). The data were
also fitted to a recently developed combined mechanistic release kinetics (zero-order and
square root of time Equation 15; 177). It was assumed that that release occurred as soon
as the matrix is placed in contact with fluid and thus predicts an intercept at the origin.
1

Q = kt 2
log ( Mt / M ) = log k + n log t

Q=
1

DKCs
t
L

Q = Kt 2 +

DKCs
t
L

ln (100 − Q ) = ln Q 0 - k 1 t

Where k1 is the first order release equation coefficient.

Eqn. 7
Eqn. 9

Eqn. 12

Eqn.15

Eqn. 28

126

5. Statistical analysis
The influence of the independent variables on the characteristics of
microparticulates was analyzed by the ANOVA method using the JMP software. Pareto
and interaction plots were also used as described earlier (245).

b. Hard Gelatin Encapsulation of Spheroids
1. Experimental design
From our statistical analyses and the physical characteristics (bulk density,
friability, flow properties and T50) of the coated spheroids, the two replicate batches
coated with 12.5% Surelease® level were pulled for hard gelatin encapsulation. A 2x2x3
full factorial experiment was designed consisting of two spheroid preparations, uncoated
and coated (X1), and using two machine variables, (namely, two levels of machine
operational speeds (X2) each operated at three different shuttle speeds (X3). Size 0 hard
gelatin capsules were used. A cross section of the pellet feeder assembly of the Index
K150i series (Figure 15) used for the pellet encapsulation is shown in Figure 21A, while
Table XIX shows the experimental matrix /design.
The shuttle gate controls the length of time the male and female gates could
remain open (Figures 21A & B). These gates regulate the amount of pellets that could be
filled into pellet feeder, which feeds the empty capsules. It is therefore expected that the
capsules filled at longer shuttle speed will contain higher amount of pellets since the gates
will be left open long enough for enough pellets to be collected into the feeder.
In the matrix of the factorial plan represented in Table XIX, each line identifies
the experimental condition for each batch of the factors (X1 – X3), and each experiment
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gives a result (Y) that will be applied to a general linear model based on the algorithm of
Yates, as shown in equation 29:
Yijk = µ + ai + b j + ab ij+ ck + ac ik+ bcjk + eijk

Eqn. 29

where Yijk is the response variable, µ is the mean value, while ai, bj and ck are the main
effect coefficients, type of formulation, operational speed and shuttle speed respectively.

A

B

Figure 21. Cross-section of pellet feeder assembly (A)
Inner feed plate assembly (B) (217)
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Table XIX Experimental Design Matrix for Encapsulation of Coated and
Uncoated Ibuprofen Microparticulates
Number of runs

X1

X2

X3

1

1

1

1

2

1

1

0

3

1

1

-1

4

1

-1

1

5

1

-1

0

6

1

-1

-1

7

-1

1

1

8

-1

1

0

9

-1

1

-1

10

-1

-1

1

11

-1

-1

0

12

-1

-1

-1

X1: Type of formulation; coated or uncoated; X2: Operational speeds; 1, 2;
X3: Shuttle speeds; 1 – 3

The parameters abij, acik, and bcjk are the second level coefficient of interactions,
and eijk is the error value. The experiments were not replicated due to limitations of
materials. Consequently, the interaction factors were eliminated from the analyses to
increase the statistical power of the error. The equation involving only the main effects
therefore becomes:
Yijk = µ + a i + b j + c k + eijk

Eqn. 30
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2. Pellet encapsulation
The theoretical pellet fill weight was calculated based on the drug content and
release, and also in Equation 31.

Density =

Weight
Volume

Eqn. 31

The “0” or “00” capsule sizes will be required to fill 430 or 600 mg respectively of our
coated pellets that will contain 300 - 400 mg ibuprofen drug/capsule. As stated on page
51, the equivalent total daily dose should generally be the same in switching a patient
from immediate release to prolonged release product, although in most cases, an effective
response has been achieved with a lower dose of the sustained release product (168). By
filling 300 - 400 mg/capsule, it would be easy to study the efficacy of the drug at different
doses. However, the available encapsulation machine did not have the capabilities
required for filling size 00 capsules. Consequently, the highest amount of the pellets that
could fill the “0” capsule size was used as our target weight. This enabled extrapolation
of results obtained to calculate the amount of pellets required to fill the “00” capsule size,
using the information provided in Figure 14.
The pellets were filled into size 0 hard gelatin capsules on a Romaco K-series
(Figure 15) automatic tamp filling (gravity filled) machine with a 15 mm dosing disk. The
operational speeds used were 75 and 85 rpm and the shuttle speeds were 260, 280 and
300 milliseconds. These variables were chosen based on the flowability of the pellets, as
well as conditions that will prevent pellet losses, considering the small batch size of the
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coated pellets (~ 1 kg). Approximately 200 capsules were collected from each run and
were stored in tight polyethylene bags for further studies.

3. Physical characterization
The determination of the geometric mean diameter, friability, flowability, bulk
and true densities of the pellets have been previously reported (pp 123 and 124).

i. Fill weight and coefficient of fill variation
The capsule fill weight and the coefficient of fill variation (CV) of 20 individual
capsules were determined. Filled capsules were weighed on Denver Instruments balance
and a set of 20 readings was used for calculating the average, standard deviation and
percentage of fill weight variation (%CV). The average weight of 20 empty gelatin
capsules was used as the blank weight.

ii. Dissolution test
Based on the results of the average fill weight, SD and %CV, the dissolution
studies of the formulations encapsulated at 75 rpm and 280, 300 msecs were performed
accordingly. Six randomly selected capsules were used to investigate the ability of the
capsule contents to be released. The drug release profiles were compared using difference
and similarity factors. The data were also fitted to Higuchi, Peppas, zero-order, firstorder, as well as the combined kinetics equations, as already described, in order to
determine the mechanisms of drug release from the formulations.
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4. Statistical analysis
The mathematical and statistical analyses were performed with Microsoft Excel
and JMP software packages, as already described. Studentized residuals test statistic was
used to check for patterns and outliers while Dubin-Watson test statistic was used to test
for possible correlations between the pairs of observations. The statistical significance
was set at p < 0.05.
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III. RESULTS AND DISCUSSIONS

Phase 1
Feasibility Studies in the Spheronization and Scale-up of Ibuprofen
Microparticulates

a. Drying time
The time it took for the product made with similar plates to reach 50oC increased
as percentage yield and batch size increased. For the batches made with stainless steel
smooth plates, the times were 29 – 40 minutes for the 1 kg batches and 36 – 79 minutes
for the scale-up batches. For teflon waffle plate batches, the drying times were 47 – 64
minutes for the 1 kg batches and 47 – 90 minutes for the scale-up batches. Not only are
these results in agreement with previous reports that drying efficiency decreases with
increased batch size (142,251), but, as mentioned earlier, the data also confirm that the
heat conductivity of the stainless steel disk added to the overall drying efficiency of the
process (125) while teflon had insulating effect (47). Moreover, it has been shown that at
any given time, the moisture content of the granules depends on wettability and
evaporation, which in turn are controlled by liquid flow rate and inlet temperatures
respectively (252). Equilibrium liquid flow rate has been defined as one at which liquid
supply is balanced by evaporation, and a critical liquid flow rate as one above which
fluidization is impossible due to cohesion in the bed (253). Though the liquid flow rate is
the same in both plate types used, the insulating nature of the teflon material could hinder
the attainment of equilibrium during processing, thereby affecting the balance between
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liquid supply and evaporation, which in turn might have adversely affected the drying
efficiency of these batches.

b. Physical Characteristics of Developed Microparticulates
The following physical characteristics apply to all the batch sizes, i.e., 1 kg, 5 kg
and 10 kg, unless stated otherwise.

1. Yield of spheroids
i. Yield of one kilogram batches
The replicated eight 1 kg batches produced using FLM-1 had yield values ranging
from 58.0% - 91.2%, however, most of the batches yielded granules varying from 74% 85% (Table XXA). This could be considered satisfactory since even with starting
materials that are “ ideal” in formulating spheres e.g. 100% Avicel®, the process output
was approximately 80% (249). As already stated, the spheroid batches having 50 - 52%
binder content at the end of the spheronization process had better product characteristics.
Trials 4 and 7 had desirable qualities that met our set acceptance criteria ( , and
were selected for further studies.

Effect of SLS and Talc:

The batches spheronized without SLS (trial 2) as

well as that containing SLS and talc (results not shown) had lower yield. The lower yield
from trial 2 could be due to the lack of SLS that affected wetting of the powders thereby
enhancing losses to the fluid-bed walls and filters. The low yield obtained form the batch
containing SLS and talc could be caused by a possible interaction between the SLS and

134

Table XXA. Physical Characteristics of 1 kg Batches (Means of replicated batches)
Parameters

Trials
1

2

3

4

5

*Standard

No

Avicel®CL-

Smooth disk 650/SS

SLS

611

6

7

8

HPMC

500/tef

650/tef

% Yield

73.75 ± 2.33

58.0 ± 4.24

71.45 ± 3.89 85.40 ± 6.65 70.10 ± 2.55 80.0 ± 10.32 91.2 ± 32.24 79.05 ± 1.34

% Moisture content

1.75 ± 0.35

6.56 ± 2.34

1.66 ± 0.91

% Drug content

93.46 ± 1.17

Geometric mean

2.71 ± 1.70

2.96 ± 2.20

2.1 ± 0.43

6.85 ± 2.34

8.1 ± 4.10

73.77 ± 3.32 91.69 ± 2.09 94.47 ± 0.65 94.30 ± 3.88 94.3 ± 8.48

91.44 ±1.64

99.95 ± 4.08

438 ± 1.57

577 ± 1.43

445 ± 1.59

455 ± 1.57

363 ± 1.95

403 ± 1.63

417 ± 1.80

415 ± 1.78

Sphericity

0.90 ± 0.00

0.92 ± 0.01

0.89 ± 0.01

0.88 ± 0.09

0.87 ± 0.04

0.84 ± 0.01

0.91 ± 0.00

0.90 ± 0.01

Flowability (deg)

21.45 ± 1.05

23.07 ± 0.14 22.09 ± 1.88 23.36 ± 0.75 25.31 ± 1.06 24.84 ± 0.00 22.49 ± 0.83 24.37 ± 0.40

Carr’ s index (%)

8.56 ± 0.76

6.61 ± 0.40

9.85 ± 0.21

8.92 ± 3.97

9.34 ± 0.05

11.82 ± 1.19 8.92 ± 0.53

10.14 ± 0.25

True density (g/cm3)

1.29 ± 0.00

1.30 ± 0.00

1.29 ± 0.00

1.30 ± 0.00

1.29 ± 0.01

1.28 ± 0.01

1.31 ± 0.01

1.28 ± 0.00

Bulk density (g/cm3)

0.67 ± 0.00

0.77 ± 0.02

0.69 ± 0.02

0.64 ± 0.08

0.67 ± 0.05

0.58 ± 0.01

0.66 ± 0.01

0.67 ± 0.00

Tap density (g/cm3)

0.73 ± 0.00

0.82 ± 0.01

0.76 ± 0.02

0.69 ± 0.06

0.74 ± 0.05

0.65 ± 0.00

0.73 ± 0.02

0.75 ± 0.00

Q20 (%)

86.74 ± 2.39

74.66 ± 2.92 87.47 ± 4.12 83.27 ± 5.02 90.42 ± 7.64 75.14 ± 1.85 91.75 ± 2.07 85.09 ± 1.71

Friability (%)

0.34 ± 0.47

0.67 ± 0.48

diameter (µm)

LOD: % loss on drying.
Highlighted batches were used for further studies

0.17 ± 0.24

1.5 ± 1.66

1.67 ± 1.41

1.17 ± 0.71

0.33 ± 0.71

1.84 ± 0.71
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Table XXB. Physical Characteristics of Scale-up Batches (Means of replicated batches)
Plate material/contour
Batch size
Trials
Plate size

Stainless steel/smooth plate

Teflon/Waffle plate

1 kg

5 kg

10 kg

1 kg

5 kg

10 kg

4

12

13

7

14

15

12”

19”

19”

12”

19”

19”

% Yield

85.40 ± 6.65

87.16 ± 7.13

83.97 ± 2.33

91.2 ± 32.24

96.35 ± 5.5

87.84 ± 11.7

% LOD

2.71 ± 1.70

1.85 ± 0.35

2.46 ± 0.64

6.85 ± 2.34

11.21 ± 7.62

10.65 ± 11.10

% Drug content

94.47 ± 0.65

99.2 ± 4.90

90.52 ± 4.71

91.44 ±1.64

98.23 ± 1.89

98.65 ± 4.37

Geometric mean diameter (µm)

455 ± 1.57

483 ± 1.61

545 ± 1.67

417 ± 1.80

553 ± 1.54

603 ± 1.79

Sphericity

0.88 ± 0.09

0.90 ± 0.01

0.90 ± 0.01

0.91 ± 0.00

0.89 ± 0.01

0.88 ± 0.02

Flowability (deg)

23.36 ± 0.75

19.54 ± 1.08

24.11 ± 5.39

22.49 ± 0.83

19.29 ± 0.73

25.17 ± 7.59

Carr'
s index. (%)

8.92 ± 3.97

6.71 ± 1.23

6.21 ± 4.3

8.92 ± 0.53

5.33 ± 0.19

7.84 ± 2.75

True density (g/cm3)

1.30 ± 0.00

1.28 ± 0.01

1.28 ± 0.02

1.31 ± 0.01

1.28 ± 0.01

1.27 ± 0.01

Bulk density (g/cm3)

0.64 ± 0.08

0.65 ± 0.03

0.64 ± 0.04

0.66 ± 0.01

0.67 ± 0.01

0.63 ± 0.00

Tap density (g/cm3)

0.69 ± 0.06

0.70 ± 0.03

0.68 ± 0.00

0.73 ± 0.02

0.71 ± 0.04

0.69 ± 0.00

Q20 (%)

83.27 ± 5.02

82.95 ± 12.66 85.53 ± 5.08

91.75 ± 2.10

79.47 ± 12.88 86.76 ± 13.00

Friability (%)

1.50 ± 1.66

1.50 ± 1.65

0.33 ± 0.71

1.00 ± 0.00

1.50 ± 1.17

4.00 ± 4.71
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talc, that also led to delayed wetting of the granules during processing, and consequently
resulted in the powder blend losses.

Binder effect: Use of HPMC as binder improved the yield compared to the
standard formulation (Table XXA, trial 6 vs.1), although it had higher standard deviation.

Rotor speed effect:

Lower disk speed (500 rpm) produced higher yields than

higher disk speed (650 rpm, Table XXA, trials 1 and 7 vs. 5 and 8 respectively). This
could be due to reduced centrifugal forces that minimized the collision of the spheres
with the walls of the rotor container as well as losses into the cartridges. This resulted in
more efficiently fluidization of the spheroids, as has been reported with the traditional
extrusion/spheronization method (250).

Rotor-disk plate material effect:

Higher yield was obtained from the teflon

waffle plate batches in comparison to those made with stainless steel waffle plate (trials 7
and 8 vs. 1 and 5 respectively). The yield was measured immediately after the process,
thus, any free or residual moisture that was not dried by the drying process formed part of
the product yield. As can be seen from Table XXA, the moisture content for the
formulations produced with the teflon plate ranged between 6.85 to 8.10% as compared
to 1.75 to 2.96% of the stainless steel plate batches. The higher moisture content for the
teflon plate could have contributed to increase in the yield value. The teflon disk tends to
insulate the bed from some of the drying medium thus retaining a higher moisture level,
and also resulting in higher yield. In contrast, the stainless steel disk allows for better
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conduction of heat and consequently better heat transfer and drying, resulting to reduced
moisture content that consequently led to reduced product yield, compared to the output
from batches made with the teflon plate.

ii. Yield of pilot scale-up batches
The two batches selected for scale-up (smooth stainless steel 500 rpm and waffle
teflon 500 rpm) are highlighted in Table XXA. The yield values were similar for 1, 5 and
10 kg for the batches made with stainless steel smooth plate 84% - 87% (Table XXB).
For the teflon plate, the values increased (88% -96%) compared to those of the stainless
steel plate, though with higher LOD values as mentioned earlier. However, student’s ttest and one way ANOVA of the teflon plate data did not give any statistical difference
between the yield results presented in Table XX (p < 0.05). Nevertheless, increased
fluidization air was used during the drying period to ensure that the LOD values of all
future batches would be ≤ 5% at the drying end point. There was statistically no
difference in the LOD values of 10 kg and 5 kg or 1 kg batches made with the
teflon plate.

Generally, the batch size did not affect the characteristics of 5 kg and 10 kg
batches using 19” plate, which was desirable. In a previous report involving traditional
extrusion/spheronization (142), it was shown that undesirable product qualities could
result if inappropriate plate size was used relative to batch size. This is because at very
low load, there are relatively insufficient granules to interact with each other, thereby
leading to poor particle/particle interaction, while the opposite is true at high loads.
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2. Density, Carr’s index and Flowability
These qualities were used as indices for the flow properties of the spheroids. The
low values of Carr’ s index (less than 15%) signify good flowability of the granules. This
was confirmed with the angle of repose of all the formulations being less than or equal to
30 degrees (± 0.13 o to 7.59o SD; 240), as also shown in Tables XXA and B above. As
shown in Table XXA, the flowability was decreased by the use of HPMC (trial 6) and
high rotor speed (trials 5 and 8) that could have resulted in higher level of non-spherical
and smaller geometric mean size of granules respectively. Use of HPMC (trial 6) and
high speed (trials 5 and 8) also produced granules with increased tap density and percent
compressibility and thus bad flow characteristics.
The results of the true densities before and after purging were practically similar,
and almost similar results were obtained from all the batches (Tables XXA and B). From
these results, it could be inferred that the samples have similar moisture content,
indicating that the LOD (apart from influencing the yield that was measured immediately
after production), might not have affected other product characteristics determined during
storage at ambient conditions.

3. Drug content and Dissolution analyses
Calibration curve
Good linearity (r2 = 0.9996) was obtained from the calibration curve (Figure 22)
The percent accuracy ranged between 75 and 101% and the percent interday coefficient of
variation (CV) ranged between 0.10 and 11% (Table XXI), with the lowest concentration
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observed as an outlier. These results indicate acceptable accuracy and reproducibility for

Concentration (mcg/mL)

the assay method, respectively.

400
y = 1.0001x + 0.0635
R2 = 0.9996

300
200
100
0
0

50

100

150

200

250

300

350

Time (mins)

Figure 22: Calibration curve for HPLC analyses

Drug Content Analysis:

With the exception of the batch without sodium

lauryl sulfate (SLS; Tables XXA and XXB), the mean percentages of drug content
obtained from six replicate samples ranged between 90.52% ± 4.71% and 98.65% ±
4.37% ibuprofen, calculated on the content of theoretical formulation. This indicated that
the fluid-bed processes (blending, spheronization, drying) did not affect the ratio of the
ibuprofen drug to the Avicel RC-581 in the powder blend. It has been shown that by
adding surfactant to a spheronization system, the interaction between the liquid and the
powder changes (56), as a result of greater accessibility of the pore structure by the liquid
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within the powder bed. It is therefore possible that the absence of SLS delayed the
wettability of the powder blend, leading to the loss of the lighter-weighted
ibuprofen drug.

Table XXI: Accuracy and precision of HPLC Assay
Concentration (µg/mL)
Expected

Obtained

% Accuracy

Interday CV (%)

5

3.77

75.4

11.64

10

8.68

86.8

3.44

20

19.14

95.68

2.69

40

40.45

101.12

2.14

50

49.55

99.11

3.02

100

102.63

102.63

1.72

150

151.88

101.25

0.23

200

202.12

101.06

1.3

250

251.97

100.79

0.11

300

295.61

98.54

0.25

Dissolution studies:

The Q20 for all the formulations calculated using the

obtained drug content was ≥ 80%, except the batch containing HPMC and that without
SLS that released 75% and 74% respectively of ibuprofen at the same time (Tables XXA
and B, and Figures 23A and B). The variability between the replicate batches was
generally around 5%. The slower release from granules made with HPMC as binder or in
the absence of SLS could be attributed to densification, retardation of diffusion from the
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Figure 23. Panel A: Profiles of 1 kg replicated batches. Panel B: Profiles of pilot scale-up
batches. Trial 4: SS/Sm/1 kg; Trial 12: SS/Sm/5 kg; Trial 13: SS/Sm/10 kg; Trial 7:
Tef/Waf/1 kg; Trial 14: Tef/Waf/5 kg; Trial 15: Tef/Waf/10 kg. SS/Sm: stainless
steel/smooth; Tef/Waf: Teflon/waffle.
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granules and larger particle size (Figure 23A) that then reduced the surface area of the
granules respectively. There was no difference in drug release in batches made with
Avicel® RC and CL cellulose types contrary to previous reports in which extrusion
spheronization technique was used (254,255).

4. Friability
As shown in Table XXA, the percentage weight loss from the batches was
generally less than 5% (± 0.00 to 4.71 SD). However, increased rotor speed (trials 5 vs. 1
and 8 vs. 7), use of HPMC (trial 6 vs. 1), and use of different plate contours (trial 4 vs. 1)
increased the friability due to attrition and weakly agglomerated particles.

5. Sphericity and morphology of the granules
The sphericity of the microparticulates was in the range of 0.84 ± 0.01 to 0.92 ±
0.01, which is close to 1.0, the optimal value for sphericity (Table XXA). The sphericity
was reduced by the use of HPMC as binder (Figure 24G). HPMC increases the viscosity
of the binder, which could influence the resistance of liquid to flow. This has been shown
to affect the consistency of the wet powder mass, which in turn would influence the
process ability to produce spherical pellets (56). Moreover, a 5% HPMC solution was
used as the binder. It could be that a lower percentage with a lesser effect on binder
viscosity would have resulted in a more spherical product.
Sphericity was not affected by the use of SLS although the SLS is supposed to
enhance the wetting, which could enhance formation of spherical particles (54).
Moreover, neither batch nor process scale-up seemed to affect the sphericity of the
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granules (Table XXB). The results represented in Tables XXA and XXB are the
sphericity means of 30 - 60 pellets from replicate batches. Figures 24A-C show the
morphology of 1 kg, 5 kg and 10 kg batches of both plate material types (teflon and

A

B

C

D

E

F

Figure 24. Scanning electron micrographs (x30) of ibuprofen granules made with
stainless steel and with Teflon/waffle plates (see below).
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G

Figure 24 (Contd). Scanning electron micrographs (x30) of ibuprofen granules made with
stainless steel plate, 1 kg (Panel A); 5 kg (Panel B); 10 kg (Panel C); and with
Teflon/waffle plate 1 kg (Panel D); 5 kg (Panel E); 10 kg (Panel F). 1 kg batch made with
HPMC as binder on a stainless steel plate (Panel G).
A

B

C

Figure 25. Scanning electron micrographs (x200) of ibuprofen granules made with
stainless steel plate, 1 kg (Panel A); 5 kg (Panel B); 10 kg (Panel C).
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stainless steel), and the 1 kg produced with HPMC as binder using the stainless steel
plate. Figures 25A-C show typical morphology of the microparticulates at higher
magnification.

6. Size distribution of granules
Size distributions for most of the batches depicted log normal distribution (results
not shown), with the values of the 20/60 mesh products ranging between 88 - 96%,
except for the 1 kg batch made with stainless steel waffle plate at 650 rpm (trial 5) and
that containing HPMC as binder (trial 6).
For the loboratory scale batches, the presence of surfactant (SLS; trial 1 vs. 2) and
use of water (in the standard) as binder (trial 6 vs. 1) decreased particle size (Figure 26A).
Mean particle size increased in the absence of SLS, probably because in this situation, the
surface energy required to reduce the particle size to what would be obtainable under
similar conditions in the presence of the surfactant increases. It could also be due to
decreased wettability that made these spheroids less vulnerable to attrition during drying.
Type of Avicel hydrocolloid (trial 1 vs. 3), and disk contour type (trial 4 vs. 1) did not
affect the distribution. Rotor speed (650 rpm) decreased the particle size of the products
made with stainless steel plate compared to the 500 rpm used in the standard (trial 5 vs.
1), while plate type slightly increased the particle size at higher speed (formulations 8 vs.
5; Figure 26A). The geometric mean diameters of the granules together with the
geometric standard deviations are shown in Table XXA and Figure 26A.
The difference in size distribution between the batches could be attributed mainly
to the formulation components and process variables, because the size distribution of the
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Figure 26. Panel A: Geometric mean diameter of 1 kg replicated batches.
Panel B: Geometric mean diameter of scale-up batches. The error bars did not show
because of the very low geometric standard deviation (1.43 -1.95 µm).
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starting raw materials were kept uniform by sieving the powders through a 16 mesh size
prior to blending and spheronization. The decrease in the mean diameter with increased
rotor speed (trial 1 vs. 5), could be due to surface defects on the pellets by the high speed,
thereby producing more fines (7,256).
In the scale-up batches, the particle size, especially that of the teflon plate batches,
appeared to increase with larger batch size (Figure 26B). This is due to greater attrition by
the smaller sized batches that are lighter, more readily fluidized, falling from higher
heights during drying. It could also be due to increased tendency of the particles to bind
together due to the increased surface area of the larger batch sizes. The stainless steel
batches had less attrition presumably because the spheroids dry up more easily than the
products of equivalent batch sizes made with the teflon plate. Despite the increased
particle size, the 20/60 mesh sizes yield in each of the scale-up batches was up to 85%
thereby meeting the set acceptance criteria (page 94). These observations however did
not correlate with the report that the granule size is inversely related with the batch size
(142), and will therefore be further investigated.

In summary, trials 4 and 7 (Table XXA & B) were chosen as desirable
preparations based on the acceptance criteria such as yield, drug content, dissolution and
sphericity studies for rational screening and statistical design, as will be shown in the
next phase.
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Phase 2
Optimization of the Developed Process and product Variables Using Statistically
Designed Factorial Experiment

a. Experimental Design
Tables XXII and XXIII show the respective results of the means of replicate
batches and p-values of the independent variables (block and main effects) obtained from
the statistically analyzed full factorial blocked randomized design. Table XXIV
summarizes the qualities of the pellets by grouping them according to the used plate types
and contours. The effect of the main factors on spheroid qualities will be discussed in the
sections addressing affected physical characteristics.

Binder level: The importance of water, used as binder or granulating liquid in the
spheronization process, and the moisture content in the product, with respect to the
physical performance of the end product have been reported in various studies (78,257).
We have also shown that good spheroid qualities were obtained when the moisture
content in the bed at the end of spheronization process was 50 – 52% (47), at defined
parameters. It is therefore evident that variation in the amount of water used for the
production of formulations of similar composition and batch size will affect most of the
spheroid qualities, as will be discussed in the respective sections. Higher binder content
implied higher yield of the spheroids and vice versa. These results are shown in Tables
XXII and XXIII and also in the Pareto charts (Figure 27).
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Estimated effect on Yield

Significance (p)
<.0001
0.0311
0.1887
0.5166
0.4792
0.5964
0.6287
-

Estimated effect on Geometric Mean Diameter

Significance (p)
<.0001
0.0006
0.0023
0.0066
0.0110
0.8113
0.9404

Estimated effect on Drug content

Significance (p)
<.0001
0.0011
0.0036
0.0291
0.7523
0.5405
0.9789

Figure 27. Pareto plots of effects of main factors on the specified product qualities
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Estimated effect on Q20

Significance (p)
0.0003
0.0007
0.0071
0.0554
0.0198
0.1287
0.5856

Estimated effect on Usable fraction

Significance (p)
<.0001
0.0037
0.0063
0.0088
0.1627
0.7055
0.8616

Estimated effect on Sphericity

Significance (p)
0.0003
0.0023
0.0014
0.0058
0.1170
0.5756
0.6120

Pareto plots of effects of main factors on the specified product qualities (Contd.).

Surfactant level:

Surfactant level significantly affected the Q20, the geometric mean

diameter, the LOD and the usable fraction (p < 0.05). In the presence of high binder and
high surfactant levels, increase in geometric mean diameter, which consequently
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decreased the Q20 of the spheroids was observed (Table XXII). Thus, in the presence of
high amount of water as the granulating liquid, SLS appears to lose some of its surfaceactive property that should reduce the particle size of the spheroids. This result was
confirmed by the highly statistical significance observed in the interaction between the
high binder and surfactant levels.

Plate type:

As seen in Table XXIII, plate type significantly influenced the

yield, sphericity, friability; bulk density, geometric mean diameter, the Q20 and usable
fraction (p < 0.05). Stainless steel smooth plate gave more consistent product quality
especially with respect to yield, drug content, usable fraction. The effects of plate type on
product yield, geometric mean diameter, drug content, Q20, usable fraction and sphericity
are also represented with the Pareto plots of some of the response variables (Figure 27).

Blocking effect:

Blocking had no significant effect on eleven of the twelve

product characteristics studied (Table XXIII), and also had no significant interactions
with the main factors [(X1 - X3), indicating batch-to-batch reproducibility. A significant
blocking effect (p = 0.0014) was observed with the sphericity response variable, which
could actually be considered insignificant. This is because the data showed that the
difference between the sphericity values [that should range between 0.1 (non spherical) –
1 (most spherical)] of the two blocks was very minute such that any slight change
appeared statistically significant. However, although the observed difference would not
be clinically important, this effect was tested further.
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To test the significance of the blocking effect, statistical analysis was performed
on the formulations within the individual blocks. Significant effect (p = 0.02) was
observed only with the binder level in block 1 of Table VII, which was found to be
insignificant for the whole model test (p > 0.05). In block 2, significant effects were
observed with two of the main factors, namely, binder level (p = 0.0008) and plate type
(p = 0.0033), and there was also significant interaction between binder level and plate
type (p = 0.013). This blocking effect could be attributed to extraneous factors like
humidity and temperature changes which have been shown to have possible effects on
spheroid preparation (9), since the formulations in each of the blocks were produced at
two different periods. However, the results from both blocks were generally within our
set acceptance criteria and the variability between blocks was very minute.

Interaction:

Some of interaction results are shown in Figure 28. There was

significant interaction (p < 0.05) between binder level and plate type on the drug content,
sphericity, friability and LOD response variables. Low binder yielded lower and less
spherical spheroids as well as reduced usable fraction with teflon plate (Formulations 7
and 9). There were also significant interactions between the binder and the surfactant
levels on the drug content, true density, LOD, the Q20, usable fraction and geometric
mean diameter response variable. High binder-High surfactant levels resulted in bigger
spheroids for the batches made with the stainless steel plates. Significant (p < 0.05)
interactions were also observed between the plate type and surfactant level on the drug
content, bulk density and geometric mean diameter response variables.

153

Figure 28. Interaction plots of the effects of main factors on specified qualities.
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b. Physical Characteristics of the Spheroids
1. Scanning electron microscopy
As shown in Tables XXII & XXIV and Figures 29 and 30, and also as already
explained in the interaction studies, high binder/high surfactant (HbHs) levels with
stainless steel smooth or waffle plates (Formulations 3 and 6 respectively) produced
spherical but very big spheroids (~1 mm). In contrast, low binder/high surfactant (LbHs)
and high binder/low surfactant (HbLs) levels with stainless steel smooth plate
(Formulations 5 and 11 respectively) resulted in spherical and smaller microparticulates
within the acceptable criterion range of 0.35 –0. 5 mm. However, batches made with low
binder/low surfactant (LbLs) or low binder/high surfactant (LbHs) levels and with teflon
waffle plate (Formulations 7 and 9) produced very small spheroids (0.036 and 0.130 mm)
with low sphericity. These results correlated with other observations and statistical
analysis with regard to significance of binder level in the formation of well granulated
spheroids (93,122). Typical morphology of the three different spheroid groups is shown
in Figures 29 and 30.

2. Moisture content determination (Loss on drying)
Following our observations from previous studies, the moisture content at the end
of drying of the products was generally ≤ 5% (Table XXII). The highest values were
obtained with the batches (Formulations 3 and 6) made with high binder-high surfactant
(HbHs) levels and using the stainless steel plates. This could be due to the large sizes
(949 and 1070 µm) of these pellets that could reduce the efficient drying of the stainless
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C

D
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F

Figure 29: Scanning electron micrographs (30x) of ibuprofen granules. Formulations 3
and 6 (Panels A & B); Formulations 5 and 11 (Panels C & D); Formulations 7 and 9
(Panels E & F).
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Figure 30: Scanning electron micrographs (100x) of ibuprofen granules.
Formulations 3 (A); 11 (B); 7 (C).

steel plate material. In contrast, the formulation (#10) made with the teflon plate using
HbHs levels at a fixed binder level had smaller sized pellets (356 µm). This observation
indicated that the teflon plate required higher amount of binder to yield products of
similar sizes as those made with the stainless steel plate. The results were also supported
by previous report that was obtained with the teflon plate. The smaller sized pellets
obtained with this plate must have contributed to the effects of plate type on most of the
spheroid qualities. In addition, these smaller sized pellets were easier to dry than the
larger sized pellets obtained with the stainless steel plates, despite the insulating nature
(lower drying efficiency) of the teflon material.
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TABLE XXII. Physical Characteristics of Optimized Ibuprofen Spheroids.
Form. 1

Form. 2

Physical characteristics

Form. 3

Form. 4

**Form. 5

Form. 6

HbLsTef-waf

LbHsSS-sm

HbHsSS-waf

Experimental variables
LbHsSS-waf

LbLsSS-sm

HbHsSS-sm

% Yield

80.85 ± 3.04

77.15 ± 9.83

95.85 ± 6.86

87.75 ± 7.57

89.7 ± 3.54

97.3 ± 1.56

% Moisture content

2.10 ± 0.13

2.00 ± 0.01

5.15 ± 0.23

1.52 ± 0.56

1.55 ± 0.23

4.22 ± 0.01

% Drug content

93.43 ± 2.17

92.57 ± 3.91

93.06 ± 1.40

96.67 ± 3.38

98.74 ± 0.81

92.76 ± 3.47

Geometric mean diameter (µm)

350 ± 1.55

354 ± 1.42

949 ± 1.40

460 ± 1.41

396 ± 1.35

1070 ± 1.40

Sphericity

0.87 ± 0.01

0.87 ± 0.00

0.89 ± 0.02

0.88 ± 0.00

0.89 ± 0.03

0.89 ± 0.02

Flowability (deg)

18.76 ± 0.54

20.38 ± 0.33

17.85 ± 0.00

17.92 ± 1.94

17.60 ± 1.95

19.14 ± 0.65

Carr’s index. (%)

7.43 ± 1.55

9.12 ± 2.35

3.00 ± 0.59

7.48 ± 1.86

8.11 ± 0.24

3.78 ± 0.09

True density (g/cm3)

1.30 ± 0.00

1.25 ± 0.01

1.22 ± 0.02

1.29 ± 0.01

1.29 ± 0.01

1.23 ± 0.00

Bulk density (g/cm3)

0.63 ± 0.01

0.61 ± 0.09

0.78 ± 0.01

0.65 ± 0.07

0.64 ± 0.01

0.77 ± 0.00

Q20 (%)

89.85 ± 1.48

91.00 ± 1.13

47.55 ± 7.14

84.35 ± 5.02

89.90 ± 0.28

47.25 ± 0.49

Friability (%)

0.67 ± 0.00

0.67 ± 0.94

0.33 ± 0.00

0.67 ± 0.47

0.67 ± 0.47

0.5 ± 0.24

Usable fraction (%)

92.00 ± 2.83

81.00 ± 7.07

54.00 ± 14.14

93.00 ± 1.41

97.00 ± 1.41

43.00 ± 1.41

Low binder (Lb), High binder (Hb)
Low surfactant (Ls), High surfactant (Hs)
Stainless steel smooth (SS-sm), Stainless steelwaffle (SS-waf), Teflon waffle (Tef-waf)
Form.: Formulation
**The highlighted formulations showed the most acceptable spheroid qualities
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TABLE XXII. Physical Characteristics of Optimized Ibuprofen Spheroids (Contd.).

Form. 7

Form. 8

Physical characteristics

Form. 9

Form. 10

**Form. 11

Form. 12

HbLsSS-sm

LbLsSS-waf

Experimental variables
LbLsTef-waf

HbLsSS-waf

LbHsTef-waf HbHsTefwaf

% Yield

68.65 ± 6.29

104.00 ± 9.9

60.4 ± 2.26

92.65 ± 18.87

92.10 ± 0.99

71.85 ± 4.6

% Moisture content

0.37 ± 0.13

0.44 ± 0.13

2.60 ± 0.30

1.69 ± 0.13

1.80 ± 0.43

2.50 ± 0.28

% Drug content

89.24 ± 2.18

99.96 ± 6.75

92.66 ± 0.94

99.79 ± 3.20

96.80 ± 0.47

93.96 ± 5.20

Geometric mean diameter (µm)

130 ± 2.54

417 ± 1.47

36 ± 5.93

356 ± 1.74

386 ± 1.48

384 ± 1.61

Sphericity

0.84 ± 0.01

0.88 ± 0.02

0.84 ± 0.00

0.89 ± 0.02

0.88 ± 0.01

0.88 ± 0.01

Flowability (deg)

24.36 ± 1.41

18.42 ± 0.44

26.47 ± 3.57

20.52 ± 1.88

20.93 ± 1.8

18.95 ± 1.85

Carr’s index. (%)

10.85 ± 0.48

7.42 ± 1.39

18.61 ± 13.95

9.24 ± 0.86

8.07 ± 2.44

7.63 ± 1.41

True density (g/cm3)

1.31 ± 0.00

1.28 ± 0.00

1.27 ± 0.04

1.28 ± 0.02

1.29 ± 0.00

1.29 ± 0.00

Bulk density (g/cm3)

0.56 ± 0.02

0.65 ± 0.02

0.54 ± 0.05

0.60 ± 0.02

0.62 ± 0.03

0.65 ± 0.06

Q20 (%)

88.90 ± 5.23

88.95 ± 6.01

89.25 ± 1.48

91.80 ± 2.12

92.45 ± 3.61

87.35 ± 3.61

Friability (%)

0.37 ± 0.24

0.44 ± 0.24

7.62 ± 2.76

0.50 ± 0.71

1.00 ± 0.00

0.67 ± 0.94

Usable fraction (%)

37.00 ± 15.56

95.00 ± 1.41

13.00 ± 7.07

78.00 ± 19.80

94.00 ± 0.00

87 00 ± 9.90

Low binder (Lb), High binder (Hb)
Low surfactant (Ls), High surfactant (Hs)
Stainless steel smooth (SS-sm), Stainless steelwaffle (SS-waf), Teflon waffle (Tef-waf)
Form.: Formulation
**The highlighted formulations showed the most acceptable spheroid qualities
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TABLE XXIII: P-values of Independent Variables for the Optimized Ibuprofen Spheroids

Dependent
variables

Independent variables
Blocking Plate type Binder level Surf. level
1

Yield
Drug cont.
Q20
Carr’s Index
Flowability
Friability
Bulk density
True density
Geom. m. diam.
Moisture content
Usable fraction
S
Sphericity

NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
(0.0014)

2

3

S (0.03)
S (<.0001)
NS
S (<.0001)
S (0.0198) S (0.0003)
NS (0.06)
S (0.03)
NS (0.067)
NS
S (0.0001) S (0.0001)
S (0.0046) S (0.0017)
NS
NS
S. (0.0006) S (<.0001)
NS
NS (0.0857)
S (0.0037)
NS
S (0023)
S (0.0003)

4

NS
NS
S (0.0071)
NS
NS
NS
NS (0.08)
NS (0.06)
S (0.0066)
S (0.0026)
S (0.0063)
NS

Interactions
2*3
2*4
NS
NS
S (0.0291) S (0.0011)
NS
NS (0.055)
NS
NS
NS
NS
S (0.0001)
NS
NS
S (0.0522)
NS
NS
NS
S (0.011)
S (0.0049)
NS
S (<.0001)
NS
S (0.0058)
NS

3*4
NS
S (0.0036)
S (0.0007)
NS
NS
NS
S (0.0572)
S (0.0468)
S (0.0023)
S (0.0007)
S (0.0088)
NS

S: Significant
NS: Non-significant
Bold: indicates the few NS results obtained with the binder level factor in comparison to those obtained with the plate type and
surfactant level factors.
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TABLE XXIV: Summary of the Optimized Ibuprofen Spheroid Qualities

Plate type

SS-Waf

SS-Sm

Tef-Waf

Form.
number

12
1
8
6
2
5
11
3
7
9
4
10

Form.
vars

Lb-Ls
Lb-Hs
Hb-Ls
Hb-Hs
Lb-Ls
Lb-Hs
Hb-Ls
Hb-Hs
Lb-Ls
Lb-Hs
Hb-Ls
Hb-Hs

Physical Charateristics
Yield (%)

Q20 (%)

71.85 ± 4.6
80.85 ± 3.04
104.00 ± 9.9
97.3 ± 1.56
77.15 ± 9.83
89.7 ± 3.54
92.1 ± 0.99
95.85 ± 6.86
68.65 ± 6.29
60.4 ± 2.26
87.75 ± 7.57
92.65±18.87

87.35 ± 3.61
89.85 ± 1.48
88.95 ± 6.01
47.25 ± 0.49
91.00 ± 1.13
89.90 ± 0.28
92.45 ± 3.61
47.55 ± 7.14
88.90 ± 5.23
89.25 ± 1.48
84.35 ± 5.02
91.80 ± 2.12

Geom. Mean
diam. (mm)
384 ± 1.61
350 ± 1.55
417 ± 1.47
1070 ± 1.40
354 ± 1.42
396 ± 1.35
386 ± 1.48
949 ± 1.40
130 ± 2.54
36 ± 5.93
460 ± 1.41
356 ± 1.74

Usable
fraction (%)
87.00 ± 9.90
92.00 ± 2.83
95.00 ± 1.41
43.00 ± 1.41
81.00 ± 7.07
97.00 ± 1.41
94.00 ± 0.00
54.00 ± 14.14
37.00 ± 15.56
13.00 ± 7.07
93.00 ± 1.41
78.00 ± 19.80
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TABLE XXIV: Summary of the Optimized Ibuprofen Spheroid Qualities (Contd.)

P late typ e

F o rm .
num b er

F o rm .
vars

P hysical characteristics
D rug co nt.
(% )

S S -W af

S S -S m

T ef-W af

C arr’s
ind ex (% )

S p hericity

12
1
8
6

L b -L s
L b -H s
H b -L s
H b -H s

9 3 .9 6 ± 5 .2 0
9 7 .3 ± 1 .5 6
9 9 .9 6 ± 6 .7 5
9 2 .7 6 ± 3 .4 7

7 .6 3
7 .4 3
7 .4 2
3 .7 8

±
±
±
±

1 .4 1
1 .5 5
1 .3 9
0 .0 9

0 .8 8
0 .8 7
0 .8 8
0 .8 9

2
5
11
3

L b -L s
L b -H s
H b -L s
H b -H s

9 2 .5 7
9 8 .7 4
9 6 .8 0
9 3 .0 6

9 .1 2
8 .1 1
8 .0 7
3 .0 0

±
±
±
±

2 .3 5
0 .2 4
2 .4 4
0 .5 9

0 .8 7 ± 0 .0 0
0 .8 9 ± 0 .0 3
0 .8 8 ± 0 .0 1
0 .8 9 ± 0 .0 2

7
9
4

L b -L s
L b -H s
H b -L s

8 9 .2 4 ± 2 .1 8 1 0 .8 5 ± 0 .4 8
9 2 .6 6 ± 0 .9 4 1 8 .6 1 ± 1 3 .9 5
9 6 .6 7 ± 3 .3 8
7 .4 8 ± 1 .8 6

0 .8 4 ± 0 .0 1
0 .8 4 ± 0 .0 0
0 .8 8 ± 0 .0 0

10

H b -H s

9 9 .7 9 ± 3 .2 0

0 .8 9 ± 0 .0 2

±
±
±
±

3 .9 1
0 .8 1
0 .4 7
1 .4 0

9 .2 4 ± 0 .8 6

±
±
±
±

0 .0 1
0 .0 1
0 .0 2
0 .0 2
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The statistical analyses also showed that surfactant level significantly affected the
moisture content of the products (p = 0.0026). This might have led to the significant
interaction (p = 0.0007) between these two factors that resulted in the yield of oversized
granules. The same reasons already given for the stainless steel and teflon plates might
have led to the significant interaction (p = 0.0049) observed between plate type and
binder level.

3. Yield and usable fractions of spheroids
The yield of the formulations ranged from 60.4 ± 2.26% - 104 ± 9.9% with the
usable fractions (250 - 850 µm) ranging between 37 ± 15.56% - 97 ± -1.41% respectively
(Table XXII).
Comparing batches made with similar plates, the formulations with low binder
level gave lower yield values (1 and 12 vs. 6 and 8 respectively; 2 and 5 vs. 11 and 3
respectively; 7 and 9 vs. 4 and 10 respectively). The lower yield obtained from the low
binder batches could be attributed to insufficient amount of binder being added to the
powder blend leading to the production of more fines that were lifted up by the
fluidization air into the filters, and also coated the walls of the fluid-bed. These
observations were made more apparent from the results obtained with the geometric mean
diameter (see below).
By comparing different batches made with plate material types of similar contours
[Teflon waffle (TW) and stainless steel waffle (SSW)], it was observed that the latter
yielded more products than the former (Formulations 4 vs. 8; 10 vs. 6; 9 vs. 1; 7 vs. 12).
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This could be attributed to the production of more fines by the teflon material than the
stainless steel material that could also lead to more losses, as already explained.
Plate contour was affected by the binder and (more or less) by the surfactant
levels. At low binder level, the stainless steel smooth contour yielded higher
microparticulates and more usable fractions than the SSW plate irrespective of the
surfactant levels (Formulations 5 vs. 1 and 2 vs. 12). This could be due to the loss of
products in the waffle contour, as previously explained (47). However, at higher binder
levels, the SSW plate yielded more products and more or less equal usable fractions
(Formulations 6 vs. 3 and 8 vs. 11) than the SS-smooth plate. The latter observation could
be due to the formation of large sized spheroids that were neither lost in the filters nor in
the waffle contours. The high binder-high surfactant batches are however practically
unusable within our set acceptance criteria.
The results from Tables XXII & XXIV are supported by those of the p-values
obtained using the JMP® software analyses (Table XXIII). These show that binder level
and plate type significantly affected the product yield (p < 0.0001 and p = 0.0311
respectively). However, there was no significant interaction observed between any of the
main factors (p > 0.05) on the yield product variable.

4. Drug content
Binder level significantly affected this response variable (p < 0.0001). Low
binder levels generally resulted in reduced drug content, probably due to some losses that
could occur from insufficient wetting of the product at any stage of its development. As
already explained, there was also significant interaction between plate type and binder
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level (p = 0.0291), plate type and surfactant level (p = 0.0011) and also binder and
surfactant levels (p = 0.0036) on this spheroid quality. However, the results obtained
from all the formulations are within our set acceptance criteria (≥ 85%), as shown in
Table XXII.

5. Friability
As shown in Table XXII, the percentage weight loss from all the formulations was
generally < 1%, except that of the batch made with teflon plate and low binder
(formulation 9) that also produced the smallest sized spheroids (geometric mean diameter
36 ± 5.93) and the lowest usable fraction (13 ± 6.7%). It was observed that both binder
level and plate type significantly affected this response variable (p < 0.0001), and there
was also significant interaction observed between these two factors (p < 0.0001).
Generally, low binder content produced more friable spheres. These results could
be related to the explanations given under the LOD section. At low binder levels there
will not be enough binder for particle-particle contact and adhesion that will lead to the
formation of primary and strong secondary nuclei (76), thereby forming friable spheroids.

6. True density and compressibility
The statistical analyses showed that none of the main factors significantly affected
the true density of the microparticulates. The closest was the effect of the surfactant level
(p = 0.06) and its interaction with binder level (p = 0.048). Different binder and
surfactant levels might have led to different pellet sizes, which might have affected the
true density of the pellets. Bulk density was significantly affected by plate type
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(p = 0.0046) and binder level (p = 0.0017), however, no significant interaction was
observed between these factors (p > 0.05). Our results correspond with previous reports
(using the traditional extrusion-spheronization process) that bulk density which greatly
influences the packing properties of spheres is greatly dependent on the diameter of the
pellets (134,258). Thus, there would be no change in the volume occupied by pellets of
high geometric mean diameter leading to high bulk density of the microparticulates
(Formulations 3 and 6). For true density that directly affects the compactness of
substances, high geometric mean diameter is indicative of larger air pockets, and
consequently, lower true density. However, we observed the lowest true density values
for the spheroids with the highest geometric mean diameter (Table XXII), as was also
observed by other authors (259). This is probably due to larger air pockets entrapped by
these bigger microparticulates that are practically open porous structures, as shown in
Figure 30 above, and therefore would result in low true density (low compactedness)
spheroids.
The percent compressibility (Carr’s index) was significantly affected by binder
level (p = 0.032). It has been shown that during spheronization, agglomerates grow by
coalescence (44), which depends on plastic deformability of the wet material mass.
Sufficient binder is therefore required for the powder materials to achieve plastic
deformation, which is related to the compressibility of the product, Hence the observed
statistically significant effect at two binder levels. The p-value for plate type was 0.0642
but there was no significant interaction observed. The results of the Carr’s index
(generally < 15%) indicate that the granules have acceptable bulk and true densities for
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the production of unit dosage forms except for formulation 9, which also has the lowest
usable fraction, smallest geometric mean diameter and the poorest flowability
(Table XXII).
Flowability was slightly affected by plate type (p = 0.067), though not statistically
significant (p > 0.05), which could be attributed to the higher fines produced by the teflon
plate material as already discussed.

7. Sphericity of the granules
The sphericity values of most of the microparticulates were within our set
acceptance criterion (≥ 0.85), which is close to 1.0, the optimal value for sphericity (Table
XXII). The sphericity was reduced by the use of teflon waffle plate except in the
presence of high binder levels (Formulations 7 and 9 vs. 4 and 10). This could be due to
the production of more fines in the presence of low binder levels by this plate type, thus
producing less spheronized microparticulates, and also indicating the need for higher
binder level by this plate type. Statistically, it was observed that binder level and plate
type significantly affected this response variable (p = 0.003 and 0.023 respectively), and
there was also significant interaction between these factors (p = 0.0058). Batch
replication (blocking) was also observed to affect the sphericity of the batches
(p = 0.0014). This effect has been elaborated on page 152.
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8. Size distribution of granules
The geometric mean diameter of the microparticulates ranges from 36 ± 5.93 µm 1070 ± 1.14 µm (Table XXII; Figure 31) respectively. Three groups can be distinguished
from the observed experimental results. The first group comprised of formulations 3 an6
that present very large spheroid sizes caused probably by the simultaneous use of high
binder and high surfactant levels, which could lead to excessive agglomeration (260).
The second group included formulations 7 and 9 with very small spheroid sizes due to
low binder level with the teflon plate material which tends to produce more fines than
similar batches made with the stainless steel plates. The results from both groups are in
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Figure 31: Geometric mean diameters of experimentally designed replicated batches.
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accordance with previous experiments that showed that the higher the amount of binder,
the more spherical the particles and the larger their sizes, and vice versa (261).
The last group consisting of intermediate sizes (e.g. Formulations 5 and 11) with
geometric mean diameter ranging from 350 ± 1.55 µm - 460 ± 1.41 µm respectively are
mostly results of low levels of either the binder or the surfactant. This group, with usable
fractions mostly > 85% fell within our set acceptance criteria and comprised our most
acceptable formulations.
As explained in various sections, the statistical data show that the three main
factors significantly affected this response variable (Table XXIII), namely, binder level
(p < 0.0001), plate type (p = 0.0006) and surfactant level (p = 0.0066). There was
significant interaction between plate type and surfactant level (p = 0.011) and also binder
and surfactant levels (p = 0.0023). Both effects could be related to our observation of the
smaller pellets obtained with the different binder and surfactant levels when used with the
different plate types. Thus, the simultaneous presence of high binder and surfactant
levels in the formulation made with teflon plate material (Formulation 4) did not lead to
the production of big sized spheres (Table XXII; Figure 31), as seen with formulations 3
and 6. This could be attributed to the hydrophobic nature of the teflon material that
prevented fast spreading of the hydrophilic binder. Consequently higher amount of binder
was required for miscibility with the powder and formation of good spheroids.
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9. Ibuprofen release from granules
All the formulations released > 80% of the drug within 20 minutes (Q20), except
the batches with large sizes (Formulations 3 and 6) that consequently reduced the surface
area of the granules (Table XXII; Figures 32A & B). These formulations consisted of
HbHs levels and made with stainless steel smooth and waffle plates respectively.
Statistically, it was observed that plate type (p = 0.0198), binder level (p = 0.0003) and
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Figure 32: Dissolution profiles of experimentally designed replicated batches.
Formulations 1-6, 11 (Panel A); Formulations 5, 7-12 (Panel B).
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surfactant level (p = 0.0071) significantly affected this response variable (Table XXIII),
which could be related to their effects on the spheroid sizes. As already explained, there
was significant interaction between binder and surfactant levels (p = 0.0007). High
binder level might have resulted in reduced surface active properties of SLS that
ordinarily would result in smaller particle sizes. Consequently, larger spheroids were
produced. The interaction between plate type and surfactant level (p = 0.0554) should
also be noted though not statistically significant (p > 0.05).

Based on the results of the statistical analyses (effects of binder, SLS and plate
type) and our set acceptance criteria such as yield, drug content, dissolution and sphericity
studies, Formulation 11 (Tables XXII and XXIV) was chosen as the optimized
preparation and was subsequently used to study the effects of particle size and drug load
on spheroid qualities.

Phase 3
The Effects of Drug particle Size, Drug Loading and Intermediate Size Scale-up on
the Characteristics of Ibuprofen Microparticulates

a. Effects of drug particle size and drug loading
1. Experimental design
Drug micron size:

Drug particle size significantly (p < 0.05) affected some of

the physical characteristics studied, namely, moisture content (p = 0.0203), bulk density
(p = 0.0088), flowability (p = 0.0028), sphericity (p = 0.0034) and usable fractions
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(p = 0.0214). These results are as expected as similar observations have been previously
reported necessary for most of these variables (52,153). The bigger micron sized
ibuprofen (40 µm) resulted in higher LOD, lower sphericity and lower bulk density. The
latter two observations could be a result of the bigger sizes breaking up during drying,
leading to lower bulk density of the spheres. These outcomes would affect the sphericity
and bulk density of the pellets. These results are shown in Tables XXV and XXVI and in
Figure 33.

Estimated effect on Drug content

Significance (p)
0.0108
0.0777
0.0446
0.9973

Estimated effect on Geometric mean diameter

Significance (p)
0.0196
0.019
0.8874
0.8601
-

Estimated effect on Q20

Significance (p)
<.0124
0.0303
0.2738
0.4663

Figure 33. Pareto plots of effects of main factors on the specified product qualities.
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Drug load:

Drug load significantly affected most of the qualities of the

spheroids, except the yield, flowability and Carr’s index. The insignificant effect on
Carr’ s index was not expected since the bulk and tapped densities (p < 0.001) from which
it was calculated were significantly affected by drug load (Tables XXV and XXVI).
However, these observations conform with the reports that there may be other factors
such as GMD and LOD contributing to the qualities of the finished product. The
observed increase in GMD with increased drug load could be due to the reduced amount
of Avicel® RC-581 (a spheronization enhancer) in the system, which might have exposed
the products to be easily over granulated.

Replication:

Replication had no significant effect on ten of the twelve product

characteristics studied (Table XXVI), as well as no significant interactions with the main
effects [(drug load & drug micron size); results not shown], indicating batch-to-batch
reproducibility. The result obtained with the drug content response variable could be
considered statistically significant (p = 0.0446). However, this result falls on the
borderline of our set level of significance (p = 0.05). In addition, the drug contents of all
the response variables were > 90% (above our set acceptance criteria). Although
statistical significance (p = 0.0069) was observed with friability, the friability values of
all the response variables could be considered negligible (< 2%).

Interaction:

There was significant interaction (p < 0.05) between drug micron

size and drug load on the flowability (p = 0.0371) and Q20 (p = 0.0303) variables (Table
XXVI). These results are also shown in interaction plots (Figure 34).
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Figure 34. Interaction plots of the effects of main factors on specified qualities.

2. Physical characterization of granules
i. Scanning electron microscopy
Figure 35 shows typical morphology of the spheroids obtained from the three drug
loads. As shown in Table XXV and Figure 35, the size of the microparticulates increased
with increased drug load. This could be due to the reduced amount of Avicel®, the water
absorber in the system that increased the chances of over granulation of the spheroids.
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Figure 35: Scanning electron micrographs (30x) of ibuprofen formulations (20 µm drug
size and 1 kg batch) for the different drug loads, A (50%); B (65%); and C (80%).

ii. Moisture content/Loss on drying analyses
Binder amount:

As expected, the amount of binder needed for

spheronization of the different drug levels was inversely related to drug load (Table XI).
This indicates that, as previously reported (44,49), Avicel® acted as molecular sponge that
absorbed water, thus the requirement for higher amount of binder as Avicel® level
increased. It was also observed that at each drug level, less binder was required to
spheronize the 40 micron sized ibuprofen, however, these batches took longer
processing time.
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Table XXV. Physical Characteristics of Drug Micron Size/Drug Load Batches (Means of replicated batches)

20 micron size ibuprofen
% ibuprofen

50

65

40 micron size ibuprofen
80

50

65

80

Physical characteristics
% Yield

90.85 ± 7.99

87.7 ± 1.56

76.35 ± 10.11

85.60 ± 0.00

94.27 ± 0.07

93.6 ± 2.83

% Moisture content

1.7 ± .14

0.89 ± 0.01

0.71 ± 0.28

1.72 ± 0.14

1.69 ± 0.15

0.94 ± 0.20

% Drug content

98.55 ± 5.08

98.79 ± 0.95

91.57 ± 1.27

94.96 ± 1.10

99.13 ± 1.11

94.81 ± 1.12

Geometric mean diameter (µm)

485 ± 1.52

605 ± 1.45

697 ± 1.98

456 ± 1.37

528 ± 1.42

802 ± 1.35

Sphericity

0.91 ± 0.00

0.91 ± 0.01

0.88 ± 0.01

0.871 ± 0.017 0.882 ± 0.00

0.873 ± 0.00

Flowability (deg)

22.15 ± 0.00

21.43 ± 1.16

23 72 ± 1.73

20.63 ± 0.11

19.88 ± 0.11

17.95 ± 0.21

Carr’s index. (%)

8.03 ± 1.67

6.02 ± 0.06

7.23 ± 1.38

6.79 ± .32

6.83 ± 0.92

8.43 ± 5.29

True density (g/cm3)

1.29 ± 0.02

1.24 ± 0.00

1.18 ± 0.00

1.29± 0.00

1.21 ± 0.04

1.18 ± 0.01

Bulk density (g/cm3)

0.69 ± 0.01

0.63 ± 0.01

0.58 ± 0.03

0.64 ± 0.02

0.57 ± 0.01

0.57 ± 0.00

Q20 (%)

83.94 ± 4.00

86.87 ± 1.34

82.80 ± 6.19

89.48 ± 4.93

88.38 ± 3.73

67.04 ± 0.26

Friability (%)

0.50 ± 0.24

0.50 ± 0.24

1.17 ± 0.71

0.84 ± 0.23

1.00 ± 0.47

1.17 ± 0.23

Usable fraction (%)

91.00 ± 1.41

85.00 ± 1.41

59.00 ± 7.07

97.00 ± 1.41

92.00 ± 0.00

70.00 ± 5.66
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TABLE XXVI: P-values of Independent Variables of Drug Micron Size/Drug Load Batches

Dependent variables
Physical characteristics

Yield
Moisture content

Independent variables
Replication

Micron size (MS)

Drug load (DL)

Interactions

[1, 2]

[20 µm, 40 µm]

[50%, 65%, 80%]

(MS * DL)

NS

NS
NS

NS
S (0.0108)

NS (0.0681)
NS (0.0777)

S (0.0446)

LOD

NS

S (0.003)

NS (0.0689)

NS

S (0.0203)
NS

Q20

S (0.0124)

S (0.0303)

Geometric mean diameter
True density

NS
NS

NS
NS

S (0.0196)
S (0.0003)

NS
NS

Bulk density
Carr’ s index

NS
NS

S (0.0088)
NS

S (0.001)
NS

NS
NS

Flowability
Friability

NS

S (0.0028)
NS (0.0584)

NS
S (0.0315

S (0.0371)
NS

S (0.0034)

S (0.0282)

S (0.0214)

S (0.0004)

Sphericity
Usable fraction

S (0.0069)
NS
NS

NS (0.0613)
NS
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Moisture content in the fluid-bed:

A plot of the moisture content for both drug

particle sizes during spheronization and drying processes in function of time (Figure 36)
showed that, as stated above, with the two drug micron sizes, the amount of the liquid
binder needed for the spheronization of the powder blends decreased as the drug load
increased. It was also observed that the products containing 20% Avicel® or 80% drug
load were easily overspheronized, resulting in larger particle sizes. This is in accordance
with the report that the lower the amount of Avicel® in the spheronization of most model
drugs, the more difficult the spheronization process (49). The moisture content at the end

% Moisture content

of drying of the products was generally < 2% (Table XXV).
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Figure 36: The moisture content profile of 20 micron ibuprofen as a function of time
(1 & 2 represent replicate batches).

iii. Yield and usable fractions of spheroids
The yield of the formulations ranged from 76.35 ± 10.11% - 94 ± 0.07% with the
usable fractions (250 - 850 µm) ranging between 59 ± 7.07%– 97 ± 1.41% respectively
(Table XXV). Comparing batches made with 20 micron sized ibuprofen, the percent
yield decreased as drug load increased. This could be attributed to the poor wettability of
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the batch due to increased ibuprofen that led to more losses in the system. The 40 micron
sized ibuprofen yielded slightly more products although this was not statistically
significant (Table XXVI).
The usable fraction was significantly affected by both drug micron size
(p = 0.0004) and drug load (p = 0.0214). As shown in Table XXV, the fraction
decreased as drug load increased, possibly due to greater percentage of oversized fraction
that increased with increased drug load.

iv. Drug content
Although drug content was significantly affected by replication (p = 0.0446) and
drug load (p = 0.0108), all the formulations had drug contents > 90% thereby meeting
our set acceptance criteria (≥ 85%). The lower drug content obtained with the 80% drug
loaded 20 micron sized batch supports the hypothesis that the poor wettability of this
more micronized drug size led to more losses of the drug to the fluid-bed walls, and
consequently to decreased drug content.

v. Friability
As shown in Table XXV, the percentage weight loss from all the formulations
was generally less than 2%, indicating that all the formulations could withstand
processing frictional forces. The statistical importance of these results has been discussed
above.
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vi. True density and compressibility
In both particle sizes, bulk and true densities decreased with increased drug loads.
Considering the nature or composition of the blend, Avicel® is bulkier and has higher
particle density than ibuprofen. Consequently, increasing the amount of ibuprofen, i.e.
decreasing Avicel® content should lead to decreased bulk and true densities as observed.
In addition, at each drug level, the densities of the 20 micron sized ibuprofen are higher
than those of the 40 micron sizes. These could be explained by the higher geometric
mean sizes obtained from the 20 micron sizes, as already explained on page 168. The
50% drug loads of both drug micron sizes have almost similar GMDs and consequently
slightly similar densities. These results are supported by those of the statistical analyses
shown in Table XXVI. It was observed that drug load (p = 0.0003) significantly affected
the true density of the microparticulates.
Bulk density was also significantly affected by drug load (p = 0.001) as well as
micron size (p = 0.0088), however, no significant interaction was observed between these
factors (p > 0.05). The percent compressibility (Carr’s index) was generally < 15%,
indicative of the acceptable flowability of the spheroids as well as good bulk and true
densities for the production of both single unit- (tablets) and multi unit (capsules) dosage
forms.

vii. Flowability
The finer sized ibuprofen resulted in lower flowability (Table XXV). These
results were as previously reported (52,153).

180

viii. Sphericity of the granules
The sphericity of most of the microparticulates fell within our set acceptance
criteria (≥ 0.85), which is close to 1.0, the optimal value for sphericity (Table XXV). The
sphericity of the 20 micron sized ibuprofen batches were slightly higher than the 40
micron sized batches. This could be explained by the smaller size of the particles that
could form less porous bond with Avicel®, thereby leading to smoother surface texture.
Statistically, sphericity was significantly affected by drug load (p = 0.0282) and micron
size (p = 0.0034), but no significant interaction was observed between these factors.

ix. Size distribution of granules
The geometric mean diameter of the microparticulates ranged from 456 ± 1.37 µm
- 802 ± 1.35 µm (Table XXV; Figure 37) respectively. Within the batches made of the
two ibuprofen micron sizes, the GMD increased with increased drug load, which could be
either due to overgranulation or improved bonding due to higher amount of ibuprofen.
This observation was also found to be statistically significant (p = 0.0196), as already
discussed on page 168.

x. Ibuprofen release from granules
All the formulations released more than 80% of the drug within 20 min, except
the batch containing 80% ibuprofen spheronized using the 40 micron sized drug. This
could be due to the bigger GMD that consequently reduced the surface area of the
granules (Table XXV; Figure 38). For the same reason, the Q20 was lower with the 80%
drug load.

Geometric mean diameter
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181
800
700
600
500
400
300
200
100
0
Ibu 2050

Ibu 2065

Ibu 2080

Ibu 4050

Ibu 4065

Ibu 4080

Batches

Figure 37: Geometric mean diameters of drug particle size/drug load batches.
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Figure 38. Dissolution profiles of drug particle size/drug load batches.

Statistically, it was observed that drug micron size (p = 0.0034) and drug load
(p = 0.0282) significantly affected this response variable (Table XXVI). There was also
interaction between these main factors, although this was not statistically significant
(p = 0.0613) based on our set significant level (p < 0.05).
In addition, the 65% drug loaded formulation of the 20 µm ibuprofen had similar
characteristics with the previously optimized 50% and had the most significant positive
effects on the products. This was therefore chosen for intermediate batch size scale-up.
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b. Effect of Intermediate Size Scale-up on the Characteristics of Ibuprofen
Microparticulates
1. Experimental design
Batch size:

Batch size significantly (p < 0.05) affected some of the physical

characteristics studied, namely, bulk density (p = 0.0072), tapped density (p = 0.0124),
friability (p = 0.0146) and usable fractions (p = 0.0009). These results were as expected
as similar observations have been reported for most of these variables (101,140).
Increased batch size led to higher densities, lower friability and lower usable fractions.
The latter could be due to increased spheroid size as it affected only the 1 kg batches that
have considerably big differences in their particle sizes. These results are shown in
Tables XXVII and XXVIII and in the Pareto plots (Figure 39).

Drug load:

Drug load significantly (p < 05) affected the densities of the

spheroids (Table XXVIII). This is due to the difference in the densities of the powder
blends used in the formulations, which contained different percentages of Avicel® and
the drug. As was previously obtained, higher drug loads resulted in lower bulk
(p = 0059), tapped (p = 0071) and true (p = 0022) densities.

Replication:

Replication had no significant effect (p > 0.05) on all twelve

product characteristics studied (Table XXVIII), as well as no significant interactions with
the main effects [(batch size and drug load); results not shown], indicating batch-to-batch
reproducibility.
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Estimated effect on Bulk density

Significance (p)
0.0059
0.0072
0.3120
0.5195

Estimated effect on Tapped density
Significance (p)
<.0071
0.0124
0.8543
0.8543

Estimated effect on True density

Significance (p)
0.0022
0.0753
0.2530
0.8235

Estimated effect on Friability
Significance (p)
0.0146
0.1817
1.000
1.000
Estimated effect on LOD

Significance (p)
0.0178
0.0602
0.0813
0.0953

Estimated effect on Usable fraction

Significance (p)
0.0009
0.0255
0.2937
0.4561

Figure 39. Pareto plots of effects of main factors on the specified product qualities.

Interaction:

The interaction results are shown in Figure 40. There was

significant interaction (p < 0.05) between batch size and drug load on the LOD
(p = 0.0178) and usable fraction (p = 0.0255) variables (Table XXVIII; Figure 40).
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Figure 40. Interaction plots of the effects of main factors on specified qualities.

Considering the significant interaction obtained with the usable fraction, and the fact that
significant effect was obtained from batch size alone, it can be inferred that increased
batch size resulted in decreased usable fraction.
However, the results obtained are within our set acceptance criteria that were
based on published results from other reporters (6,9).

185

2. Physical characteristics of pellets
i. Scanning electron microscopy
Figure 41 shows typical morphology of the spheroids obtained from the two drug
loads (Figures 41A & B) and the two batch sizes (Figures 41B & C). As shown in Table
XXVII and Figure 41, the size of the microparticulates increased with increased drug load
at the 1 kg level. This effect was not pronounced at the scale-up level. This could be due
to the fact that although the percentage of Avicel® present in the fluid-bed is the same in
both batch sizes, the increased batch size of Avicel® might have enhanced
its water-absorbing properties in the system and therefore reduced the chance of over
granulation.
A

B

C

Figure 41: Scanning electron micrographs (30x) of ibuprofen formulations (20 µm drug
particle size) containing different drug loads, A (1 kg, 50%); B (1 kg, 65%),
and C (50 kg, 65%).
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Table XXVII. Physical Characteristics of Batch Size/Drug Load Batches (Means of replicated batches)

Batch size
% ibuprofen

1 kg
50

50 kg
65

50

65

Physical characteristics
% Yield

90.85  7.99 87.7  1.56

95.70  0.18

91.38  0.76

% Moisture content

1.7  .14

1.50  0.27

1.74  0.35

% Drug content

98.55  5.08 98.79  0.95 101.5  2.16

0.89  0.01

102.09  0.06

Geometric mean diameter (mm) 485  1.52

605  1.45

522.00  2.04

538.00  1.95

Sphericity

0.91  0.00

0.91  0.01

0.91  0.00

0.91  0.01

Flowability (deg)

22.15  0.00 21.43  1.16 22.99  0.47

20.84  0.46

Carr’s index. (%)

8.03  1.67

6.14  0.16

6.85  1.94

True density (g/cm3)

1.287  0.02 1.235  0.00 1.27  0.01

1.22  0.00

Bulk density (g/cm3)

0.69  0.01

0.63  0.01

0.77  0.02

0.68  0.01

Tapped density

0.75  0.02

0.67  0.01

0.82  0.02

0.73  0.00

Q20 (%)

83.1  1.68

83.1  1.68

83.1  1.68

87.45  1.05

Friability (%)

0.50  0.24

0.50  0.24

0.00  0.00

0.00  0.00

Usable fraction (%)

91.0  1.41

85.0  1.41

69.8  2.12

73.75  2.19

6.02  0.06
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TABLE XXVIII: P-values of Independent Variables of Batch Size/Drug Load Batches

Dependent variables

Independent variables

Physical characteristics Replication

Interactions

Batch size

Drug load

Interactions

1

2

3

2*3

Yield

NS

NS

NS

NS

Drug content

NS

NS

NS

NS

LOD

NS

NS (0.0602)

NS (0.0813)

S (0.0178)

Q20

NS

NS

NS

NS

Geometric mean

NS

NS

NS

NS

True density

NS

NS (0.0753)

S (0.0022)

NS

Bulk density

NS

S (0.0072)

S (0.0059)

NS

Tapped density

NS

S (0.0124)

S (0.0071)

NS

Carr’ s index

NS

NS

NS

NS

Flowability

NS

NS

NS (0.0774)

NS

Friability

NS

S (0.0146

NS

NS

Sphericity

NS

NS

NS

NS

Usable fraction

NS

S (0.0009)

NS

S (0.0255)

diameter

188

ii. Moisture content/Loss on drying analyses
Binder amount:

As expected and also as was previously observed, the

amount of binder needed for spheronization of the different drug levels was inversely
related to drug load (Table XV), although the amount used for the 50 kg-65% drug load
appeared to be high. This could be due to some human error as both the total time used
for spheronization and the percent moisture at the end of the spheronization process
reflect an inverse relationship to the drug load. These results indicated that, as previously
stated, Avicel® acts as molecular sponge that absorbed water. Additionally, the amount
of binder needed for the process also decreased as the batch size increased. From Table
XV, it is apparent that a processing time was reduced by 13x for intermediate batch
compared to the small scale batch irrespective of the drug load used (Equations 32 and
33). This confirmed the reproducibility of the process.

For the 50% drug load:
67 min (Average value for two batches of the 1 kg batches) * 50
= 13
246 min (Average value for two batches of the 50 kg batches)

Eqn. 32

For the 65% drug load:
54.5 min (Average value for two batches of the 1 kg batches) * 50
= 13
198 min (Average value for two batches of the 50 kg batches)

Moisture content in the fluid-bed:

Eqn. 33

A plot of the moisture content for both batch

sizes during spheronization and drying processes in function of time (Figure 42) showed
that with the two sizes, the amount of the liquid binder needed for the spheronization of
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the powder blends decreased as the drug load increased. These correlated with previous
reports and our earlier explanations about the function of microcrystalline cellulose as a
molecular sponge for water absorption. The moisture content at the end of drying of the
products was generally < 2% (Table XXVII).

60

% LOD

50
40
30
20
10
0
0

60

120

180

240

300

1kg-50%-1
1kg-50%-2
1kg-65%-1
1kg-65%-2
50kg-50%-1
50kg-50%-2
50kg-65%-1
50kg-65%-2

Time (mins)

Figure 42: The moisture content profile of scale-up batches as a function of time.
(1 & 2 represent replicate batches).

iii. Yield and usable fractions of spheroids
The yield of the formulations ranged from 87.7 ± 1.56% - 95.7 ± 0.18% with the
usable fractions (250 - 850 µm) ranging between 69.8 ± 2.12% - 91 ± 1.41% respectively
(Table XXVII). Comparing the two batch sizes, increased batch resulted in increased
product output, which could be attributed to decreased amount lost as a percentage of the
initial powder blend input. Comparing the two drug loads within each of the batch sizes,
increased load resulted in decreased product output, as was observed in the previous
section, which could be attributed to higher amount of the lower weighted ibuprofen in
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the larger drug load formulation. However, the analysis showed that these observations
were not statistically significant (Table XXVIII).
The usable fraction was influenced by both batch size and drug load (Table
XXVII). The fraction decreased as drug load increased, however, increased batch size
appeared to have positively affected the usable fraction since the 50 kg-65% batch yielded
slightly higher amount than the 50 kg-50% formulation. These results were supported by
the statistical results that showed a significant effect (p = 0.0009) of the batch size on this
variable, as well as a significant interaction effect (p = 0.0255).

iv. Drug content
All the formulations had drug contents > 90% thereby meeting our set acceptance
criteria (≥ 85%).

v. Friability
As shown in Table XXVII, the percentage weight loss from all the formulations
was generally less than 1. Thus, although the statistical results show a significant effect of
batch size on friability (p = 0.0146), this effect was obtained between 0 and 0.5% values
and could be considered clinically unimportant.

vi. True density and compressibility
In both batch sizes, bulk, tapped and true densities decreased with increased drug
loads, which could be due to the reasons explained in the previous section. In addition, at
each drug level, the true densities were similar as could be expected, being the same
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formulation and moreover, true density is indicative of the importance of compactness of
substances. However, the bulk and tapped densities, which reflect the packing properties
of spheres, increased with increased batch size. These could be as a result of other
product qualities including pellet sizes. The percent compressibility (Carr’s index) was
generally < 15%, indicative of the acceptable flowability of the spheroids as well as good
bulk and true densities for the production of both single unit- and multi unit
dosage forms.

vii. Flowability
The flowability of the products fall within our set acceptance criteria (θ < 30o). In
addition, no significant effect was observed on this variable by the main factors.

viii. Sphericity of the granules
The sphericity of all the microparticulates fall within our set acceptance criteria
(≥ 0.85), which is close to 1.0, the optimal value for sphericity (Table XXVII).

ix. Size distribution of granules
The geometric mean diameters of the microparticulates range from 485 ± 1.52 µm
- 605 ± 1.45 µm (Table XXVII; Figure 43). Within the 1 kg batches, the GMD increased
with increased drug load, which could either be due to over granulation or improved
bonding due to higher amount of ibuprofen. For the 50 kg batches, the effect of drug load
on GMD appeared to be improved with the increased batch size, although these results
were statistically insignificant (p > 0.05).

Geometric mean diameter
(microns)
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Figure 43: Geometric mean diameters of batch size/drug load batches.

x. Ibuprofen release from granules
All the formulations released more than 80% of the drug within 20 min. As
observed by other reporters, the Q20 was higher for the higher drug loaded batches at each
batch size, despite the larger GMD of the 1 kg batch containing 65% drug load (Table
XXVII; Figures 43 & 44).

% Released
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1kg-65%
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50kg-50%

20
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0
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Figure 44. Dissolution profiles of batch size/drug load batches.

In summary, increased batch size reduced the processing time at both drug loads
and also improved some spheroid qualities such as geometric mean diameter (Table XVII
and Figure 43). The dissolution of the 65% drug load 50 kg batch size was the most
acceptable (highest Q20). This formulation was therefore chosen for coating.
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Phase 4
Coating and Encapsulation of Spheronized Ibuprofen Microparticulates Using
Hard Gelatin Capsules

a. Effects of coating
1. Experimental design
Polymer type:

Polymer type significantly (p < 0.05) affected most of the

qualities of the spheroids, except the T50, geometric mean diameter (GMD), the friability
and the sphericity. The core pellets used in this experiment were similar for both
Eudragit® and Surelease®. The levels were chosen such that the medium level in each
case represented the company recommended level to obtain satisfactory coating. It is
therefore evident from our results that these recommended levels are somehow equivalent
in the coating capacities of the two polymers. However, the polymer level necessary to
achieve the objective (prolonged drug release) is formulation-dependent. These results
are shown in Tables XXIX and XXX and also in the Pareto plots in Figure 45.

Polymer level:

Polymer level significantly (p < 0.05) affected some of the

physical characteristics studied, namely, yield (p = 0.0370), T50 (p = 0.0165), bulk
density (p = 0.0462), true density (p = 0.0072), flowability (p < 0.0001), and usable
fractions (p = 0.0071). Most of these results were as expected. Drug release has been
variously reported to decrease with increased polymer level (175,176). Increased polymer
level was also expected to increase particle size/geometric mean diameter, which will
affect the flowability and densities of the formulations, as already explained in previous
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Estimated effect on Yield

Significance (p)
0.0016
0.0374
0.3140
0.4061
-

Estimated effect on T50

Significance (p)
0.0165
0.3789
0.2115
0.3318
-

Estimated effect on Flowability

Significance (p)
<.0001
<.0001
0.3537
0.3042

Estimated effect on Bulk density

Significance (p)
0.0013
0.0462
0.1717
0.2888

Estimated effect on True density

Significance (p)
0.0008
0.0072
0.4447
0.9927

Estimated effect on Usable fraction

Significance (p)
0.0083
0.0071
0.1262
0.6793

Figure 45. Pareto plots of effects of main factors on the specified product qualities.

sections. The discrepancy observed within the batches coated with the Eudragit® polymer
could be due to an uncontrollable sedimentation of talc present in the coating solution

195

tubing that might have altered most of the results expected from this polymer type and
levels. Possible explanations with regard to this observation will be discussed at the
various sections of the product quality variables. The statistical results obtained with this
variable are shown in Tables XXIX and XXX and also in the Pareto plots in Figure 45.

Replication:

Replication had no significant (p > 0.05) effect on all the product

characteristics studied (Table XXIX), as well as no significant interactions with the main
effects [(polymer type and level); results not shown]. Although these results support
batch-to-batch reproducibility of the process, some effort and experience with the fluidbed are required in order to achieve this goal.

Interaction:

There was no significant interaction (p > 0.05) between polymer type and

Figure 46. Interaction plots of the effects of main factors on specified qualities.
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polymer level. There were also no significant interactions between these main factors and
replication. These results, some of which are presented in Figure 46 support the feasibility
of the process.

2. Physical characterization of granules
i. Scanning electron microscopy
The size of the microparticulates increased directly with coating Table XXIX and
Figures 47 & 48. The pore size decreased, suggestive by the smoother surface of the
coated pellets. Thus, the particle size distribution and drug release were subsequently
affected, as will be discussed further in the respective sections.
A

B

C

Figure 47: Scanning electron micrographs (30x) of ibuprofen granules (65 % drug load).
Uncoated ibuprofen (A); Surelease® 12.5% (B); Eudragit® NE 30D 15.5% (C).
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A

B

C

Figure 48: Scanning electron micrographs (100x) of ibuprofen granules (65 % drug load).
Uncoated ibuprofen (A); Surelease® 12.5% (B); Eudragit® NE 30D 15.5% (C).

ii. Yield and usable fractions of spheroids
The yield of the formulations ranged from 82.36 ± 0.53% – 98.05 ± 1.47% with
the usable fractions (250 - 850 µm) ranging between 68 ± 2.83% – 83 ± 2.82%
respectively (Table XXIX). The percent yield of the batches coated with Surelease® was
greater than that of the Eudragit® batches. The percent yield was calculated based on the
ratio of the product output to the total weight of solids present in the fluid-bed. This, as
referred to earlier could be due to talc sedimentation in the tubing. This observation was
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TABLE XXIX. Physical Characteristics of Coated Ibuprofen Spheroids (Means of replicated batches)
Polymer type
% Coating level

Surelease
0 (Uncoated)

7.5

10

Eudragit
12.5

12.5

14

15.5

Physical characteristics
% Yield

91.38 ± 0.76

% LOD

1.74 ± 0.35

93.35 ± 2.35 98.05 ± 1.47

96.76± 0.54

82.36 ± 0.53 88.31 ± 4.76 90.76 ± 2.81

0.66 ± .21

0.81 ± 0.14

0.87 ±

0.76 ± 0.21

1.25 ± 0.19

1.29 ± 0.28

106.41 ±

105.95 ±

105.43 ±

1.34

1.28

1.13

2.47

680 ± 0.06

685 ± 0.05

725 ± 0.00

670 ± 0.01

669 ± 0.02

0.85 ± 0.026 0.86 ± 0.05

0.87 ± 0.01

0.86 ± 0.01

0.88 ± 0.01

0.88 ± 0.01

0.0.07
% Drug content

102.09 ± 0.06

108.22 ±

107.57 ± 0.55 109.02 ±

0.25
Geometric mean

538.00 ± 1.95

643 ± 0.04

diameter (µm)
Sphericity

0.91 ± 0.01

Flowability (deg)

20.84 ± 0.46

True density g/cm3)

1.22 ± 0.00

Bulk density g/cm3)

0.68 ± 0.01

T50 (min)

< 15

Friability (%)

0.00 ± 0.00

Usable fraction (%)

73.75 ± 2.19

21.06± 0.35

22.78 ± 0.00

23.75 ± 0.00 26.57 ± 0.00 28.73 ± 0.12 29.47 ± 0.30

1.14 ± 0.01

1.12 ± 0.02

1.11 ± 0.01

1.19± 0.00

1.12 ± 0.01

1.15 ± 0.01

0.63 ± 0.01

0.62 ± 0.02

0.63 ± 0.01

0.60 ± 0.00

0.57 ± 0.00

0.60 ± 0.00

45 ± 7.07

75 ± 21.21

105 ± 21.21

60 ± 0

105 ± 21.21

100 ± 14.14

0.33 ± 0.00

0.34 ± 0.47

0.17 ± 0.23

0.17 ± 0.23

0.33 ± 0.00

0.33 ± 0.00

80.00 ± 0.00 86.00 ± 2.82

83.00 ± 4.24 68.00 ± 2.83 81.00 ± 1.41 80.00 ± 0.00
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TABLE XXX: P-values of Independent Variables of Coated Ibuprofen Spheroids
Dependent variables

Independent variables

Interactions
(PT*PL)

Physical characteristics

Replication (2x)

Polymer type (PT)

Polymer level (PL)

[Surelease, Eudragit] [Low, Medium, High]
1

2

3

2*3

Yield

NS

S (0.0016)

S (0.0370)

NS

Drug content

NS

S (0.0269)

NS

NS

LOD

NS

S (0.0248)

NS

NS

t50

NS

NS

S (0.0165)

NS

Geometric mean

NS

NS

NS

NS

True density

NS

S (0.0008)

S (0.0072)

NS

Bulk density

NS

S (0.0013)

S (0.0462)

NS

Carr’ s index

NS

NS

NS

NS

Flowability

NS

S (<.0001)

S (<.0001)

NS

Friability

NS

NS

NS

NS

Sphericity

NS

NS

NS

NS

Usable fraction

NS

S (0.0083)

S (0.0071)

NS

diameter
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confirmed with the fact that within the batches coated with Eudragit®, the percent yield
increased with the theoretical coating level and increased solid content. The talc effect
would be more pronounced on the batches coated with the lower polymer level as any
effect on the ratios (used for yield calculation) would have greater effect on the lower
polymer level.
The usable fractions were mostly < 85% of the product output. This could be
attributed to some amount of agglomeration that led to increased particle size. However,
values as lower than this have been reported acceptable usable fraction in literature (9).

iii. Drug content
The drug content ranged between 105 ± 1.13% – 109 ± 1.34%. Although these are
greater than 100%, they fell within the USP recommended range for drug content.
Additionally, standard solution analyzed with these samples (without the extraction
process) also gave a drug content greater than 100%. The results could be due to some
random analytical errors.

iv. Friability
During coating, pellets are subjected to appreciable frictional forces, thus friable
pellets generate significant amount of fines, which can mix with the coating solution and
affect the topography of the coated pellets. The pellets to be coated must therefore
withstand the vigorous agitation that occurs in the coating chamber. As shown in Table
XXIX, the percentage weight loss from the uncoated ibuprofen formulation used for
coating was zero, indicating its suitability for the coating processes. The percentage
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weight losses from all the coated formulations were also less than 2%. These
formulations are therefore suitable for the hard gelatin encapsulation process that will be
subsequently performed.

v. Densities
Coating with both polymers decreased both the bulk and true densities (Table
XXIX). This could be attributed to increased pellet sizes due to coating. There were
generally no significant difference between the densities of pellets coated with the same
polymer, except with the batch coated with 14% Eudragit®. The inconsistencies observed
with this polymer could be due to the presence of talc as has already been explained, that
made it difficult to calculate the actual amount of polymer in the batches. This
inconsistency was also made obvious with the release pattern observed with these
Eudragit® batches, as will be shown below.
It was not possible to calculate the tapped density of the batches because the
volume of most of the formulations increased with successive taps, thus making the
tapped density higher than the bulk density. This phenomenon was not problematic for
future (encapsulation) study as it has been reported that the bulk and not the tapped
density is used to calculate the fill weight for pellets. Consequently, the compressibility
index could also not be calculated.

vi. Flowability
The flowability of the products fell within the generally acceptable flowability
criterion (θ < 30o). However, flowability decreased with increased polymer level.
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Considering the batches coated with Surelease®, the flowability trend could be due to
increased diameter of the pellets that retarded flow properties, while the reduced flow
within the Eudragit® batches could be due to increased tackiness with increased polymer
caused by the absence of the sedimented talc in the products. This tackiness must have
led to the difference in the flowability between the two polymer types that resulted in high
significant level observed from this variable with both polymer type (p < 0.0001) and
level (p < 0.0001). It could therefore be better to add the talc directly to the fluid-bed
instead of dissolving it in the coating solution.

vii. Sphericity of the granules
The sphericity of both the coated and uncoated spheroids fell within our set
acceptance criteria (≥ 0.85; Table XXIX). No significant difference was observed
between the results obtained from these analyses. However, the pellets coated with
Surelease® appeared to be better spheres visually.

viii. Size distribution of granules
The geometric mean diameters of the microparticulates ranged from 643 ± 0.04
µm - 725 ± 0 - 0.00 µm (Table XXIX; Figure 49). As expected, all the coated batches
were larger than the uncoated formulation, confirming an increased diameter of the
pellets due to the coating levels. Within the batches coated with Surelease®, there was
slight but statistically insignificant increase in diameter as the coating level increased.
This indicated the consistency of this coating material. With the batches coated using
Eudragit® polymer, a discrepancy in the geometric diameter was observed. The batch
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with the theoretical lowest polymer level was larger than the batches coated with higher
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Figure 49: Geometric mean diameters of uncoated and coated ibuprofen pellets.

ix. Ibuprofen release from pellets
The uncoated formulation released 50% (T50) of its drug content within 15 min.
On the contrary, the release rates of the coated formulations were retarded (Table XXIX
and Figure 50). The T50 of the replicate batches of these coated formulations ranged
between 45 ± 7.07 min - 105 ± 21.21 min, depending on the coating level.
Several factors affected the release rate of modified release formulations
(175,176,262). These include the type of equipment used for coating, the porosity of the
products, surface area, type of dissolution medium, coating level, physical characteristics
of the model drug, etc. In the case of pellets, type of spheronization technique and pellet
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sizes have been reported as among the major factors affecting their release characteristics.
Potter et al. (263), showed that at the same coating level using Surelease®, the T50 of
chloropheniramine pellets was 40 min (500 – 600 µm), 3 hrs (850 – 1000 µm) and 5 hrs
(1000 – 1400 µm). The mean diameter of our pellets was between 642 – 725 µm (Figure
49), with the mode value lying generally at 425 µm. Pellet size could therefore explain
the results obtained from our dissolution analysis.
As shown in Figure 50, the release rates of the formulations decreased as the
coating levels increased. This observation was more consistent with the batches coated
A
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Figure 50. Dissolution profiles of ibuprofen pellets. Uncoated pellet and pellets coated
with Surelease® polymer (Panel A), Uncoated pellet and pellets coated with Eudragit®
polymer (Panel B).
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with Surelease® polymer. The batches coated with 14% and 15.5% Eudragit® released
equivalent amount of drugs till 60% of their contents were released, consistent with the
discrepancy that has been observed in the product qualities of these batches. However, at
the highest polymer coating level for both polymers, a prolonged release was
observed generally.

x. Kinetics of drug release
Kinetically, the decreased drug release observed with increased polymer levels is
due to simultaneous increase in coating thickness and length of diffusion pathway
(175,188). These confirmed that the coating process was successfully achieved. With
uncoated pellets as well as at low coating levels, pores exist at the pellet surface or at
pellet-coating interface of the latter due to the coating imperfections achieved at these
levels. Drugs readily diffuse through these pores, thus the cumulative drug release in this
case is linear with the square root of time (Equation 7). The pores are sealed as coating
levels increase so that drug is released through an intact membrane and consequently
follow the zero order release kinetics (Equation 12). The transition point where drug
release is defined by the zero order kinetics is called the critical coating level. Drug
release has also been shown to follow first order kinetics (Equation 28). Our data were
therefore fitted to these equations, to Peppas empirical equation (Equation 9) and to a
recently proposed combined mechanistic kinetics (Equation 15; 177). The Peppas
equation constant incorporates the structural and geometric characteristics of the release
device (264). The combined mechanistic equation constants incorporate the Higuchi and
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zero-order release kinetics. The results of these studies are shown in Figures 51, 52 and
Table XXXI.
1

Q = kt

Eqn. 7

2

log ( Mt / M ) = log k + n log t

F =

DKCsA
L

Q = Kt

1
2

+

Eqn. 12

DKCs
t
L

ln (100 − Q) = ln Q - k t
0

Uncoated pellets:

Eqn. 9

1

Eqn. 15

Eqn. 28

Drug release from uncoated beads can be described by the

pore controlled release model, and mathematically by the square root equation (Equation
7). Figure 51 shows plots of cumulative percent drug release vs. square root of time of all
the formulations. Table XXXI shows the results of the parameters of the drug release
equations. The best correlation coefficients were achieved with the combined mechanistic
and Higuchi equations. Howere, the release rate of uncoated formulation depicted by the
Higuchi constant (kH) shows a high linear release constant compared to the coated pellets.
These indicate that the uncoated pellets follow an inner matrix (Higuchi) release model.

Coated pellets:

As previously discussed, Surelease® and Eudragit®

polymers form water permeable but insoluble polymeric membranes that allow controlled
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Figure 51. Mathematically modeled drug release of uncoated and coated ibuprofen
pellets
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Table XXXI. Results of Regression Equations for Drug Release from Uncoated and
Coated Pellets According to Equations 7, 12, 28, 15, and 9 Respectively.

Formulations

Kinetic models

Higuchi equation
R2
kH

Zero order
R2
ko

First order
R2
k1

Uncoated

0.9543

19.491

0.7445

3.7974

0.9358

0.0395

SR 7.5%

0.9639

5.6918

0.7977

0.3163

0.9545

0.0034

SR 10%
SR 12.5%
EUD 12.5%
EUD 14%
EUD 15.5%

0.9815
0.9899
0.9796
0.9892
0.9821

5.2065
5.1117
5.6065
5.1572
4.9152

0.8473
0.908
0.8494
0.9183
0.8811

0.2955
0.2991
0.319
0.3036
0.2844

0.9553
0.9794
0.9698
0.9833
0.9609

0.0026
0.0024
0.003
0.0024
0.0022

Formulations

Kinetic models

Combined mechanistic equation
R2
k0
kH
Uncoated
SR 7.5%
SR 10%
SR 12.5%
EUD 12.5%
EUD 14%
EUD 15.5%

0.9997
0.9959
0.9938
0.99
0.9904
0.9893
0.9843

3.03
0.23
0.13
0.01
0.13
0.01
0.05

32.55
9.27
7.22
5.28
7.63
4.96
5.72

Peppas equation
R
kP
n
0.8594 0.2303 1.5443
0.9041
0.304
0.7648
0.935
0.2428 0.7578
0.9758 0.1431 0.7722
0.9414 0.2313 0.7746
0.9828 0.1153 0.7812
0.9708 0.1477 0.7677
2

release of the model drug. Drug release from such systems can either be dissolutioncontrolled (Equation 7), membrane-controlled (Equation 12) or a combination of both
processes (Equation 15), depending on the coating levels (265,266). As shown in the
scanning electron micrographs in Figures 47 & 48, the uncoated pellets used for coating
have pores. If all the pores of the core ibuprofen pellets are blocked by permeable coating
membranes of the polymers, the coating is complete, and the drug release is controlled by
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Figure 52: First order release profiles from uncoated (Unctd) and coated ibuprofen pellets

the coating film. The release rate will depend on the polymer film/dissolution medium
partition coefficient and zero order kinetics will be followed. Table XXXI shows that the
highest correlation coefficient was achieved with the combined mechanistic and Higuchi
equations. The correlation coefficients obtained with the first order kinetics appeared to
be better than those of the zero order kinetics. However, the n values from the Peppas
equation were > 0.75 for all the coated formulations, an inclination towards the zero order
release mechanism. These results, together with the first order plot shown in Figure 52
exclude first order kinetics from the release mechanism of the coated pellets.
Figure 51 also shows that although good correlation was obtained with the coated
pellets for the Higuchi model, the coated pellets did not follow pure Higuchi mechanism.
Therefore, the kinetics of drug release from these coated pellets follows either a complex
system or a combination of square root of time and zero-order kinetics (Equation 15).
Thus, a non-Fickian diffusion through the polymer films (0.5<n<1) was followed.
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xi. Comparison of in vitro dissolution profiles using difference and similarity factors
Drug release decreased as polymer levels increased. Table XXXII lists some time
points and (their respective) percentage dissolution of both the uncoated and coated pellet
formulations. Table XXX shows the p-values of some of the product qualities. The time
taken for both 50% (p = 0.0165) and 80% dissolutions (T50 and T80 respectively) varied
for the different formulations, and were significantly affected by the coating levels.
Results from difference and similarity factors calculations (Table XXXIII) showed that
the profile of the uncoated pellets was different from those of all the coated pellets
(f1 > 15 and f2 < 50). These indicated that the release was dependent on the coating level.

TABLE XXXII: Mean Percent Dissolution of Ibuprofen Spheroids at the Specified
Time Points
Time (min)

10

20

60

120

240

480

Mean percent dissolution ± SD

Batches
Uncoated

75.32
± 1.22

87.43
± 0.03

92.36
± 0.28

93.63
± 0.52

93.90
± 0.46

93.90
± 0.20

Surelease® 7.5%

21.55

31.8

56.94

72.91

85.61

92

± 0.66

± 0.35

± 4.43

± 9.25

± 8.3

± 6.16

Surelease 10%

16.36
± 0.94

24.19
± 1.78

46.82
± 3.76

62.41
± 7.56

76.98
± 4.72

87.47
± 3.38

Surelease®

11.00

16.56

37.23

55.24

72.66

83.63

12.5%

± 0.35

± 0.4

± 2.96

± 3.44

± 3.09

± 2.41

16.26
± 2.37

22.91
± 4.07

50.62
± 0.98

66.69
± 1.25

82.06
± 4.21

92.09
± 0.01

Eudragit® 14%

9.42
± 1.80

15.76
± 3.11

37.3
± 5.16

53.00
± 2.77

73.13
± 4.10

88.04
± 6.14

Eudragit®
15.5%

11.18 ±
0.93

15.28
± 2.35

39.05 ±
3.35

55.44 ±
3.97

71.12 ±
4.26

80.39
± 0.90

®

Eudragit
12.5%

®
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TABLE XXXIII: Values of Difference and Similarity Factors (f1 and f2 respectively)
for Uncoated and Coated Pellets
Reference formulation
Uncoated

Test formulation

F1 value

F2 value

®

32.04

23.10

®

Surelease 7.5%

Uncoated

Surelease 10%

40.81

19.25

Uncoated

Surelease® 12.5%
®

Surelease 7.5%
®

Surelease 7.5%
®

47.95

16.2

®

12.91

54.44

®

23.42

41.71

®

Surelease 10%
Surelease 12.5%

Surelease 10%

Surelease 12.5%

12.06

58.68

Uncoated

Eudragit® 12.5%

Uncoated

37.72

19.9

®

47.89

15.89

®

Eudragit 14%

Uncoated

Eudragit 15.5%

48.68

16.13

Eudragit® 12.5%

Eudragit® 14%

®

Eudragit 12.5%
®

Eudragit 14%

16.33

50.65

®

17.59

49.87

®

1.51

71.75

Eudragit 15.5%
Eudragit 15.5%

For the pellets coated with Surelease®, the f2 values indicate that the batch coated
with 7.5% was similar (f2 > 50) to the profile of 10% coating level batch, but was
significantly different (f2 < 50) from the pellets coated with 12.5% polymer. The same
trend of f2 values was obtained from the batches coated with Eudragit®, although to a very
limited level. The f2 values indicated that the batch coated with 12.5% polymer level was
not significantly different from those coated with 14% (f2 = 50.65) and was slightly
different (f2 = 49.87) from the batch coated with 15.5% polymer. However, the
results of the 15.5% coating level showed some discrepancies, as already observed from
other product variables.
Generally, f1 values confirmed the results of the f2 factor. However, the results of
comparisons between Eudragit® 12.5% and 14% and Eudragit® 12.5% and 15% appeared
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to be on a borderline. Thus, the more generally accepted results from f2 factor were
considered more conclusive in these cases. The batch coated with 12.5% Surelease® was
therefore chosen to study the effects of encapsulation on the uncoated and coated
spheroids.

b. Effect of Encapsulation on the Characteristics of Ibuprofen Microparticulates
1. Experimental design and Physical characteristics of pellets
A major objective of encapsulated formulations is to ensure that each capsule
provides the expected dose of drug and that the drug should be released from the
capsule to ascertain its bioavailability. Tables XXXIV and XXXV show the
respective results of the effects of encapsulation on pellet qualities and the p-values of
the independent variables obtained from the statistically analyzed factorial design.

i. Formulation type
Fill weight:

Formulation type significantly (p < 0.05) affected the average fill

weight of the pellets (Figure 53). As has been previously reported by other authors, this
could be due to the effects of factors, e.g. flowability of the pellets (224,225,228). Based
on the results of the angle of repose of the pellets before encapsulation, (Table XXIX),
the XQFRDWHGSHOOHWV  o ZHUHPRUHIORZDEOHWKDQWKHFRDWHGSHOOHWV  o),
and consequently resulted in higher fill weights within the experimentally specified time
(Table XXXIV). Studentized residuals test statistic showed some likely pattern, however,
based on Dubin-Watson there was no correlation between the observations (p < 0.05).
The result causing the observed pattern could therefore be an outlier.
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TABLE XXXIV: Effects of Encapsulation Variables on Uncoated and Coated Ibuprofen Spheroids

Operational Shuttle speed
speed (rpm) (msecs)
Average fill
weight (mg)
260
517.03
75
280
528.2
300
528.35

85

Unencapsulated

260
280
300

511.51
503.91
487.24
528.35

SD
16.95
8.87
7.24

Uncoated
%CV
Drug
~ T50 Average fill
content (mg) (mins) weight (mg)
3.28
467.8
1.68
358.47
7
463.15
1.37
363.24
6
483.2

10.22 2
16.58 3.29
26.8 5.51

-

-

460.7
470.33
471.58

352.23

5

483.2

Coated
SD %CV
Drug
~ T50
content (mg) (mins)
14.97 3.2
12.92 2.79
292.25
90
10.78 2.23
302.65
120
18.48 4.01
18.32 3.89
11.63 2.47

-

-

300.68

120
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Estimated effect on Av. fill wt.

Significance (p)
0.0004
0.0809
0.7135
0.9493

Estimated effect on SD

Significance (p)
0.1791
0.7860
0.9013
0.9833

Estimated effect on %CV

Significance (p)
0.1658
0.7443
0.7817
0.9009

Figure 53. Pareto plots of effects of main factors on the specified product qualities

TABLE XXXV: P-values of Independent Variables of Encapsulated and
Unencapsulated (Uncoated and Coated) Ibuprofen Spheroids
Dependent variables

Independent variables

Physical characteristics

Formulation type

Operational speed

Shuttle speed

Average Fill weight

S (0.0004)

NS

NS

SD

NS

NS

NS

%CV

NS

NS

NS

Standard deviation and coefficient of fill weight variation: The more flowable
uncoated pellets resulted in lower standard deviations and consequently in lower fill
weight variations. The bar diagram presented in Figure 54 shows that with the two
formulation types (uncoated and coated), the SD and %CV were generally lower for the
uncoated than with the coated pellets. The highest variability was however observed with
the uncoated pellets encapsulated at the highest operational and shuttle speeds. This result
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could be due to some interactions between the flowability of the pellets and these
different factors. There was no pattern observed with this variable and autocorrelation
result was also not significant (p > 0.05).

ii. Operational speed
Although the operational speed was observed to be statistically insignificant (p >
0.05), Table XXXIV shows that within each formulation type at different operational
speeds, the average fill weight was slightly higher for the lower speed than the higher
speed. Figure 53 also shows that the lower speed (75 rpm) contributed more to the
operational speed effect than the higher speed (85 rpm). This implied that for
formulations of similar flowability, a certain amount of speed is required for machine
operation as to achieve a desirable fill weight for the capsules.
As can be seen from the Pareto plots (Figure 53) and Table XXXIV, the
operational speed had more effect on the standard deviation and consequently on the
coefficient of fill variation than the other factors. Although these results were observed to
be statistically insignificant (p > 0.05), they were similar to those obtained previously in
literature with tamp filling machines using powders (216). Higher speeds generally led to
higher SD and %CV. This could be because with high operational speed, there was
insufficient time to achieve consistent fill weight and reproducibility, thereby introducing
more filling errors. There was no pattern observed with this variable and autocorrelation
result was also not significant (p > 0.05).
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iii. Shuttle speed
The results obtained with the shuttle speed (which regulates how long the feeder
assembly stays open to fill the capsules) varied for each formulation type. For the
uncoated pellets with very good flow properties, there was no difference between fill
weight at the medium and highest shuttle speeds. This indicated that 280 msecs was
sufficient for maximum fill weight of this formulation (Figure 5). For the coated batches,
the highest fill weight was also obtained at the lowest operational speed. However, higher
shuttle speed (300 msecs) was required to achieve higher fill weights compared to those
obtained with the lower shuttle speeds (260 and 280 msecs). These results were as
expected because higher shuttle speed allows more time for the capsule feeder to obtain

600

Av. fill wt. (mg)

500
400
300
200
100

U

nc
te
d75
U
/2
nc
60
te
d75
U
/2
nc
80
td
-7
U
5
/3
nc
00
te
d8
U
5/
nc
26
te
0
d85
U
/
nc
28
te
0
d85
/3
C
00
te
d75
/2
C
60
te
d75
/2
C
80
te
d75
/3
C
00
te
d85
/2
C
60
te
d85
/2
C
80
te
d85
/3
00

0

Form ulation type

Figure 54. Average fill weight (± SD) of ibuprofen pellets at different shuttle sizes
and operational speeds.
Uncted: Uncoated pellets; Cted: Coated pellets
75, 85: Operational speeds, 75 rpm and 85 rpm
260, 280, 300: Shuttle speeds, 260 msecs, 280 msecs, 300 msecs.
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more pellets that will be fed into the capsules. The results obtained with the high shuttle
speed at high operational speed might therefore be due to possible interactions between
the product qualities, e.g. flowability, and these different factors.
Apart from the uncoated formulation filled at high operational (85 rpm) and
shuttle (300 msecs) speeds, the SD and %CV decreased as shuttle speed increased (Table
XXXIV). A possible explanation to this has been given above, i.e. there was enough time
for sufficient pellets to fill the gelatin capsules, leading to filling consistency and
reproducibility. This could lead to reduced variability in the capsule fill weight. These
observations shown in Figures 54 and 55, were however statistically insignificant
(p > 0. 05).
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Figure 55. %CVs of the fill weight of ibuprofen pellets at different shuttle sizes and
operational speeds.
Uncted: Uncoated pellets; Cted: Coated pellets
75, 85: Operational speeds, 75 rpm and 85 rpm
260, 280, 300: Shuttle speeds, 260 msecs, 280 msecs, 300 msecs.
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In summary, formulation type had significant effect on the average capsule fill
weight. Within similar formulation types, high operational speed generally led to
increased SD and CV. Additionally, with the two formulation types and using the lower
speed (75 rpm), high shuttle speed resulted in higher fill weight, lower SD and
consequently to reduced %CV. The formulations encapsulated at low operational speed
(75 rpm) and at the medium (280 msecs) and high (300 msecs) shuttle speeds were
therefore selected to study the content uniformity and release profiles of the encapsulated
pellets.

iv. Drug content
The drug content was calculated as the amount of drug / capsule content used for
the dissolution experiments. Table XXXIV shows that the drug content was directly
related to the fill weight of the capsules, with the drug content of the uncoated pellets
being higher than that of the coated pellets per capsule. These results confirm the
reproducibility of the processes involved in the spheronization and encapsulation steps.

v. Ibuprofen release from granules
The percent drug release was normalized for drug content. The uncoated
formulations (encapsulated and unencapsulated) consistently released more than 80% of
the drug within 20 min. As was observed before encapsulation, the T50 of the coated
formulation was ~ 120 min. The T50 of the pellets encapsulated at 300 msecs was higher
than that encapsulated at 280 msecs, although the former had more ibuprofen content.
Although the gelatin capsules dissolved within 5 min of the dissolution analysis, the
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pellets remained undispersed throughout the analytical period. Thus, the release of the
capsules containing higher amount of pellets might have been retarded by the higher
packing of the content (Table XXIV and Figure 56).
Figure 56 also show that while the uncoated pellets released almost all their drug
contents within 40 min, the coated pellets sustained ibuprofen release up to 12 hr. This
confirmed that encapsulation had no undesirable effect on the formulated ibuprofen
micrpoparticulates.

100

% Released

80
Uncted-Unencap

60

Uncted-75-280
Uncted-75-300

40

Cted-Unencap
Cted-75/280

20

Cted-75/300

0
0

100 200 300 400 500 600 700
Time (min)

Figure 56. Dissolution profiles of encapsulated and unencapsulated (uncoated and coated)
ibuprofen spheroids.

Uncted: Uncoated pellets;
Cted: Coated pellets;
Unencap: Unenapsulated pellets
75, 85: Operational speeds; 75 rpm and 85 rpm;
280, 300: Shuttle speeds; 280 msecs, 300 msecs.
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vi. Drug release kinetics
The release mechanism also showed similar results with the unecnapsulated
pellets (Table XXXVI). However, encapsulation of the uncoated pellets, especially at 75
rpm and 300 msecs yielded higher correlation coefficients. The Higuchi release constant
was however comparatively unaffected. It is possible that smoother release profile was
achieved by adding the encapsulated pellets in the dissolution baskets, than by pouring

Table XXXVI. Results of Regression Equations for Drug Release from
Encapsulated and Unencapsulated (Uncoated and Coated) Pellets According to
Equations Equations 7, 12, 28, 15, and 9 Respectively.

Formulations

Kinetic models

Higuchi equation
2
R
kH

Zero order
2
R
ko

First order
2
R
k1

Uncted-Unencap

0.9543

19.491

0.7445

3.7974

0.9358

0.0395

Uncted-75/280

0.9981

18.402

0.8848

3.82

0.9925

0.0359

Uncted-75/300

0.9985

18.149

0.9255

3.85

0.0361

0.9975

Cted-Unencap

0.9899

5.1117

0.908

0.2991

0.9794

0.0024

Cted-75/280
Cted-75/300

0.9698
0.9873

5.4677
5.0532

0.8712
0.8954

0.3166
0.294

0.9563
0.9697

0.0026
0.0023

Formulations

Kinetic models

Combined mechanistic equation
2
R
k0
kH
Uncted-Unencap
Uncted-75/280
Uncted-75/300
Cted-Unencap
Cted-75/280
Cted-75/300

0.9997
0.999
1
0.99
0.9717
0.9882

3.03
0.3924
0.4966
0.01
0.05
0.03

32.55
20.09
16.01
5.28
6.3212
5.5603

Peppas equation
R
kP
n
0.8594 0.2303 1.5443
0.899
0.1878 1.5209
0.9103 0.1751 1.5128
0.9758 0.1431 0.7722
0.9792 0.0451 0.8242
0.9755 0.1368 0.7753
2
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them in the basket. For the coated pellets, encapsulation, especially at the same
conditions (75 rpm, 300 msecs) yielded results that were very similar to the
unencapsulated spheroids. The n values of Peppas equation were also > 0.75, thereby
depicting a non-Fickian diffusion through the polymer film membrane.

vii. Comparison of in vitro dissolution profiles using difference and similarity factors
Table XXXVII shows some time points and (their respective) percentage
dissolution of both the uncoated and coated, unencapsulated and encapsulated pellet
formulations.
Results from difference and similarity factors calculations (Table XXXVIII)
showed that the profiles of all the batches of each formulation type (uncoated and coated)
were similar (f1 < 15 and f2 > 50). However, the profiles of all the uncoated pellets were
different from those of all the coated pellets (f1 > 15 and f2 < 50). These show that the
ibuprofen release profile depended on the formulation type (coated vs. uncoated). These
results also confirmed that encapsulation did not alter the release properties of the pellets.
Consequently, the encapsulated pellets could be used for immediate (uncoated) and
controlled (coated) delivery of ibuprofen.

Using capsule size 0, the results showed that the highest fill weight and least
variabilities were obtained in both coated and uncoated ibuprofen pellets with operational
speed 75 rpm and shuttle speed 300 msecs on the K150i (tamp filling) encapsulation
machine. The encapsulation process did not affect the drug content and release profiles
of the pellets (Table XXXIV and Figure 56). Under these conditions, about 530 mg of
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TABLE XXXVII: Mean Percent Dissolution of Encapsulated and Unencapsulated (Uncoated and Coated) Ibuprofen
Spheroids at the Specified Time Points

Time (min)
Formulation type
Uncoated-Unencapsulated
*Uncoated-75/280
*Uncoated-75/300
Coated-Unencapsulated
*Coated-75/280
*Coated-75/300
*: Encapsulated batches
75, 85: Operational speeds; 75 rpm and 85 rpm
280, 300: Shuttle speeds; 280 msecs, 300 msecs.

10
66.55
60.89
55.68
4.19
5.92
9.6

20

60
120
240
Mean percent dissolution
81.95 96.16 96.00
81.41 91.49 94.72
81.48 90.09 91.97
12.27 36.00 54.76 72.13
15.11 40.97 61.11 73.93
18.60 37.52 56.26 71.36

480
83.84
81.61
82.29
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TABLE XXXVIII: Values of Difference and Similarity Factor (f1 and f2) for
Encapsulated and Unencapsulated (Uncoated and Coated) Pellets
REFERENCE

TEST

F1VALUE

F2 VALUE

FORMULATION

FORMULATION

1

2

3.57

74.68

1

3

6.29

63.22

1

4

68.53

15.75

1

5

63.86

17.11

2

3

2.83

78.7

2

5

62.52

18.32

2

6

64.85

17.80

3

5

61.43

19.18

3

6

61.79

19.32

4

5

5.87

70.56

4

6

4.73

71.49

5

6

1.08

72.69

Bold: The release profiles of reference and test formulations were different.
1. Uncoated and unencapsulated; 2. Uncoated and encapsulated at 75 rpm and 280 msecs
3. Uncoated and encapsulated at 75 rpm and 300 msecs; 4. Coated and unencapsulated
5. Coated and encapsulated at 85 rpm and 280 msecs
6. Coated and encapsulated at 85 rpm and 300 msecs

uncoated ibuprofen spheroids could be filled into this capsule size while about 485 mg
coated pellets could be filled into the same capsule size (Table XXXIV). Based on the
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results of the drug content, these pellet weights contained 365 and 302 mg ibuprofen
respectively.
Thus, the following information could be deduced using the information in Figure
14: Uncoated pellets; capsule size “ 0” , 0.68 mL contained 365 mg ibuprofen/capsule,
therefore, capsule size “ 00” , 0.95 mL could hold 510 mg ibuprofen/capsule theoretically.
Coated pellets; capsule size “ 0” contained 302 mg ibuprofen/capsule, therefore, 420 mg
ibuprofen could be encapsulated into the “ 00” size capsule.
It is expected that ≥ 25% of the content of the coated pellets will be released
within 15 min of delivery to achieve a therapeutic level for the drug. The use of
microparticulate system would also facilitate dose adjustment by varying capsule sizes
and fill weights without reformulating the product (9). It is also possible to mix coated
and uncoated pellets at different levels. The initial burst effect will be achieved with drug
release from the uncoated pellets, while sustained delivery will be maintained with the
coated pellets (177).
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IV. CONCLUSIONS

Phase 1
Ibuprofen spheres with good physical characteristics were developed using the
rotor-disk fluid-bed technology, a one-step closed process that did not require additional
unit processes. Based on plate radius and centrifugal force used as similarity factors for
scale-up, the batch size and process could be scaled up to 5x and 10x. An attempt to
simultaneously characterize spheronized ibuprofen granules, as well as process and batch
scale-up was made. Consequently, further efforts were centered on experimental design
for critical study of important process variables and formulation, on scale-up and coating
for slow release properties.

Phase 2
Experimentally designed studies on different process and product variables, and
based on our set acceptance criteria showed that the formulations spheronized using low
binder level, high surfactant level, stainless steel smooth plate (Formulation 5) and also
that produced with high binder level, low surfactant level, stainless steel smooth plate
(Formulation 11) were most acceptable. The statistical design or approach also
highlighted complexity and interplay of various variables in the outcome or predicted
characteristics. It also showed the importance of rational approach in product
development especially in multivariable unit process, as the case of rotor-disk fluid-bed
operated. In consideration of the obtained data as well as previous reports
(134,249,252,257) in which binder level had significant effect on most of the desirable
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spheroid characteristics, with low binder level forming spheroids with low product
quality, the conditions set in formulation 11 were used for further studies.

Phase 3
Using the optimized formulation to study some of the major formulation variables
in rotor-disk fluid-bed technology, such as drug load, drug particle size and scale-up, our
results showed that both particle sizes of ibuprofen are spheronizable at the different drug
levels studied. Although the time and amount of binder required for the formulations
decreased with increased drug concentration while spheroid size increased, there were
generally no differences observed in the physical characteristics of equivalent load of
both ibuprofen particles. The reduced surface area due to increased size slowed the rate
of drug release with the highest drug load, while the low and medium sized drug loads
showed very similar characteristics.
Intermediate size (50 kg) scale-up of the 65% drug load showed that, in contrast to
the 1 kg batches, increased batch size reduced the effects of drug load on spheroid size
and drug release, possibly due to an observed interaction between these two factors (batch
size and drug load). Statistical analysis showed that true and bulk densities were
significantly affected by both ibuprofen drug load and batch size, while replication did
not alter the physical characteristics of both spheroid batch sizes, showing batch-to-batch
reproducibility.
However, in future work, process parameters, e.g. rate of binder addition and end
point for the binder addition will need to be optimized. These might solve the problem
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encountered with spheronization processes using increased drug loads. From the results,
it can be inferred that the rotor-disk spheronization process is scalable.

Phase 4
Coating of 0.7 kg batches of the scaled-up formulation showed that ibuprofen
product characteristics, e.g. pellet size, drug release, bulk density, etc. depended on the
coating levels. As previously reported, we observed slower release with increased coating
level. This confirmed the successfulness of the coating process. The average fill weight of
the encapsulated spheroids was mostly affected by the formulation types. Encapsulation
of the microparticulates had no undesirable effect on the qualities of both formulation
types. Therefore, the formulation has a lot of pharmaceutical market potentials (70).

We have statistically studied the effects of various formulation and product
variables on the development of spheronized microparticulates using the rotor-disk fluidbed technology. Our experience showed that a tighter spheroid fraction would be obtained
if an in-process means of monitoring moisture content in the fluid-bed is introduced. This
is because the moisture content is closely associated with the spheroid size and size
distribution (44).
Although ibuprofen was used as the model drug, the process could be extended to
other poorly water soluble drugs. Additionally, with careful manipulation of the variables
and parameters studied in this work, the process could be applied to water soluble drugs
as well. These will aid in the production of several pharmaceutical products with reduced
cost e.g. amount of excipients and production time.
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IV. APPENDIX

This appendix consists of typical examples of raw data generated during
the study
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Figure 57. Log-Probability Profiles for Sieve Analysis of 1 kg Replicated
Batches from Feasibility Studies
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Figure 58. Log-Probability Profiles for Sieve Analysis of Pilot Size Scale-up
(1 kg, 5kg and 10 kg) Replicated Batches from Feasibility Studies
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Table XXXIX. Sphericity Analysis of SS/Sm/1 kg (Trial 4) Batch from
Feasibility Studies
Sample #

Area

Perimeter Roundness Sphericity

1

172440.77

1596.66

1.11

0.85

2

85836.72

1095.65

1.05

0.90

3

140054.00

1397.66

1.04

0.90

4

145441.75

1425.75

1.05

0.90

5

117719.24

1278.26

1.04

0.91

6

129925.26

1362.54

1.07

0.88

7

171147.28

1545.15

1.04

0.90

8

135543.20

1369.57

1.03

0.91

9

161336.42

1495.99

1.04

0.91

10

88412.76

1102.68

1.03

0.91

11

91745.16

1135.45

1.05

0.89

12

159993.59

1505.35

1.06

0.89

13

138333.00

1378.93

1.03

0.91

14

145737.72

1421.07

1.04

0.91

15

118678.41

1287.63

1.04

0.90

16

144636.05

1460.87

1.10

0.85

17

125809.09

1374.25

1.12

0.84

18

114332.04

1292.31

1.09

0.86

19

110314.52

1259.53

1.08

0.87

20

95691.42

1208.03

1.14

0.82

21

171695.36

1627.09

1.15

0.82

22

87930.44

1133.11

1.09

0.86

23

97401.47

1177.59

1.06

0.88

24

113997.70

1322.74

1.15

0.82

25

106412.10

1261.87

1.12

0.84

26

115866.70

1294.65

1.08

0.87

27

101599.85

1238.46

1.13

0.83

28

122586.31

1474.92

1.33

0.71

29

129963.63

1385.95

1.11

0.85

30

95691.42

1208.03

1.14

0.82

Average 124542.45

1337.26

1.09

0.87
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Table XL. Sphericity Analysis of SS/Sm/5 kg (Trial 12) Batch from
Feasibility Studies

Sample #

Area

Perimeter

Roundness

Sphericity

1

99462.30

1186.96

1.06

0.89

2

335744.80

2172.58

1.05

0.89

3

121013.30

1311.04

1.06

0.88

4

181539.10

1601.34

1.06

0.89

5

121375.00

1311.04

1.06

0.89

6

115614.60

1275.92

1.05

0.89

7

137582.10

1409.36

1.08

0.87

8

162777.90

1526.42

1.07

0.88

9

100925.70

1179.93

1.03

0.91

10

151536.50

1449.16

1.04

0.91

11

139423.70

1388.29

1.03

0.91

12

99462.30

1186.96

1.06

0.89

13

388208.20

2380.94

1.09

0.86

14

162777.90

1526.42

1.07

0.88

15

100925.70

1179.93

1.03

0.91

16

141687.31

1404.68

1.04

0.90

17

178617.77

1582.61

1.05

0.90

18

277367.50

1947.83

1.02

0.92

19

281505.70

1964.21

1.03

0.92

20

185627.88

1638.80

1.08

0.87

21

187502.34

1603.68

1.03

0.92

22

172588.80

1540.47

1.03

0.91

23

124493.66

1325.08

1.05

0.89

24

158585.00

1479.60

1.03

0.91

25

218655.91

1734.78

1.03

0.91

26

288532.20

1996.99

1.03

0.91

27

172210.58

1545.15

1.04

0.91

28

180048.30

1570.90

1.03

0.92

29

166417.20

1512.38

1.03

0.91

30

148330.20

1449.16

1.06

0.89

Average

176684.65

1546.09

1.05

0.90
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Table XLI. Sphericity Analysis of SS/Sm/10 kg (Trial 13) Batch from
Feasibility Studies
Sample #

Area

Perimeter RoundnessSphericity

1

233279.02

1805.02

1.04

0.90

2

258869.44

1898.66

1.04

0.90

3

312812.66

2128.09

1.08

0.87

4

349101.84

2217.06

1.05

0.89

5

212555.64

1734.78

1.06

0.89

6

350811.91

2221.74

1.05

0.89

7

199445.28

1666.89

1.04

0.90

8

183276.56

1603.68

1.05

0.90

9

183276.56

1603.68

1.05

0.90

10

332516.59

2151.51

1.04

0.90

11

211388.20

1709.03

1.03

0.91

12

211892.45

1711.37

1.03

0.91

13

269036.53

1938.46

1.04

0.90

14

191865.16

1652.84

1.06

0.88

15

291963.25

2032.11

1.06

0.89

16

153180.81

1467.89

1.05

0.89

17

114600.60

1261.87

1.04

0.90

18

143265.83

1442.14

1.09

0.87

19

121281.84

1292.31

1.03

0.91

20

93252.41

1151.84

1.06

0.88

21

110166.53

1245.49

1.05

0.89

22

104943.22

1210.37

1.04

0.90

23

104406.09

1224.42

1.07

0.88

24

156935.25

1533.45

1.12

0.84

25

87376.86

1130.77

1.09

0.86

26

109262.18

1238.46

1.05

0.90

27

158848.08

1488.96

1.04

0.90

28

135252.72

1367.22

1.03

0.91

29

101621.77

1205.69

1.07

0.88

30

102005.45

1222.07

1.10

0.86

Average

186283.02

1585.26

1.06

0.89
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Table XLII. Sphericity Analysis of Tef/Waf/1 kg (Trial 7) Batch from
Feasibility Studies
Sample #
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Average

Area
Perimeter Roundness Sphericity
186444.53 1624.75
1.06
0.89
128922.25 1332.11
1.03
0.91
154353.73 1479.60
1.06
0.89
91410.82 1144.82
1.07
0.88
149968.98 1442.14
1.04
0.91
89010.17 1116.72
1.05
0.90
117576.74 1282.94
1.05
0.90
92523.45 1142.48
1.06
0.89
100350.20 1186.96
1.05
0.90
132906.88 1367.22
1.05
0.89
144986.83 1423.41
1.05
0.90
107053.38 1238.46
1.07
0.88
128418.01 1343.81
1.05
0.89
106116.13 1238.46
1.08
0.87
124970.51 1350.84
1.09
0.86
122476.69 1313.38
1.05
0.89
220431.72 1805.02
1.11
0.85
112090.34 1238.46
1.02
0.92
133619.41 1376.59
1.06
0.89
118267.34 1289.97
1.05
0.89
136255.72 1390.64
1.06
0.89
169672.91 1540.47
1.05
0.90
157368.23 1479.60
1.04
0.90
93756.66 1156.52
1.07
0.88
147201.13 1449.16
1.07
0.88
102789.21 1184.62
1.02
0.92
137543.73 1428.09
1.11
0.85
158530.19 1481.94
1.04
0.91
94140.32 1144.82
1.04
0.90
109547.19 1254.85
1.08
0.87
128956.78 1341.63
1.06
0.89
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Table XLIII. Sphericity Analysis of Tef/Waf/5 kg (Trial 14) Batch from
Feasibility Studies

Sample #
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Average

Area

Perimeter

Roundness

79599.43

1058.19

1.05

104449.93

1229.10

1.08

88133.23

1121.41

1.07

123797.59

1315.72

1.05

120646.06

1318.06

1.08

223632.58

1797.99

1.08

233322.86

1826.09

1.07

78300.45

1048.83

1.05

123797.59

1315.72

1.05

139051.00

1418.73

1.08

85102.28

1121.41

1.11

103989.54

1219.73

1.07

108933.33

1250.17

1.07

137335.47

1400.00

1.07

141479.05

1402.34

1.04

365150.00

2277.93

1.06

234342.31

1797.99

1.03

211985.63

1706.69

1.03

287041.38

2067.22

1.11

295553.25

2039.13

1.05

335103.59

2160.87

1.04

205118.03

1716.05

1.07

206789.72

1697.32

1.04

361494.22

2289.63

1.08

210999.06

1725.42

1.06

307726.38

2076.59

1.05

214605.50

1760.54

1.08

226740.27

1788.63

1.06

282135.94

2013.38

1.07

334314.31

2214.72

1.10

199022.33

1639.19

1.06

Sphericity
0.89
0.87
0.88
0.90
0.87
0.87
0.88
0.89
0.90
0.87
0.85
0.88
0.88
0.88
0.90
0.88
0.91
0.91
0.84
0.89
0.90
0.88
0.90
0.87
0.89
0.90
0.87
0.89
0.87
0.86
0.88
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Table XLIV. Sphericity Analysis of Tef/Waf/10 kg (Trial 15) Batch from
Feasibility Studies
Sample #
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Average

Area
259647.72
247162.19
181413.05
277932.09
215515.34
233465.36
276194.63
192506.42
368345.38
230390.56
244279.22
243468.05
270680.81
242169.06
186296.55
153202.73
109240.26
105579.00
87338.49
94743.22
80569.56
122997.38
148702.91
114496.46
105688.63
119275.83
94798.03
159730.52
115921.50
129936.22

180389.57

Perimeter Roundness Sphericity
1926.76
1.07
0.88
1879.93
1.07
0.88
1580.27
1.03
0.91
2008.70
1.09
0.87
1758.19
1.07
0.88
1816.72
1.06
0.89
1999.33
1.08
0.87
1631.77
1.03
0.91
2259.20
1.04
0.91
1774.58
1.02
0.92
1849.50
1.05
0.90
1863.55
1.07
0.88
1957.19
1.06
0.89
1837.79
1.04
0.90
1624.75
1.06
0.89
1491.30
1.09
0.87
1252.51
1.07
0.88
1231.44
1.07
0.88
1121.41
1.08
0.87
1172.91
1.09
0.87
1062.88
1.05
0.90
1376.59
1.15
0.82
1474.92
1.09
0.86
1292.31
1.09
0.86
1273.58
1.15
0.82
1322.74
1.10
0.86
1172.91
1.09
0.87
1514.72
1.07
0.87
1285.28
1.07
0.88
1374.25
1.09
0.86
1572.93
1.07
0.88
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Table XLV. Dissolution Data for Ibuprofen Release of Pilot Size Scale-up
Replicated Batches from Feasibility Studies
Time (mins)

% Ibuprofen Released (S.D.)
SS/Sm/1 kg

SS/Sm/5 kg

SS/Sm/10 kg

5

62.02 (21.29)

60.35 (22.25)

63.64 (10.37)

10

75.73 (13.92

72.89 (19.62)

77.53 (12.88)

20

83.27 (5.02)

82.95 (12.66)

85.53 (5.08)

40

85.86 (1.03)

88.97 (6.74)

87.61 (2.45)

60

86.27 (0.92)

90.18 (4.79)

87.79 (2.38)

120

86.41 (0.54)

90.06 (4.15)

87.96 (4.1)

Time (mins)

% Ibuprofen Released (S.D.)
Tef/Waf/1 kg

Tef/Waf/5 kg

Tef/Waf/10 kg

5

61.28 (5.42)

60.43 (24.86)

63.64 (10.37)

10

82.82 (5.83)

70.56 (21.64)

77.53 (12.88)

20

91.75 (2.07)

79.47 (12.88)

85.53 (5.08)

40

94.30 (1.64)

85.64 (5.30)

87.61 (2.45)

60

94.68 (1.66)

87.75 (1.65)

87.79 (2.38)

120

94.69 (2.01)

89.55 (0.07)

87.96 (4.10)
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Figure 59. Log-Probability Profiles for Sieve Analysis of Experimentally
Designed Replicated Batches

0.1

1

Cumulative % frequency undersize

10

30
50
70

90

Mean micron siz v HbHsSS-sm
Mean micron siz v LbHsSS-sm
Mean micron siz v HbHsSS-waf
Mean micron siz v LbLsTef-waf
Mean micron siz v LbHsTef-waf
Mean micron siz v HbLsSS-sm

99

99.9

99.99
200

300

400

500

600

Particle size (micron)

700 800 9001000

239

Table XLVI. Sphericity Analysis of LbHSSS-sm (Formulation 5) Spheroids
from Experimentally Designed Batches
Sample #
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Average

Area
224969.938
191974.781
164076.891
99791.148
86921.945
251371.531
124669.055
179505.688
124669.055
179505.688
176228.094
83973.211
170566.297
118683.891
116913.547
207814.641
190445.594
174304.281
253969.484
219083.422
289814.719
241209.906
130884.422
84373.313
184137.063
104707.539
189130.188
226405.938
259472.328
293201.938

178092.52

Perimeter Roundness Sphericity
1751.17
1.019
0.92
1620.067
1.022
0.92
1510.033
1.039
0.90
1172.91
1.031
0.91
1102.676
1.046
0.90
1865.886
1.035
0.91
1315.719
1.038
0.91
1566.221
1.022
0.92
1315.719
1.038
0.91
1566.221
1.022
0.92
1549.833
1.019
0.92
1081.605
1.041
0.90
1533.445
1.031
0.91
1271.237
1.018
0.92
1266.555
1.026
0.92
1723.077
1.068
0.88
1662.207
1.085
0.87
1580.267
1.071
0.88
1908.027
1.072
0.88
1765.217
1.063
0.88
2022.742
1.055
0.89
1847.157
1.057
0.89
1353.177
1.046
0.90
1095.652
1.064
0.88
1631.772
1.081
0.87
1236.12
1.091
0.86
1659.866
1.089
0.86
1828.428
1.104
0.85
1959.532
1.106
0.85
2081.271
1.104
0.85
1561.46
1.05
0.89
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Table XLVII. Sphericity Analysis of HbLsSS-sm (Formulation 11)
Spheroids from Experimentally Designed Batches
Sample #
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Average

Area

Perimeter

Roundness

83627.906

1069.9

1.023

137658.844

1390.635

1.05

123797.586

1339.13

1.083

73005.883

1004.348

1.033

68259.406

962.207

1.014

62997.719

952.843

1.077

76069.719

1046.488

1.076

125474.75

1325.083

1.046

77160.422

1041.806

1.052

110078.844

1240.803

1.046

110034.992

1243.144

1.05

72337.211

994.983

1.023

152857.438

1456.187

1.037

110150.094

1247.826

1.057

251678.469

1931.438

1.108

207814.641

1723.077

1.068

190445.594

1662.207

1.085

174304.281

1580.267

1.071

253969.484

1908.027

1.072

219083.422

1765.217

1.063

219083.422

1765.217

1.063

241209.906

1847.157

1.057

130884.422

1353.177

1.046

84373.313

1095.652

1.064

259472.328

1959.532

1.106

184137.063

1631.772

1.081

104707.539

1236.12

1.091

149108.484

1470.234

1.084

189130.188

1659.866

1.089

226405.938

1828.428

1.104

148977.31

1424.43

1.06

Sphericity
0.92
0.89
0.87
0.91
0.93
0.87
0.87
0.90
0.89
0.90
0.89
0.92
0.91
0.89
0.85
0.88
0.87
0.88
0.88
0.88
0.88
0.89
0.90
0.88
0.85
0.87
0.86
0.87
0.86
0.85
0.88
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Table XLVIII. Dissolution Data for Ibuprofen Release of Experimentally
Designed Replicated Batches

Time (mins)

% Ibuprofen Released (S.D.)
LbHsSS-waf

LbHsSS-sm

HbHsSSwaf

(Formulation 3)

(Formulation 5)

(Formulation 6)

5

21.93 (3.20)

69.20 (2.06)

22.48 (0.19)

10

31.76 (3.66)

83.52 (0.59)

32.29 (0.64)

20

47.56 (7.17)

89.87 (0.30)

47.23 (0.47)

40

61.62 (4.58)

91.19 (0.68)

63.98 (0.06)

60

72.66 (3.20)

90.325 (1.20)

77.86 (1.19)

120

86.12 (1.57)

91.11 (2.48)

90.15 (0.04)

Time (mins)

% Ibuprofen Released (S.D.)
LbsTef-waf

LbHsTef-waf

HbLsSS-sm

(Formulation 7)

(Formulation 9)

(Formulation 11)

5

82.08 (3.26)

77.04 (2.75)

78.89 (4.95)

10

86.62 (4.27)

84.46 (2.09)

89.02 (1.37)

20

88.90 (5.25)

89.23 (1.45)

92.47 (3.61)

40

89.53 (3.91)

92.44 (1.03)

93.23 (3.30)

60

90.30 (3.54)

93.51 (0.15)

93.63 (3.87)

120

90.08 (3.17)

93.83 (0.83)

93.67 (3.56)
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Figure 60. Log-Probability Profiles for Sieve Analysis of Drug Load/Drug Particle
Size Replicated Batches
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Table XLIX. Sphericity Analysis of Ibuprofen Spheroids from Drug Load/Drug
Particle Size Replicated Batches (1kg, 20 Micron Size, 65% Drug Load)
Sample #

Area

Perimeter Roundness Sphericity

1

158058.83

1517.06

1.09

0.86

2

169914.06

1531.10

1.03

0.91

3

169914.06

1531.10

1.03

0.91

4

289491.34

2008.70

1.04

0.90

5

140152.66

1383.61

1.02

0.92

6

230428.92

1779.26

1.03

0.91

7

281631.69

2004.01

1.07

0.88

8

301708.31

2076.59

1.07

0.88

9

348685.31

2195.99

1.03

0.91

10

317049.44

2137.46

1.08

0.87

11

81495.83

1053.51

1.02

0.92

12

275821.94

2004.01

1.09

0.86

13

258737.89

1912.71

1.06

0.89

14

270735.63

1924.42

1.02

0.92

15

207376.17

1706.69

1.05

0.89

16

149810.05

1428.09

1.02

0.92

17

258710.48

1877.59

1.02

0.92

18

295262.75

2015.72

1.03

0.91

19

174254.95

1552.17

1.03

0.91

20

190966.30

1606.02

1.01

0.93

21

260650.73

1889.30

1.02

0.92

22

313782.78

2069.57

1.02

0.92

23

192122.77

1622.41

1.02

0.92

24

206559.52

1699.67

1.05

0.90

25

236112.64

1797.99

1.02

0.92

26

174814.02

1549.83

1.03

0.91

27

224536.94

1758.19

1.03

0.91

28

239203.89

1816.72

1.03

0.91

29

216945.86

1718.40

1.02

0.92

30

279384.53

1950.17

1.02

0.92

Average 230477.34 1770.60

1.04

0.91
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Table L. Sphericity Analysis of Ibuprofen Spheroids from Drug Load/Drug Particle
Size Replicated Batches (1kg, 40 Micron Size, 65% Drug Load)
Sample #

Area

Perimeter Roundness Sphericity

1

200963.48

1673.91

1.04

0.90

2

249179.16

1901.00

1.08

0.87

3

223007.77

1793.31

1.08

0.87

4

154370.17

1467.89

1.04

0.90

5

314402.13

2118.73

1.07

0.88

6

260267.06

1933.78

1.07

0.87

7

171350.06

1568.56

1.07

0.88

8

261467.39

1908.03

1.04

0.90

9

133838.64

1397.66

1.09

0.86

10

274462.66

1985.28

1.07

0.88

11

206882.89

1706.69

1.05

0.89

12

218940.92

1765.22

1.06

0.88

13

146461.20

1444.48

1.07

0.88

14

185342.86

1624.75

1.07

0.88

15

188143.61

1638.80

1.07

0.88

16

157439.48

1495.99

1.06

0.88

17

207469.34

1711.37

1.06

0.89

18

232955.64

1821.41

1.07

0.88

19

120207.59

1301.67

1.05

0.89

20

196173.17

1664.55

1.06

0.89

21

112950.84

1271.24

1.07

0.88

22

193257.31

1648.16

1.05

0.89

23

319822.78

2153.85

1.08

0.87

24

287644.28

2029.77

1.07

0.88

25

268543.25

1961.87

1.07

0.88

26

144334.61

1444.48

1.08

0.87

27

164712.67

1540.47

1.08

0.87

28

126686.03

1339.13

1.06

0.89

29

189530.28

1636.46

1.06

0.89

30

178075.16

1594.31

1.07

0.88

Average

202962.75

1684.76

1.07

0.88
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Table LI. Dissolution Data for Ibuprofen Release of Drug Load/Drug Particle Size
Replicated Batches
Time (mins)

% Ibuprofen Released (S.D.)
Ibu 20-50

Ibu 20-65

Ibu 20-80

5

48.82 (7.73)

54.21 (6.32)

54.51 (14.00)

10

65.36 (10.95)

70.31 (6.17)

67.78 (12.92)

20

83.94 (4.00)

86.87 (1.34)

82.80 (6.19)

40

88.98 (2.67)

88.49 (0.69)

89.02 (5.04)

60

90.34 (2.13)

90.29 (0.12)

91.61 (3.95)

120

91.00 (0.90)

91.20 (0.11)

95.55 (0.78)

Time (mins)

% Ibuprofen Released (S.D.)
Ibu 40-50

Ibu 40-65

Ibu 40-80

5

61.21 (6.38)

56.25 (3.55)

39.92 (3.46)

10

75.10 (6.03)

71.78 (2.36)

54.14 (4.75)

20

89.48 (4.93)

88.38 (3.73)

74.34 (0.50)

40

91.35 (2.84)

92.13 (3.18)

86.07 (7.21)

60

94.04 (5.60)

93.09 (2.67)

93.33 (7.61)

120

94.01 (4.82)

93.22 (3.04)

99.65 (7.16)
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Figure 61. Log-Probability Profiles for Sieve Analysis of Intermediate Size Scale-up
Replicated Batches
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Table LII. Sphericity Analysis of Intermediate Scale-up Ibuprofen Replicated
Batch (20 Micron, 50% Drug Load, 50kg Batch Size)
Sample #

Area

Perimeter

Roundness

Sphericity

1.00

84844.67

1069.90

1.01

0.93

2.00

114019.63

1243.14

1.01

0.93

3.00

113783.95

1264.21

1.05

0.89

4.00

110330.96

1243.14

1.05

0.90

5.00

196485.58

1645.82

1.03

0.91

6.00

122125.91

1296.99

1.03

0.91

7.00

128538.59

1329.77

1.03

0.91

8.00

140432.19

1407.02

1.05

0.89

9.00

133444.02

1355.52

1.03

0.91

10.00

132287.53

1357.86

1.04

0.90

11.00

105030.91

1219.73

1.06

0.89

12.00

125524.08

1327.43

1.05

0.90

13.00

85677.77

1079.26

1.02

0.92

14.00

137757.50

1376.59

1.03

0.91

15.00

78053.81

1037.12

1.03

0.91

16.00

132638.31

1357.86

1.04

0.90

17.00

93652.52

1140.13

1.04

0.91

18.00

122800.06

1292.31

1.02

0.92

19.00

126883.34

1322.74

1.03

0.91

20.00

248844.83

1856.52

1.04

0.91

21.00

147168.23

1411.71

1.01

0.93

22.00

130418.54

1350.84

1.05

0.90

23.00

84948.81

1086.29

1.04

0.90

24.00

107332.90

1210.37

1.02

0.92

25.00

178338.25

1582.61

1.05

0.89

26.00

161254.20

1500.67

1.04

0.90

27.00

116546.33

1271.24

1.04

0.91

28.00

88801.90

1109.70

1.04

0.91

29.00

139873.14

1383.61

1.02

0.92

30.00

80673.70

1067.56

1.06

0.89

Average

125617.07

1306.59

1.03

0.91
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Table LIII. Sphericity Analysis of Intermediate Scale-up Ibuprofen Replicated
Batch (20 Micron, 65% Drug Load, 50 kg Batch Size)
Sample #

Area

Perimeter

Roundness

Sphericity

1.00

83874.56

1079.26

1.04

0.90

2.00

86752.04

1095.65

1.03

0.91

3.00

211404.64

1702.01

1.02

0.92

4.00

183040.88

1599.00

1.04

0.90

5.00

83677.23

1067.56

1.02

0.92

6.00

218343.50

1727.76

1.02

0.92

7.00

150763.72

1432.78

1.02

0.92

8.00

132517.73

1348.50

1.03

0.92

9.00

177647.64

1563.88

1.03

0.91

10.00

130933.75

1339.13

1.02

0.92

11.00

126905.27

1334.45

1.05

0.90

12.00

213525.77

1704.35

1.02

0.92

13.00

178880.86

1587.29

1.05

0.89

14.00

209552.09

1690.30

1.02

0.92

15.00

102071.21

1182.27

1.02

0.92

16.00

158650.77

1486.62

1.04

0.90

17.00

113285.18

1259.53

1.05

0.90

18.00

283385.59

1973.58

1.03

0.91

19.00

83046.93

1076.92

1.04

0.90

20.00

170878.70

1554.52

1.06

0.89

21.00

108401.68

1236.12

1.05

0.89

22.00

114836.28

1275.92

1.06

0.89

23.00

129788.23

1336.79

1.03

0.91

24.00

348723.66

2205.35

1.04

0.90

25.00

150089.58

1446.82

1.04

0.90

26.00

137012.09

1378.93

1.04

0.91

27.00

117193.08

1282.94

1.05

0.89

28.00

231903.30

1788.63

1.03

0.91

29.00

120931.06

1304.01

1.05

0.89

30.00

129788.23

1336.79

1.03

0.91

Average

156260.18

1446.59

1.04

0.91
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Table LIV. Dissolution Data for Ibuprofen Release of Intermediate Batch size
(Replicated Batches)

Time (mins)

% Ibuprofen Released (S.D.)
1 kg-50%

1 kg-65%

50 kg-50%

50 kg-65%

5

48.82 (7.73)

54.21 (6.32)

50.09 (2.7)

62.25 (2.44)

10

65.36 (10.95)

70.31 (6.17)

63.74 (2.94)

75.32 (1.22)

20

83.94 (4.00)

86.87 (1.34)

83.10 (1.68)

87.43 (0.03)

40

88.98 (2.67)

88.49 (0.69)

88.02 (1.13)

90.82 (0.75)

60

90.34 (2.13)

90.29 (0.12)

91.29 (0.02)

92.36 (0.28)

120

91.00 (0.90)

91.20 (0.11)

93.01 (0.67)

93.63 (0.52)
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Figure 62. Log-Probability Profiles for Sieve Analysis of Uncoated and Coated
Ibuprofen Spheroids (Replicated Batches)
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Table LV. Sphericity Analysis of SR 12.5% Coated Ibuprofen Spheroids
Replicated Batches)
Sample #

Area

Perimeter

Roundness

Sphericity

1

157675.17

1493.65

1.06

0.89

2

128461.85

1348.50

1.06

0.89

3

170889.67

1554.52

1.06

0.89

4

337635.75

2205.35

1.08

0.87

5

167897.09

1545.15

1.06

0.88

6

116551.81

1275.92

1.04

0.90

7

212122.66

1734.78

1.06

0.89

8

170675.92

1563.88

1.07

0.88

9

96869.82

1165.89

1.05

0.90

10

122701.41

1299.33

1.03

0.91

11

117160.20

1287.63

1.06

0.89

12

99506.14

1170.57

1.03

0.91

13

196518.47

1669.23

1.06

0.89

14

208329.84

1727.76

1.07

0.88

15

123753.74

1296.99

1.02

0.92

16

257696.52

1903.34

1.05

0.89

17

106362.77

1212.71

1.03

0.91

18

220705.77

1748.83

1.04

0.91

19

106554.61

1217.39

1.04

0.90

20

181604.88

1573.24

1.02

0.92

21

192084.39

1634.11

1.04

0.90

22

114047.03

1257.19

1.04

0.91

23

78448.44

1037.12

1.03

0.92

24

157318.91

1463.21

1.02

0.92

25

233640.75

1814.38

1.05

0.89

26

135334.92

1374.25

1.04

0.90

27

72852.41

1018.40

1.06

0.88

28

185293.53

1634.11

1.08

0.87

29

171311.70

1547.49

1.05

0.90

30

227239.03

1781.61

1.04

0.90

Average

162241.51

1485.22

1.05

0.90
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Table LVI. Sphericity Analysis of EUD15.5% Coated Ibuprofen Spheroids
(Replicated Batches)
Sample #

Area

Perimeter

Roundness

Sphericity

1

154222.19

1486.62

1.07

0.88

2

113175.56

1250.17

1.03

0.91

3

89514.42

1140.13

1.09

0.87

4

198398.42

1659.87

1.04

0.91

5

199023.25

1662.21

1.04

0.91

6

141895.59

1402.34

1.04

0.91

7

143622.08

1411.71

1.04

0.91

8

142427.25

1418.73

1.06

0.89

9

93318.18

1165.89

1.09

0.86

10

93531.94

1140.13

1.04

0.90

11

154863.45

1486.62

1.07

0.88

12

148034.22

1437.46

1.04

0.90

13

186488.38

1636.46

1.07

0.88

14

186581.55

1624.75

1.06

0.89

15

191624.00

1664.55

1.08

0.87

16

154249.59

1481.94

1.06

0.88

17

145228.00

1430.44

1.05

0.89

18

141199.52

1395.32

1.03

0.91

19

97823.50

1170.57

1.05

0.90

20

91202.55

1140.13

1.07

0.88

21

125255.52

1320.40

1.04

0.90

22

154249.59

1481.94

1.06

0.88

23

179127.50

1582.61

1.05

0.90

24

242728.13

1840.13

1.04

0.90

25

191624.00

1664.55

1.08

0.87

26

107376.74

1224.42

1.04

0.90

27

321406.75

2135.12

1.06

0.89

28

267617.00

1964.21

1.08

0.87

29

146159.75

1428.09

1.04

0.90

30

278809.03

1973.58

1.04

0.90

Average

162692.59

1494.04

1.05

0.89
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Table LVII. Dissolution Data for Ibuprofen Release Coated Replicated Batches

Time (mins)

% Ibuprofen Released (S.D.)
Uncoated

SR 7.5%

SR 10%

SR 12.5%

5

62.25 (2.44)

10

75.32 (1.22)

21.55 (0.67)

16.36 (0.93)

11 (0.35)

20

87.43 (0.03)

31.80 (0.37)

24.19 (1.78)

16.56 (0.40)

40

90.82 (0.75)

47.39 (1.46)

37.27 (3.05)

28.53 (0.98)

60

92.36 (0.28)

56.94 (4.43)

46.82 (3.76)

37.23 (2.96)

66.88 (6.58)

56.17 (5.78)

48.29 2.28)

72.91 (9.25)

62.41 (7.56)

55.24 3.44)

150

77.14 (7.59)

68.64 (8.63)

61.96 4.06)

180

80.26 (7.91)

70.01 (8.44)

66.92 (4.52)

85.61 (8.30)

76.98 (4.72)

72.66 (3.09)

360

90.76 (6.89)

84.12 1.46)

79.77 (3.95)

480

91.00 (6.16)

87.47 (3.38)

83.63 (2.41)

93.63 (5.39)

90.2 (4.01)

86.14 (3.27)

90
120

240

720

93.63 (0.52)

93.9 (0.46)

93.9 (0.20)

Time (mins)

% Ibuprofen Released (S.D.)
Uncoated

EUD 12.5%

EUD 14%

EUD 15.5%

5

62.25 (2.44)

10

75.32 (1.22)

16.26 (2.37)

9.43 (1.80)

11.18 (0.93)

20

87.43 (0.03)

22.91 (4.07)

15.76 (3.11)

15.28 (2.35)

40

90.82 (0.75)

39.88 (1.34)

27.67 (5.78)

30.09 (2.49)

60

92.36 (0.28)

50.62 (0.98)

37.30 (5.16)

39.05 (3.35)

58.97 (0.21)

47.38 (6.80)

49.47 (4.75)

66.69 (1.25)

53 (2.77)

55.44 (3.97)

150

71.49 (1.44)

60.11 (4.75)

60.34 (3.69)

180

75.20 (2.07)

68.43 (9.38)

61.64 (0.16)

82.06 (4.21)

73.13 (4.10)

71.12 (4.26)

360

88.42 (0.55)

81.68 (5.30)

74.87 (1.74)

480

92.09 (0.01)

88.04 (6.14)

80.39 (0.90)

96.61 (2.58)

93.80 (6.65)

89.22 (2.28)

90
120

240

720

93.63 (0.52)

93.9 (0.46)

93.9 (0.20)
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Table LVIII. Fill Weight and Statistical Parameters of Uncoated Ibuprofen
Spheroids Encapsulated at 75 rpm and 280 msecs

Sample #

Average fill weight (mg)

Wt. capsule + Av. wt. 20 empty Fill wt. spheroids
spheroids (mg)

capsules (mg)

(mg)

1

622.19

94.88

527.31

2

624.65

94.88

529.77

3

635.32

94.88

540.44

4

629.86

94.88

534.98

5

624.57

94.88

529.69

6

627.08

94.88

532.20

7

631.62

94.88

536.74

8

631.95

94.88

537.07

9

624.08

94.88

529.20

10

625.21

94.88

530.33

11

622.86

94.88

527.98

12

610.10

94.88

515.22

13

629.29

94.88

534.41

14

634.01

94.88

539.13

15

623.22

94.88

528.34

16

625.39

94.88

530.51

17

601.91

94.88

507.03

18

609.91

94.88

515.03

19

616.29

94.88

521.41

20

612.11

94.88

517.23
528.20

Standard deviation

8.87

Coefficient of variation (%)

1.68
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Table LVIX. Fill Weight and Statistical Parameters of Uncoated Ibuprofen
Spheroids Encapsulated at 75 rpm and 300 msecs

Sample # Wt. capsule + Av. wt. 20 empty Fill wt. spheroids

Average fill weight (mg)

spheroids (mg)

capsules (mg)

(mg)

1

617.23

94.88

522.35

2

608.26

94.88

513.38

3

611.68

94.88

516.80

4

617.65

94.88

522.77

5

625.15

94.88

530.27

6

626.09

94.88

531.21

7

630.84

94.88

535.96

8

629.47

94.88

534.59

9

621.19

94.88

526.31

10

627.60

94.88

532.72

11

629.39

94.88

534.51

12

616.45

94.88

521.57

13

620.57

94.88

525.69

14

628.66

94.88

533.78

15

624.45

94.88

529.57

16

613.77

94.88

518.89

17

632.14

94.88

537.26

18

625.23

94.88

530.35

19

635.21

94.88

540.33

20

623.54

94.88

528.66

528.35

Standard deviation

7.24

Coefficient of variation (%)

1.37
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Table LX. Fill Weight and Statistical Parameters of Coated Ibuprofen Spheroids
Encapsulated at 75 rpm and 280 msecs

Sample #

Wt. capsule + Av. Wt. 20 empty Fill wt. spheroids
spheroids (mg)

capsules (mg)

(mg)

1

552.89

94.88

458.01

2

547.78

94.88

452.90

3

569.09

94.88

474.21

4

554.30

94.88

459.42

5

536.72

94.88

441.84

6

536.67

94.88

441.79

7

573.11

94.88

478.23

8

581.93

94.88

487.05

9

566.62

94.88

471.74

10

554.00

94.88

459.12

11

537.81

94.88

442.93

12

551.14

94.88

456.26

13

552.14

94.88

457.26

14

557.43

94.88

462.55

15

560.84

94.88

465.96

16

574.71

94.88

479.83

17

556.03

94.88

461.15

18

574.26

94.88

479.38

19

565.69

94.88

470.81

20

557.52

94.88

462.64

Average fill weight (mg)

463.15

Standard deviation

12.92

Coefficient of variation (%)

2.79
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Table LXI. Fill Weight and Statistical Parameters of Coated Ibuprofen
Spheroids Encapsulated at 75 rpm and 300 msecs

Sample # Wt. capsule + Av. Wt. 20 empty Fill wt. spheroids
spheroids (mg)

capsules (mg)

(mg)

1

587.86

94.88

492.98

2

577.59

94.88

482.71

3

589.83

94.88

494.95

4

578.74

94.88

483.86

5

583.14

94.88

488.26

6

564.94

94.88

470.06

7

569.66

94.88

474.78

8

563.18

94.88

468.30

9

585.63

94.88

490.75

10

573.47

94.88

478.59

11

591.24

94.88

496.36

12

583.00

94.88

488.12

13

558.88

94.88

464.00

14

570.62

94.88

475.74

15

596.40

94.88

501.52

16

571.49

94.88

476.61

17

571.94

94.88

477.06

18

566.51

94.88

471.63

19

587.53

94.88

492.65

20

590.02

94.88

495.14

Average fill weight (mg)

483.20

Standard deviation

10.78

Coefficient of variation (%)

2.23
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Table LXIIA. Dissolution Data for Ibuprofen Release of Encapsulated and
Unencapsulated (Uncoated) Spheroids

Time (mins)

% Ibuprofen Released (S.D.)
Uncoated-Unencapd. Uncoated-Unencapd. Uncoated-Unencapd.
(75/280)

(75/300)

5

51.71 (0.00)

41.59 (0.00)

38.18 (0.00)

10

66.55 (0.00)

60.89 (0.01)

55.68 (0.00)

20

81.95 (0.00)

81.41 (0.01)

81.48 (0.00)

40

88.69 (0.00)

87.34 (0.01)

87.24 (0.00)

60

96.16 (0.00)

91.49 (0.00)

90.09 (0.00)

96 (0.00)

94.72 (0.00)

91.97 (0.00)

99.03 (0.01)

97.9 (0.00)

95.06 (0.00)

90
120
150
180
240
360
480
720
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Table LXIIB. Dissolution Data for Ibuprofen Release of Encapsulated and
Unencapsulated (Coated) Spheroids

Time (mins)

% Ibuprofen Released (S.D.)
Coated-Uncapd.

Coated-Encapd.

Coated-Encapd.

(75/280)

(75/300)

10

4.19 (0.01)

5.92 (0.00)

9.6 (0.00)

20

12.27 (0.00)

15.11 (0.00)

18.6 (0.00)

40

25.87 (0.01)

30.44 (0.00)

28.62 (0.00)

60

36.00 (0.01)

40.97 (0.00)

37.52 (0.00)

90

45.83 (0.00)

52.36 (0.01)

48.1 (0.00)

120

54.76 (0.01)

61.11 (0.01)

56.26 (0.00)

150

60.12 (0.01)

64.63 (0.01)

62.18 (0.00)

180

66.48 (0.01)

69.16 (0.00)

65.8 (0.00)

240

72.13 (0.01)

73.93 (0.01)

71.36 (0.00)

360

79.19 (0.01)

80.93 (0.00)

80.29 (0.00)

480

83.84 (0.01)

81.61 (0.00)

82.29 (0.00)

720

84.77 (0.01)

86.18 (0.00)

85.53 (0.00)
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VII. ABSTRACT
The aim was to develop uncoated and coated ibuprofen microparticulates in a one-step
fluid-bed machine with rotor-disk insert, for immediate and prolonged drug delivery.
Feasibilty studies using ibuprofen:Avicel® (RC-581; 50:50), sodium lauryl sulfate (1%)
as surfactant and water as binder in FLM-15 Vector Flo-coater with 12” stainless-steel
and waffle-disk inserts showed that amount of binder, plate type and the presence of
surfactant affected most of spheroid characteristics. These variables were used in a 2x2x3
full factorial (replicated) experiment. Blocking was used to study batch-to-batch
reproducibility of the process and product variables. Our results confirmed that the binder
amount, plate-type and the presence of surfactant were important variables in rotor-disk
spheronization. The amount of binder was the most critical. The batch with the most
acceptable product characteristics was chosen as the optimized formulation, and used to
statistically study the effects of other formulation variables viz, drug particle size (20 µm,
40 µm) and drug load (50%, 65%, 80%) in a 2x3 factorially designed (replicated)
experiment. The two ibuprofen particle sizes and the three drug loads were
spheronizable. However, spheronization of the higher drug load was more difficult and
yielded larger sized microparticulates that consequently retarded drug release. The 65%
drug load was therefore used for intermediate size scale-up, which resulted in spheroids
with good product characteristics.
The optimized scaled-up batch was used in a 2x3 factorially designed (replicated)
experiment to study the effects of polymer type (Surelease®, Eudragit® NE-30D) and
level (low, medium, high) on the developed microparticulates. Coating level was found to
be inversely related to the drug release. The batch coated with the highest Surelease®
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level yielded the most acceptable spheroid characteristics, including most prolonged
release. The latter and the uncoated spheroids were encapsulated using a 2x2x3
experiment in Romaco Index-K150i machine. The average fill-weight of the encapsulated
spheroids was mostly affected by the formulation type. Encapsulation of the
microparticulates had no undesirable effects on the qualities of both the uncoated and
coated pellets.
This study provides spheronized ibuprofen microparticulates that can be sold as
ready-to-use modified ibuprofen to pharmaceutical companies owing to their lots of
pharmaceutical market potentials.

